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CHAPTER I 
INTRODUCTION 
The Stem-Cell Niche Concept and its application in understanding Organ Development 
Stem-cells have a theoretically unlimited capacity for self-renewal, and because of their broad 
lineage potency (multipotency) are able to give rise to all cell types of a particular organism or 
organ [1]. In a historical sense, the phrase “stem-cell niche” is used to refer to the specific 
location of a stem-cell, the cellular components of the microenvironment surrounding the 
stem-cell, and the regulatory signals emanating from ‘support’ cells [1]. Studies on the stem-cell 
niche in diverse systems have shown that stem-cell function is controlled by extracellular cues 
that are deployed within spatially constrained ‘niche’ environments, and that activate intrinsic 
genetic programs within the stem-cell. A widely held belief is that the biological form of a niche 
is tightly integrated with niche function, and vice versa. Thus, the proper construction and 
maintenance of a niche is thought to depend on a precise regulation of cell and tissue 
architecture, which is coupled to the regulated progression of differentiating cell types from the 
stem-cell pool, and to the maintenance of reserve stem-cells that will remain within the niche. 
While concepts on stem-cell niche structure and function are remarkably well developed in 
relatively simple systems such as the Drosophila ovary and testis [2,3,4,5,6], or in homeostatic 
mammalian systems such as the bone marrow [7,8], skin/hair follicle [9,10], and the intestinal 
crypt [11] very little is known about whether and how organ-specific progenitor populations are 
assembled, maintained, and regulated within niche environments to control organ formation.  
It can be argued that the stem-cell niches that have been best characterized represent 
relatively stable, and stereotypically organized biological entities. The major gaps in our 
knowledge with respect to if and how niche environments guide organ formation can largely be 
attributed to the fact that organogenesis represents a relatively rapid, highly complex, and 
spatially dynamic process. During organ development, it is often more appropriate to refer to 
multipotent populations as organ-specific progenitor cells, rather than bona fide stem-cells. 
While it is still debated as to whether there is a strict distinction between stem and progenitor 
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cells, an organ-specific progenitor can be defined as a cell that, unlike a stem cell, has a more 
limited tendency to self-replicate, and also has a greater tendency to differentiate toward a 
“target” cell type, or a rather limited number of cell types [12] (Fig. 1.1A). Multipotentiality in 
progenitors is thus often confined to windows of time that exist only transiently during 
embryonic development, making investigations into the niches within which they reside 
technically and conceptually difficult. These collective points are especially important, because 
it is now thought that many organ systems, in their mature and functional final states, do not 
harbor a reserve pool of stem-like cells that drive appreciable self-renewing or regenerative 
capacity under normal or even injury-induced conditions. Therefore, understanding the 
mechanisms through which organ-specific progenitor cells become expanded in number versus 
lineage-committed during development, and whether these processes are controlled within 
discrete niche environments, will be critical in our ability to gain control over the cell-biological 
mechanisms that regulate tissue formation as a means toward therapeutic applications.  
The ‘Niche Framework Model’ as a basis to understand complex organ formation 
When I first began my research in the Wright Lab, we were trying to think in new ways about 
the question “how must organs form?” In trying to envision a solution, we conceived the 
process of organ formation as essentially an engineering problem. During organ formation 
there must be enough growth in the progenitor pool to ensure that the organ obtains the 
correct size, the right cell types must be formed to meet the functional requirements of the 
organ, and cells must be placed with respect to each other at the right place at the right time. In 
meeting these three requirements, an organ formation ‘program’ can accomplish the proper 
size, composition, and spatial arrangement of properly differentiated cell types necessary for 
mature organ function. The blueprints of a particular organogenesis process can thus 
conceivably be reduced to three principle programs that must be precisely coordinated during 
development: these are cell differentiation, progenitor maintenance, and tissue 
morphogenesis. But how might these programs be coordinated, or even mechanistically 
coupled? We proposed a model wherein there must be a highly integrated system of feedback-
based controls, which are organized and deployed within structured units or cell groupings, 
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which links these individual developmental programs together to guide the formation of a 
complex multi-cellular organ. We called this model the “niche framework” (personal 
communication, Christopher V.E. Wright 2009) (Fig. 1.1B).  
 
Figure 1.1. The Niche Framework Model for the study of complex organ formation. (A) Schematic showing a typical 
hierarchy of lineage potency in stem and progenitor cells during development. The earliest embryonic stem-cells, 
and stem-cells reserved in homeostatic and regenerative systems, are assembled, maintained and regulated within 
discrete niche environments. As organs form during development, it is unclear whether similar niche environments 
regulate the functions of lineage-restricted progenitor types. (B) Our proposed “Niche Framework” model has three 
main features. First, there are three obligate developmental programs (morphogenesis, progenitor growth, and 
differentiation), which must be coordinated during organ formation. Second, there are feedback mechanisms in 
place that link each of the obligate developmental programs together in a closed circuit. Last, the feedback 
mechanisms linking morphogenesis, differentiation, and progenitor growth are organized and deployed within 
discrete ‘unit’ of cells. Altogether, these three features we propose represent the minimum requirements necessary 
to comprise a functional organ-specific niche. This figure was adapted from [12]. 
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Arguably, a niche-framework model, as a basis to understand how large and complex multi-
cellular tissues arise, makes sense from a variety of perspectives. From the perspective of organ 
self-assembly, it is reasonable to presume that in order for organogenesis to proceed so 
precisely and reproducibly there must exist physiologically limited microenvironments wherein 
intracellular communication links individually wide-ranging cell behaviors (the inputs) together 
to ensure a stable and predictable large-scale outcome (the output). From the perspective of 
the acquisition of disease states, it follows that any detrimental perturbation to a 
morphogenetic, differentiation, or progenitor maintenance program has the potential to 
dismantle the coordinated organogenesis process, resulting in harmful consequences to the 
organism as a whole. Our niche-framework makes sense from the perspective of evolution, as it 
provides a limited set of ‘principal components’ that can be modified and elaborated upon over 
time to generate increasing complexity. Finally, by virtue of its non-linearity, our niche-
framework model accommodates a structure-function tissue-building system that can be used 
reiteratively, in cycles that are tuned at some physiologically established rate, during organ 
formation. A major theme of this dissertation focuses on how we have built new and potentially 
and, potentially, increasingly unifying models for how organs are assembled during 
development using the “niche framework” as a guide, and the developing mouse pancreas as a 
model. 
Pancreas development as a model to study organ-specific progenitor niches 
The developing mouse pancreas provides a tractable model for beginning to ask questions 
about whether discrete niche environments coordinate progenitor growth, differentiation, and 
morphogenesis during organ formation. The pancreas is arguably one of the most thoroughly 
studied developing organ systems in mammals, and the lineage potency, marker-defined 
identity, and in some cases locations of various pancreatic progenitor pools have been 
described. Major themes have emerged over time regarding how various pancreatic progenitor 
populations behave as they contribute to differentiated lineages. In brief, these include, but are 
not limited to, the following: 
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 There are periods of development characterized by preferential replication and growth 
in an undifferentiated progenitor state, versus periods of preferential lineage-allocation 
from the progenitor pool [13]. 
 There is a gradual decrease in lineage potency over time, with early progenitors being 
multipotent, and later progenitors being bi-potent or even unipotent [14,15,16]. 
 Progenitor “domains” with specific lineage potencies become spatially segregated as the 
pancreas undergoes epithelial budding, tubulogenesis, and arborization [14,15]. 
 The size of the initial multipotent progenitor pool determines the ultimate size of the 
organ [17]. 
  There is little-to-no homeostatic regeneration of pancreatic lineages from “reserve” 
stem or progenitor pools in the adult organ [13,15,23]. 
While these themes will not necessarily apply to every developing organ system, they provide a 
framework to ask questions about the form and function of niche-microenvironments 
regulating organ-specific progenitor cells during development. The studies in this dissertation 
focus on whether and how a distinct niche regulates a relatively late-arising bipotent progenitor 
population wherein the final decision to become a pancreatic duct or hormone-secreting 
endocrine cell is made.  
 
Early Specification and Growth of Multipotent Pancreatic Progenitors  
The pancreas is an endodermally derived glandular organ consisting of two morphologically and 
functionally distinct exocrine and endocrine cell populations. The exocrine pancreas, which is 
comprised of the acinar and ductal lineages, represents the majority of the mature pancreatic 
cell mass. Acinar cells are arranged in numerous clusters that cap the terminal ends of the 
ductal tubes. Acinar cells secrete digestive enzymes into the ducts, which then empty these and 
other secretions into the duodenum to aid in digestion [18]. The endocrine pancreas, on the 
other hand, functions primarily in regulating nutrient metabolism and glucose homeostasis 
through the secretion and action of multiple hormones. Endocrine hormone-secreting cells 
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consist of five types: glucagon-secreting -cells, insulin-secreting -cells, somatostatin-secreting 
-cells, grehlin-secreting -cells, and pancreatic polypeptide-secreting PP-cells [13]. In the 
mature organ, endocrine cells are arranged in spheroid-like aggregates known as islets of 
Langerhans, which are intimately linked to the vascular, neuronal, and mesenchymal organ 
constituents that altogether regulate glucose homeostasis throughout the body [20].  
The Primary Transition of Pancreas Organogenesis 
The beginning stages in pancreas organogenesis occur around embryonic day 9.0 (E9.0) as 
discrete dorsal and then ventral epithelial buds evaginate and begin to grow from a pre-
patterned and pancreas-specified region of the foregut endoderm. This region of the foregut is 
located at the rostral end of the developing intestine and just caudal to the liver bud, and is 
marked by expression of the pancreatic transcriptional master regulator Ptf1a [21,22]. The 
pancreatic buds initially expand and grow substantially in a state that appears to be relatively 
devoid of branches or tubes. Around E10.5, however, groups of cells begin to become more 
structured and seem to form a pseudo-stratified epithelial bud [24] (Fig. 1.2A). Within the 
pseudo-stratified epithelial buds, cells begin to specify and establish apical and basal cell 
surfaces. This process is first evident with the formation of apically targeted vesicles within 
single cells, visible as puncta within the cell marked by the tight junctional marker Zona 
Occludens-1 (ZO1), and the apical lumen marker Mucin1 (Muc1). Around E10.5-11, these 
relatively isolated groups of polarized cells become oriented to form Muc1+ apical microlumens 
[24,25,26]. These microlumens expand by recruiting more cells that develop an apical (future 
luminal) surface, coalesce with each other to form interconnected epithelial tubes, and grow 
rapidly and substantially in size, to generate a relatively continuous and interconnected 
network of polarized epithelial tubes by E12.5. The period that collectively spans these budding, 
growth, cell-polarization, and tubulogenesis processes is referred to as the “primary transition” 
[18] (Fig. 1.2A-D).  
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Figure 1.2. Early specification and growth of the pancreatic anlagen during the primary transition. (A) schematic 
showing the initial transitions in pancreas formation comprised by budding outgrowth from the foregut endoderm, 
replicative expansion and microlumen formation, and progressive tubulogenesis and compartmentalization into 
‘tip’ and ‘trunk’ domains. (B-D) Tubulogenesis (the apical surface of epithelial cells marked by Muc1) progresses 
from initial formation of microlumens in the bud, coalescence of microlumens into continuous tubes, resulting in 
the establishment of a web-like network, or plexus, of epithelial tubes. (E-F) Progression of the early bud into tip-
trunk compartmentalization phases as marked by Ptf1a in the tip, and Sox9 in the trunk. This figure was adapted 
from [13, 23,24]. 
Formation of Tip and Trunk Domains 
During the primary transition, the pancreatic epithelium becomes increasingly segregated into 
morphologically and functionally distinct “tip” and “trunk” epithelial domains [14] (Fig. 1.2A). 
Discrete patterns of gene expression in the tip and trunk have been documented [13,14,23], 
and these have allowed for studies on the functional characteristics of cells therein using Cre-
LoxP-based technologies [202]. Relatively early on in development (E9.5), pancreatic 
progenitors are thought to represent a relatively homogenous population in terms of both 
potency and gene expression, but there is evidence that spatial as well as transcriptional 
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heterogeneity is becoming established at this early stage. While there appears to be an 
appreciable degree of cell intermixing (i.e. there are no apparently abrupt boundaries between 
cell populations), gene expression pattern characterizations have shown that there are 
populations of Cpa1+Ptf1a+Sox9+ cells located near the perimeter of the pancreatic bud, and 
populations of Cpa1-Ptf1a-Sox9+ cells located interiorly [23] (Fig. 1.2E-G). Genetic lineage-
tracing studies using Cpa1CreER and Ptf1aCreER mouse strains showed that Cpa1+Ptf1a+ cells of the 
primary transition are multipotent as a population, and able to give rise to all exocrine and 
endocrine lineages [14,23] (Fig. 1.3A). These cells were named primary multipotent progenitor 
cells (MPC), and close inspections on their localization showed that they are maintained within 
the tip domains throughout the primary transition. Moreover, pulse-chase lineage tracing 
analyses using low doses of tamoxifen to activate fluorescent tracer in only small numbers of 
Cpa1-expressiong MPC showed that early-labeled Cpa1+ cells in the tip give rise to cells of the 
trunk domain, and eventually to differentiating endocrine cells [14]. The labeled cells that 
remain in the tip eventually differentiate into acinar cells. Finally, it was demonstrated that the 
multi-lineage allocation behavior of cells in the tip domain decrease dramatically over time, 
with essentially all cells being strongly biased toward a unipotent pro-acinar state by the end of 
the primary transition (Fig. 1.3B). Collectively, these experiments were repeated, independently 
confirmed, and quantified in detail in studies using the Ptf1aCreER knock-in mouse line [23]. A 
model was proposed in which the so-called multipotent progenitor domain in the “tip” guides 
pancreas growth and lineage differentiation, at least during the early primary transition of 
development [14] (Fig. 1.3C). 
Genetic Regulation of Pancreatic MPC  
Studies in pancreas developmental biology have focused largely on identifying the 
transcriptional and signaling mechanisms that regulate endoderm specification into pancreas 
(rather than other nearby organ fates), MPC maintenance and survival, and commitment 
toward specific cell lineages. The proper coordination of each of these individual 
developmental processes is vital, because the initial numbers of MPC specified during the 
primary transition determines the final size of the pancreas. Comparing the developing mouse  
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Figure 1.3. Lineage potency becomes progressively restricted in the tip domain. (A) Results from a typical lineage 
tracing experiment following the progeny of tip populations via CreER-based methods. Early Ptf1a-expressing tip 
cells readily give rise to all lineages of the pancreas, whereas Ptf1a-expressing cells later become strongly biased 
toward a unipotent pro-acinar fate. (C) Proposed model for how the tip domain guides early pancreas formation. 
MPC in the tip replicate and grow while being maintained in the tip location. Progeny from these cells maintain the 
tip, but also give rise to trunk cells as the organ undergoes a proposed mechanism of branching outgrowth. This 
figure was adapted from [14,23]. 
pancreas and liver as model systems, Stanger et al. [17] were able to manipulate, using 
inducible cell-death and blastocyst complementation experiments, the size of the initial 
pancreas or liver-specified progenitor pools.  They could then ask whether the final size of each 
organ was pre-determined by the initial numbers of organ-specified progenitors, or whether 
there were compensatory growth mechanisms in place to ensure that a final “set point” in 
organ size could be achieved independent of the initial numbers of progenitors. The authors 
found that in the pancreas, but not the liver, final organ size was limited by the size of the initial 
progenitor pool, which suggested that at least in some organs, size is constrained by an intrinsic 
growth program established early in development. Therefore, in the pancreas there must be a 
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tightly coordinated regulation of the transcriptional and signaling events that drive specification 
of the appropriate number of initial MPC, and that control the balance between progenitor 
maintenance and cell differentiation throughout organogenesis. The introduction following will 
focus on selected transcriptional and signaling factors (as they relate to our studies on later 
developmental stages) that regulate pancreas specification, progenitor maintenance, and cell 
differentiation during primary transition. 
Two of the most well studied transcriptional determinants of pancreatic fate are Pdx1 and 
Ptf1a. Both Pdx1 and Ptf1a are required for pancreas formation. Endodermal progenitors in the 
foregut that lack these transcription factors fail to become productively specified to the 
pancreatic lineage, and become incorporated early into adjacent tissues such as the bile duct 
and intestine [205, 206,207,208]. Ptf1a-expressing cells become localized within the ‘tip’ 
domain at early stages of primary transition where it marks and plays important functions in 
regulating, along with Pdx1, multipotent progenitor cell functions [13,14]. Later, Ptf1a becomes 
greatly upregulated in expression level as it becomes restricted to the pro-acinar lineage, where 
it functions as an important regulator in establishing acinar cell identity and function [209]. 
Pdx1 remains broadly expressed in essentially all undifferentiated cells of the pancreas during 
the primary transition [207,208] (Fig. 1.3C). Thus, Pdx1 and Ptf1a are used as functionally 
relevant markers of primary MPC in the early pancreatic bud and in the tip domain. 
Sox9 is a member of the SRY/HMG box (Sox) family of transcription factors [19]. Sox9 functions 
in multiple respects to regulate the proliferation, survival and maintenance of progenitor cells 
in many systems including the neural crest, hair bulge, and intestinal epithelium [27, 28, 29]. A 
number of recent reports indicate similar roles in pancreatic MPC. High levels of Sox9 
expression are first evident in the pancreatic buds at ~E10.5, and conditional lineage-tracing 
studies confirm that much like Pdx1 and Ptf1a-expressing cells, Sox9 marks cell populations 
capable of giving rise to all three lineages of the pancreas [30]. Pancreas specific inactivation of 
Sox9 results in a hypoplastic phenotype in both ventral and dorsal buds, and this effect can be 
attributed largely to increased cell death, decreased replication, precocious differentiation, and 
eventual depletion of the MPC pool [31]. Moreover, it was found that Sox9 expression regulates 
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the transcriptional repressor Hes1, which represents a critical downstream effector of the 
Notch signaling pathway (introduced below). It is now thought that a potential genetic link 
between Sox9 and Notch plays a key role in blocking the activation of lineage-commitment 
factors to maintain MPC in an undifferentiated state [31, 32].  
Notch pathway activity balances differentiation and progenitor maintenance  
The Notch signaling pathway is well known as an important regulator of stem and progenitor 
cell maintenance, and binary fate decisions, in developing and homeostatic systems [33,34]. 
Canonical Notch signaling controls fate choice when a signal-sending cell upregulates 
membrane-bound Notch ligands (Delta/Serrate/Jagged) and engages Notch receptors in 
juxtaposed cells.  This event transmits Notch signals to signal-receiving cells, resulting in the 
inhibition or induction of cell fate from within an otherwise “equivalent” group of progenitors 
[33]. Notch ligands including Delta-like 1 (Dll1), Dll3, Jagged1/2, and Serrate1/2 are expressed in 
the early pancreatic bud, as are Notch receptors Notch 1-4 [35,36,37], and transcriptional 
effectors of Notch such as RBPJ [44] and Hes1 [45, 46]. Although the exact locations and cell 
types involved in sending or receiving Notch signals remain ill defined, genetic lineage-tracing 
studies have shown that cells expressing Hes1 during the primary transition represent MPC 
[46]. Early studies on Notch pathway function in the pancreas focused on genetic deletions of 
Notch ligands and receptors, the transcriptional mediator RBP-J, or the Notch effector Hes1. 
Mice genetically deficient for RBPJ, Dll1, and Hes1 all display hypoplastic phenotypes in the 
early pancreatic bud, as well as a precocious differentiation of cells toward the endocrine 
lineage [36,37,38]. Conversely, overexpression of the Notch intracellular domain (NICD) in 
Pdx1-expressing MPC, which results in constitutive activation of the Notch pathway in these 
cells, blocks both endocrine and exocrine differentiation, and “traps” MPC in an 
undifferentiated state [39,40]. Thus, in the pancreas it appears that Notch maintains progenitor 
cells in an undifferentiated state, in part by blocking activation of lineage differentiation factors 
(Fig. 1.4A,B).  
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Figure 1.4. Roles for Notch and Notch pathway components in pancreas development. (A) List of genetic 
manipulations and phenotypes from studies on Notch pathway function in foregut or pancreatic progenitors. (B) 
Proposed mode of Notch mediated repression of endocrine differentiation. In early pancreatogenesis, cells are 
broadly sending and receiving Notch signals. The net effect is that within the cellular environment, cells are held in 
a differentiation-suppressed and replicating state. At later stages, cells become differentiated into signal receiving 
and signal sending cells 9it is not known how this occurs). Signal receiving cells remain undifferentiated through 
Notch/Hes1-midated repression of Neurog3, while signal sending cells progress through Neurog3 activation and 
upregulation to commit to the endocrine lineage. The mechanism through which Neurog3-expressing cells suppress 
differentiation in surrounding epithelial progenitors through Notch is called lateral inhibition. This figure was 
adapted from [181].  
More recent advances in understanding the precise mechanisms through which Notch 
functions during pancreas organogenesis suggest that different levels of Notch may be involved 
in diversifying progenitor cell behaviors and/or fates [34]. Studies in the zebrafish pancreas 
13 
 
used Notch-reporter alleles, as well as genetic and pharmacological interference tests targeting 
Notch, to show that stepwise decreases in Notch activity regulate states of mitotic quiescence, 
replication in an MPC condition, or endocrine cell-fate allocation, respectively [41]. In addition, 
conditionally controlled and mosaic overexpression of a dominant-negative form of 
Mastermind, which functions as an obligatory transcriptional co-activator of NICD and RBPJ, 
resulted in “tip” versus “trunk” patterning defects in MPC prior to their terminal differentiation 
[42]. Here, Notch-suppressed MPC preferentially adopt a “tip” cell fate, and eventually 
differentiated into acinar cells. Conversely, wild-type cells in these same organs predominantly 
adopted a “trunk” fate, and thus differentiated into duct and endocrine cells. These data 
suggest that, in addition to primary functions in blocking individual terminal differentiation 
events, a tight spatiotemporal “tuning” of Notch levels within the progenitor pool may be 
important for regulating the progression of MPC toward different lineage-restricted 
populations. Lastly, recent studies are beginning to link Notch pathway components to the 
regulation of the expression or biochemical activity of transcription factors important for 
lineage specification [44,42]. Of particular relevance is a proposed transcriptional antagonism 
between Ptf1a and Nkx6.1 that is important for controlling the patterning of tip (Ptf1a+) versus 
trunk (Nkx6.1+) domains during primary transition [43]. This effect on progenitor domain 
compartmentalization was suggested to be regulated by Notch via direct RBPJ binding sites on 
the Nkx6.1 promoter [43], consistent with the idea that Notch in part directs the early 
specification of trunk progenitors at the expense of pro-acinar cells in the tip. In sum, the 
implications of these collective studies are that a precise and likely highly context-dependent 
regulation of the timing and levels of Notch pathway activity are important for diversifying 
lineage potential within the progenitor pool, for delaying precocious differentiation toward 
lineage-committed states, and for coordinating the balance between epithelial growth and cell-
fate allocation in a manner that permits the developing pancreas to attain its predetermined 
size and cellular composition [13].  
 
 
14 
 
 
Figure 1.5. Secondary transition epithelial remodeling and cell differentiation from the tip and trunk domains. The 
secondary transition comprises a period of roughly E12.5 to E18.5, where the pre-established pancreatic epithelium 
remodels from a branched web-like plexus into a hierarchically organized epithelial arbor. By birth, the pancreatic 
ductal epithelium is comprised of a relatively mature population of uni-potent duct cells, and new endocrine cells 
are no longer generated from the epithelium. (B,C) Ptf1a expression localizes to the pro-acinar tip domain, while 
high levels of Sox9 and Hnf1b expression mark the trunk domain. (D,E) Sox9
CreER
-based lineage tracing at different 
time points of secondary transition shows a progressive restriction in lineage potency to favor duct and endocrine 
cells. (F,G) Ptf1a
CreER
-based lineage tracing at different time points of secondary transition shows a progressive 
restriction in lineage potency in the tip to favor pro-acinar cells. This figure was adapted from [13,23,30]. 
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Duct and Endocrine Lineage Development from the Trunk Domain  
It is now currently believed that the final binary fate decision to become a pancreatic duct cell 
versus a hormone-secreting endocrine cell is made within the confines of the trunk epithelial 
domain. The earliest entry points into the development of this model stem from studies 
describing the segregation of discrete transcription factor expression patterns into epithelial 
“tip” versus “trunk” domains at the end of the primary transition [14]. Initially, as described 
above, it was found that the potency of the Ptf1a/Cpa1 expressing tip domain becomes 
progressively and then completely restricted to the pro-acinar lineage by around E13.5 [14,23]. 
This dynamic process of pro-acinar segregation from the duct/endocrine pool suggested that 
the trunk domain must be responsible for the further allocation of non-acinar pancreatic 
lineages from mid-to-late gestation. The implications of this are highlighted by the idea that the 
most significant contribution to formation of newly born endocrine cells is made during the 
mid-to-late gestation period [13], after the tip and trunk domains have separated, and during 
what has been categorized as a major wave of cellular differentiation termed the pancreatic 
secondary transition (E13.5-E17.5). Thus, a number of important studies were initiated to try to 
gain a better understanding of how duct versus endocrine lineage specification is regulated in 
the specific context of the trunk domain (Fig. 1.5A). 
Two representative and functionally relevant transcription factors distinguishing tip and trunk 
domains are Ptf1a and Sox9, respectively. Early studies focusing on the expression patterns of 
these two transcription factors, among others, laid the groundwork for developing a model in 
which the trunk domain represents the embryonic tissue from which the bulk of the duct and 
endocrine lineages are derived. Concomitant with the end of the primary transition, Ptf1a and 
Sox9 expression are near completely exclusive, with the trunk being marked by Sox9+ cells that 
are devoid of Ptf1a+ cells [14,15,23] (Fig. 1.5B,C). Conditional lineage-tracing studies using a 
Sox9CreER transgenic mouse line showed that Sox9-expressing cells in the trunk were bipotent, 
and capable of giving rise to both duct and endocrine lineages throughout the secondary 
transition [15] (Fig. 1.5D,E). Further investigations found that in addition to Sox9, the trunk 
domain was selectively marked by the transcription factors Nkx6.1 [43], Hnf1b [47], and Hes1 
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[46]. Conditional lineage-tracing studies were performed using mouse lines where CreER 
recombinase was expressed under control of the regulatory elements of Hnf1b and Hes1, and 
were in essentially in complete agreement with the results obtained from studies using the 
Sox9CreER line [46,47]. Interestingly, a feature of all of these genetic lineage-tracing studies was 
that, as the secondary transition progressed into late gestational stages, the trunk epithelium 
appeared to gradually restrict its lineage potential to favor the duct lineage over the endocrine 
lineage. These results implied that there was a time-dependent depletion of endocrine lineage 
competence within the trunk-resident population (i.e. the lineage bipotency of the trunk 
domain was not equivalent at all stages), reflecting a stage-limited and transient potential to 
derive endocrine cells from within an increasingly duct-lineage-biased epithelial pool.  
The transcription factor Neurogenin3 regulates endocrine differentiation  
The genetic program that leads to the production of an endocrine cell from bipotent Sox9+ 
trunk progenitors is initiated upon expression of the basic helix-loop-helix (bHLH) transcription 
factor and endocrine lineage determinant Neurogenin3 (Neurog3). Neurog3 induces the 
downstream expression of a cascade of pro-endocrine transcription and maturation factors 
including, but not limited to, NeuroD1, Pax4, Arx, Rfx6, Nkx2.2, Myt1 and Insm1 
[48,49,50,51,52,53,54]. Genetic inactivation of Neurog3 in mice results in an almost complete 
blockade in the development of all of the cell types of the pancreatic endocrine lineage, and 
causes a severe diabetic phenotype in postnatal animals and eventual death [55]. Conversely, 
ectopic expression of Neurog3 can induce the differentiation of endocrine cells, both in the 
avian endoderm [56] and in an experimental mouse model where Neurog3 nuclear 
translocation (and thus function) is controlled via fusion to a tamoxifen-inducible estrogen 
receptor ligand-binding domain [57]. These studies have thus shown that Neurog3 is both 
necessary and sufficient for the production of pancreatic endocrine cells.  
Several studies suggest that the vast majority of Neurog3-expressing cells become post-mitotic 
as they undergo endocrine commitment [62,64,83]. Direct evidence to support this model 
comes from analyses of thymidine analog incorporation, clonal lineage tracing, and 
transcriptomic analyses of Neurog3+ populations. Neurog3 protein-positive cells that 
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incorporate BrdU during a three-hour pulse represent only a minor fraction (less than 5%) of 
the Neurog3-producing population as a whole, indicating that cells stop replicating their DNA 
shortly after Neurog3 becomes transcriptionally activated (this will be discussed in more detail 
below) [83]. Analyses of the expression of cell-cycle regulators in FACS-isolated Neurog3-
expressing populations have shown that these cells express elevated levels (relative to non-
Neurog3-expressing cells) of cell-cycle inhibitors such as Cdkn1a, Cdkn1b, Trp53, Rb1 and Rbl1, 
suggesting that cell-cycle progression is blocked as cells undergo endocrine commitment [83]. 
Evidence showing that Neurog3 binds to the regulatory regions of the Cdkn1a gene, moreover, 
suggested a direct role for Neurog3 in facilitating exit from the cell cycle. Consistent with this 
idea, exit from the cell cycle was shown to be Neurog3-dependent, because changes in the 
expression of cell-cycle regulators observed in normal Neurog3-expressing cells did not occur in 
these populations when Neurog3 protein was absent [83]. Finally, extensive and carefully 
quantified clonal analyses of the proliferation and differentiation properties of single Neurog3-
expressing cells using Mosaic Analyses with Double Markers (MADM) showed that the vast 
majority of Neurog3-expressing cells represent the unipotent precursors of single hormone-
producing endocrine cells [16]. Taken together, these collective studies suggest that Neurog3 
expression represents a triggering event in the production of an endocrine cell from within the 
pool of trunk epithelial progenitors, and that production of Neurog3 is associated with a rapid 
exit from the cell cycle upon endocrine commitment. 
Cellular mechanisms underlying endocrine lineage allocation 
While still a subject of much investigation and debate, the process whereby post-mitotic 
endocrine precursors become committed from the trunk appears to occur in association with a 
morphogenetic process of cell delamination from the epithelium [56,16,62,63,64]. The process 
of delamination is proposed to involve the Neurog3-dependent induction of an epithelial-to-
mesenchymal transition (EMT) [65]. However, in order to classify endocrine birth as proceeding 
through a true EMT (as opposed to simply and epithelial-to-epithelial delamination process) we 
still need strong evidence supporting that each process in the EMT sequence actually occurs. 
These include: 1) breaking tight-junctional linkage with cell neighbors, 2) reduction in cell-cell 
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adherence, 3) acquisition of migratory characteristics, 4) breakdown of the basal lamina upon 
epithelial exit, and 5) reformation of tight junctions between adjacent cells to seal the 
epithelium across the region representing the previous location of the departed cell [66]. 
Nevertheless, several features of the EMT process, such as loss of cell-cell adherence via the 
downregulation of E-cadherin [56], and the acquisition of migratory characteristics prior to 
epithelial exit [65], have been relatively well described. Thus, it is widely held that concomitant 
with Neurog3 activation, cells adopting the endocrine lineage physically delaminate from and 
exit the trunk epithelium. One additional model for endocrine cell birth, which is not mutually 
exclusive with a delamination or EMT-centric model, posits that endocrine cells are specified 
and committed via a process of asymmetric cell division (ACD). The common model for ACD 
depicts a process whereby there is an orthogonal-type division with respect to the plane of the 
epithelium to generate an apically localized daughter cell that retains progenitor characteristics, 
and a basally displaced daughter cell that exits the cell cycle to begin differentiation. Some 
evidence for this mechanism has indeed been described in the literature. Reporter-based 
single-cell live-imaging experiments indicate that a significant proportion of dividing trunk cells 
(approx 10% of Pdx1-reporting epithelial cells) acquire Neurog3 expression and immune-
reactivity shortly after a division event [67]. Retrospectively following the outcomes of these 
division events revealed that roughly half of all events result in the production of one Neurog3-
expressing cell and one daughter retained in the epithelium, while the other half result in the 
production of two Neurog3-expressing daughters. Thus, it is possible that endocrine cells are 
allocated through various cellular mechanisms, some of which may depend on the processes of 
cell division and/or delamination themselves. Nonetheless, a working model derived from these 
collective studies posits that a general feature of endocrine birth and commitment from the 
trunk involves the generation of one or two quiescent, delaminating endocrine precursors, 
which will then exit the epithelium to populate the forming islets of Langerhans.  
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Endocrine-cell birth as a regulated progression through distinct Neurog3-expressing states 
More recent studies suggest that endocrine-cell birth from the trunk epithelium does not occur 
via a simple Neurog3 “ON-OFF” switch. Rather, it appears that there is likely to be a carefully 
regulated and step-wise progression of cells through different “states” of Neurog3 activation on 
the way to generating a fully committed, mitotically quiescent, and delaminated hormone-
producing endocrine cell. There is experimental evidence suggesting that cell populations in the 
trunk epithelium progress from a Sox9+Neurog3OFF undifferentiated progenitor state, through 
to an initially endocrine-specified but perhaps reversible Neurog3LO state, and finally into a fully 
endocrine-committed Neurog3HI state, before finally down-regulating Neurog3 and acquiring a 
differentiated and hormone-producing status. The implication here is that the Neurog3LO state 
could represent a mitotic, stable, and endocrine-biased progenitor intermediate that 
represents a major and expandable source for the production of Neurog3HI endocrine 
committed cells. The idea that there could be a continuum of distinct, stable, and lineage-
biased progenitor states existing during the development of the pancreas is of great relevance 
to understanding the regulatory mechanisms that both specify and commit endocrine cells 
from within the trunk epithelium. We focus this introductory section on laying out three major 
lines of indirect evidence that are consistent with the existence of a Neurog3LO endocrine 
progenitor intermediate. 
There is a growing body of evidence suggesting that Neurog3 protein production does not mark 
all Neurog3-expressing cells existing within the trunk epithelium. In situ hybridization studies on 
the pattern of Neurog3 transcripts within the trunk epithelium show a much more broad 
expression pattern of Neurog3 expression when compared to directly detected Neurog3 
protein [78]. At E15.5, Neurog3 protein is detected in what has been often described as a salt-
and-pepper pattern, with the dominant state being characteristic of the nascent Neurog3HI cells 
that are undergoing delamination and commitment. Neurog3 transcripts, on the other hand, 
are much more widely expressed in ostensibly non-endocrine-committed epithelial cells that 
appear to lie definitively within the trunk epithelium. Under experimental conditions where 
Neurog3 has been genetically inactivated (i.e. Neurog3 protein is absent), and where Neurog3 
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transcriptional activity can be monitored via a Neurog3EGFP knock in allele, there is a broadening 
of low-level Neurog3 reporter expression in the trunk domain. This suggests that the signals 
that move cells into a Neurog3LO condition are localized broadly within the epithelium, and that 
in the absence of Neurog3 protein-dependent Notch inhibition for instance, the ‘default’ state 
for many, if not all, epithelial cells is to adopt a Neurog3LO condition [58,80]. Finally, preliminary 
studies in our lab have used immunolabeling and signal-amplification techniques to show that, 
in addition to the predominant Neurog3HI state, there are in fact, under normal conditions, an 
appreciable number of readily detectable Neurog3LO cells within the epithelium at mid 
gestation (unpublished observations, Matt Bechard, Wright Lab). While the quantitative overlap 
between Neurog3OFF epithelial states, Neurog3 transcriptionally active states, and Neurog3 
protein LO and HI states remain to be fully established, these observations provide evidence 
that there are likely to be a diversity of functionally and transcriptionally distinct progenitor 
states existing in the trunk epithelium.  
Recent genetic lineage tracing studies using BAC-transgenic Neurog3 Cre and CreER mouse lines 
to indelibly label cell types derived from Neurog3-expressing populations have provided 
additional evidence for a Neurog3 transcriptionally active and pre-endocrine committed state. 
In the Wright lab, we have utilized a highly sensitive BAC-transgenic Neurog3Cre line, where Cre 
recombinase is controlled by a large portion of flanking upstream (~82 kb) and downstream 
(~102 kb) cis-regulatory elements [68] to achieve indelible and high-fidelity lineage tracing 
capability. With this tool we have preliminary analyses on the dynamic lineage allocation 
behaviors of Neurog3-expressing populations during pancreas organogenesis [Matt Bechard, 
Wright Lab, unpublished data]. Briefly, using this tool we have observed that many lineage-
labeled cells are found in the pancreatic epithelium, even at late stages of development, which 
do not express detectable levels of Neurog3 protein, and do not exhibit the delaminating 
phenotype typical of cells undergoing endocrine lineage commitment. These results suggest 
that there exists an intermediate population of pre-endocrine-committed and Neurog3LO cells 
that are long-lived within the trunk domain. Moreover, by postnatal time points the vast 
majority of lineage-labeled cells are found in the differentiated islets, suggesting that the 
Neurog3LO population observed at earlier stages is only transiently maintained within the 
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epithelium, and that the overwhelming majority of these cells will eventually give rise to 
endocrine cells. 
Additional experimental evidence for the Neurog3LO endocrine-biasing model comes from 
studies where Neurog3 levels have been manipulated through the generation of a hypomorphic 
Neurog3 allele [69,70]. Reducing Neurog3 dosage results in an increase in the proportion of 
low-level Neurog3 expressing progenitors in the epithelium, and a reduction in the Neurog3HI 
endocrine committed population. There is also a reduction in the mass of the endocrine 
pancreas at postnatal time points, consistent with the notion that acquisition of a high 
threshold of Neurog3 protein is required for full commitment toward the endocrine lineage. 
Finally, lineage tracing experiments carried out in these animals showed that Neurog3LO 
progenitors were much more likely to adopt non-endocrine acinar and ductal lineages [69]. 
These results suggest that the transition from a Neurog3LO to Neurog3HI condition represents a 
distinct step in the progression through endocrine specification and commitment, and that if 
this transition is blocked, Neurog3-expressing populations can productively differentiate into 
non-endocrine lineages. While it can be argued that a genetic hypomorph for Neurog3 (this 
animal only makes ~25% of the normal amount of protein) is an artificial representation of what 
might or might not be a ‘normally’ physiological distinct cell state, the behavior of cells in this 
condition, combined with the lineage tracing and Neurog3 transcript localization studies, 
suggests that Neurog3LO cells in the trunk epithelium could represent a transient, stable, and 
functionally distinct progenitor intermediate that acts as a ‘source pool’ for the generation of 
endocrine committed cells.  
 
Notch Pathway Regulation of Cell Fate during Secondary Transition 
There is an increasing body of evidence suggesting that the Notch pathway functions during the 
secondary transition, much as it does during the primary transition, to inhibit cell 
differentiation and to maintain undifferentiated progenitors. Similar to the difficulties 
encountered in working out the exact details of the proposed-context specific roles for various 
Notch ligands and effector molecules in regulating diverse processes at earlier stages of 
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development, however, a simple model for Notch-mediated control of cell fate during the 
secondary transition has also proved to be elusive. As a result, the genetic programs regulating 
Neurog3 activation, and whether these are distinct from the mechanisms that activate Neurog3 
upregulation to high levels, remain poorly understood. This section on Notch pathway function 
during the secondary transition will focus on introducing results and conclusions from 
experimental manipulations that have been relatively simply designed and conservatively 
interpreted, shown to be reproducible, or that make specific connection(s) to regulatory 
influences that are relatively firmly established as essential in earlier stages of organogenesis. 
To date, there has been no focused cell/tissue-specific manipulation to target Notch pathway 
activity within the secondary transition bipotent duct/endocrine progenitor population. 
Perhaps some of the most convincing evidence that Notch may suppress Neurog3 induction at 
this stage comes from biochemical evidence showing that Hes1, the expression of which 
appears to be largely Notch-dependent in the trunk [79], plays an important role in repressing 
Neurog3 transcription [59]. Conditional Hes1 lineage-tracing experiments following the lineage 
potency of Hes1-expressing epithelial cells during the secondary transition window of 
pancreatogenesis indicates that epithelial cells that maintain Notch pathway activity do not 
become endocrine cells, but rather are destined to contribute to the ductal lineage [46]. Hes1-
expressing lineage-traced cells are capable of giving rise to endocrine cells and duct cells during 
the early stages of secondary transition (E12-E14.5), but their progeny become progressively 
duct-lineage-directed as development progresses (E15.5 and onward). Similar to models 
developed from studies during the primary transition, it is becoming apparent that specific 
levels of Notch pathway activity may be responsible for diversifying bipotent versus unipotent 
fates at later stages of pancreas formation. One study used titrated doses of a pharmacological 
inhibitor of Notch signal processing, DAPT, to build an argument that intermediate levels of 
Notch pathway activity cell-autonomously activate Sox9, which is in turn important for 
maintaining epithelial progenitors in an undifferentiated state [80]. Cells experiencing the 
highest levels of Notch will maintain both Hes1 and Sox9, eventually to give rise to the 
differentiated duct-cell lineage. Conversely, cells that receive the lowest dose of Notch pathway 
activity will rapidly adopt the endocrine lineage, via escape from Hes1-mediated repression of 
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Neurog3. While these studies collectively build upon the importance of Notch in diversifying 
lineage potency, or in executing binary fate decisions within an otherwise bipotent pool of  
 
Figure 1.6. Models for duct/endocrine progenitor dynamics during secondary transition. The duct and endocrine 
lineages are born from the trunk domain. Within the trunk, it is not known (A) how cells become committed to the 
endocrine lineage (Neurog3
HI
), (B) whether there are stable, mitotic and pre-endocrine committed endocrine-biased 
progenitors (Neurog3
LO
), (C) how and when cells become committed to the duct cell lineage, (D) whether cell fate is 
chosen during asymmetric division or otherwise, and (E) how Notch is deployed to regulate the balance between 
progenitor maintenance and cell fate allocation. 
epithelial progenitors, there remain major gaps in our understanding of when and how cells 
receive various Notch-pathway cues. Moreover, while numerous studies have shown important 
direct or indirect contributions of transcription factor activities such as Sox9, Hnf1b, Hnf6, 
Hnf3b, Foxa2 and Pdx1 [58,59,60,61] in regulating Neurog3, the event(s) that cause the initial 
activation of Neurog3 in a given progenitor cell remain(s) obscure, and still not definitively 
linked to the mechanism of ‘escape’ from Notch. A large contingent of researchers in this field 
are working specifically toward developing a much deeper understanding of the cell biological 
and biochemical details of how extrinsic signaling pathways such as Notch act together with 
24 
 
transcription factors, or other currently unconnected factors, to orchestrate cell-fate allocation 
during pancreas development [81] (Fig. 1.6). 
 
Integration of Epithelial Morphogenesis and Cell Fate in the Pancreas 
When I started my graduate studies in 2009, there were a multitude of open questions 
remaining with regards to what are the developmental properties of cells within the trunk 
epithelium, how do they vary between cells within the population, and how do they change 
over time? We knew, for instance, that trunk cells as a population were capable of giving rise to 
both duct and endocrine lineages, but were there separate pools of duct progenitors and 
endocrine progenitors? How might their identities and functions be defined? Is the potency of 
each epithelial cell relatively equivalent over space and time? If there is appreciable 
heterogeneity among cell states, how is this heterogeneity developed, and how do cells of 
different types become patterned with respect to one another? Is patterning even important? 
It is worth taking a moment to reflect on these questions, because they were part of the 
beginnings of my thought process into trying to find ways to dissect the developmental 
complexity of the trunk domain to better understand how it ‘works’ to generate duct and 
endocrine tissues. Interestingly, a paper was published the same year I joined the lab, which 
showed that trunk domain morphogenesis, unlike the branching morphogenesis observed for 
example in the lung [175] and salivary gland [26] (and in the current depictions of the 
developing pancreas [14]), proceeds through asynchronous branching and remodeling of an 
irregular, web-like plexus intermediate, before yielding a typical arborized ductal system [24]. 
While the processes through which an epithelial plexus might become remodeled into a 
hierarchically organized ductal system were not understood, it was clear that the major wave of 
endocrine differentiation in the pancreas overlapped with this process of epithelial 
morphogenesis in a plexus state. This was interesting to us, and it forced us to begin to think 
about how different patterns of cell differentiation and growth might be driving, or perhaps 
even be driven by, patterns of epithelial morphogenesis. As my research studies evolved over 
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time, the concept that morphogenesis and cell fate could be integrated though precise 
mechanisms, regulated at both tissue and cellular scales, were to become a central themes. 
One major unexplored territory in organ development regards if and how the cell-biological 
processes that regulate cell and tissue morphogenesis are linked to the activation of 
transcriptional determinants of cell fate. A central assumption of our “Niche Framework” model 
is that this must in fact be the case. The notion that morphogenesis and cell fate are linked in 
some fashion is supported by experimental evidence from numerous systems. For instance, a 
common phenotypic consequence of blocking cellular differentiation during organ formation, 
regardless of the type of experimental perturbation, is that tissue or organ morphology, at the 
micro and macro scale, becomes drastically altered. In the pancreas, blocking endocrine  
 
Figure 1.7. Neurog3 regulates cell fate and epithelial morphogenesis. (A,B) Neurog3
+/-
 and Neurog3
-/-
 pancreatic 
epithelium labeled with Muc1 in whole mount. In the Neurog3
-/-
, epithelia become fattened (yellow arrows) and 
branching is attenuated. (C,D) Neurog3-/+ or Neurog3-/- pancreatic explants treated with DMSO (vehicle) or DAPT 
(Notch inhibitor). (E,F) In the DAPT-treated condition, where endocrine differentiation is attenuated, epithelial 
lumens become more thin (yellow arrows). This effect of DAPT requires Neurog3. This figure was adapted from [72]. 
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differentiation by genetically ablating Neurog3, or accelerating endocrine differentiation by 
inhibiting Notch, causes opposite phenotypes with regards to epithelial morphology. In a 
Neurog3-deficient condition where there is no cell allocation toward the endocrine 
differentiation, the trunk epithelium becomes fattened (and probably ‘over-stuffed’ with cells), 
whereas in Notch-inhibited conditions in which endocrine differentiation is accelerated, the 
opposite happens - the epithelium becomes underpopulated or ‘thinner’ [72] (Fig. 1.7A-E).  
 
Figure 1.8. Concurrent alterations to cell fate and epithelial morphogenesis. (A,B) Immunodetection of Neurog3 
(newly born endocrine cells) and amylase (acinar cells) in control pancreas at E16.5, or in pancreas where HNF1b is 
deleted by Sox9
CreER
 (TAM injected at E12.5). (C,D) Immunodetection of insulin and glucagon in control or 
Sox9
CreER
;HNF1b
fl/LacZ
 pancreas at E16.5 (TAM injected at E12.5). (E,F) Muc1 and beta-catenin detection at E18.5 in 
control and Sox9
CreER
;HNF1b
fl/LacZ 
pancreas. Epithelial polarity is lost in the mutant condition, and epithelial lumens 
become dilated and cystic. (G,H) Immunodetection of Nkx6.1 (trunk marker) and Ecad in Prox1
+/-
 and Prox1
-/-
 
pancreata at E15.5. Note the increase in diameter of the epithelial lumens in the mutant. (H,K) Ptf1a (p48; acinar 
cells) and Islet1 (differentiating endocrine cells) immunodetection in Prox1
+/-
 and Prox1
-/-
 pancreata at E15.5. Note 
the increase in acinar cells and decreased endocrine cells. (I,L) Ecad detection in Prox1
+/-
 and Prox1
-/-
 pancreata at 
E15.5. Note the increase in lumen diameter and alterations to cell shape in the Prox1
-/-
. This figure was adapted 
from [74,75]. 
27 
 
Observations such as these are consistent with the idea that the progression of cells into 
differentiated states is important for shaping the morphological architecture of the tissues from 
which these cells arise. Moreover, tissue-specific inactivation of transcription factors expressed 
in the bipotent trunk domain, such as HNF6 [73], HNF1b [74], and Prox1 [75,76], result in 
malformed epithelia with concurrent defects in endocrine-lineage development (Fig. 1.8A-L). 
While these outcomes have traditionally been attributed to defects in transcriptional activation 
of Neurog3 (some of the aforementioned factors bind to and activate the Neurog3 promoter 
[74,77]), a number of them have roles in regulating epithelial morphology directly [256,257]. 
Thus, it is equally possible that mis-regulation of epithelial morphology in these mutants 
precludes, at least in part, efficient engagement of an endocrine differentiation program. In 
sum, while these phenomena show that mis-regulation of cell-fate allocation has consequences 
on epithelial morphogenesis, and possibly vice versa, they do not establish, nor rule out, that 
the two processes are mechanistically linked. Studies in the pancreas are beginning to shed 
light on an emerging paradigm that during organ formation, progenitor populations receive 
important inputs from morphogenetic determinants that are critical for mediating, or perhaps 
even initiating, cell fate determination. 
As introduced previously, the transition from the early budding and progenitor growth phase 
(from E9-12.5) into the major cellular differentiation phase (from E12.5-birth) is marked by a 
complex reorganization of cells into polarized epithelial tubes. By mid-gestation, these tubes 
are thought to represent essentially a monolayered epithelium. Studies using Ecad (to mark 
cell-cell contacts), Muc1 (marking the apical surface), and laminin or collagen-IV (components 
of the basal ECM) have described how a seemingly unorganized mass of un-polarized epithelial 
cells (representing the founding MPC of the pancreatic buds) becomes remodeled at around 
E12-E13.5 until essentially every cell within the epithelium contacts both an apical and a basal 
surface [24,26]. Cells within the polarized monolayer maintain continuous contacts via Ecad+ 
adherens junctions localized along the basolateral cell surface, and via subapical tight junctions 
as marked by ZO1. The apical domain of the epithelium is also marked, as expected for fully 
polarized cells, by the apical polarity determinants aPKC and Par3 [24,25]. The polarized 
architecture of the pancreatic epithelium is maintained, from the completion of tubulogenesis 
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and plexus formation, and into the later stages of cell differentiation, epithelial arborization, 
maturation, postnatal development, and adulthood [82].  
If and how the morphological properties of cells within the developing pancreatic epithelium 
contribute to the regulation of endocrine cell-fate allocation has not been explored during the 
secondary transition. A seminal report carried out during the primary transition, however, has 
reported on the effect of genetic ablation of the RhoGTPase Cdc42 on the allocation of 
endocrine and exocrine lineages, and established the new concept that molecular regulators of 
cell morphology do indeed affect cell fate in the developing pancreas [71]. Cdc42 is a master 
regulator of cell polarity, and Cre-recombinase-mediated inactivation in pancreatic MPC causes 
mis-regulated apicobasal polarization. This defect in cell polarity causes an inability of MPC to 
initiate and expand an apical surface, and coordinate the process to form microlumens, which 
leads to a massive deficiency in the formation of polarized epithelial tubes. Coincident with this 
defect in tubulogenesis, there is a penetrant misallocation of progenitors toward the pro-acinar 
tip-domain fate, at the expense of the bipotent trunk domain fate, and a resultant deficiency in 
producing cells of the endocrine lineage (Fig. 1.9A-F). Surprisingly, experiments where the 
pancreatic mesenchyme was denuded from cultured Cdc42-deficient epithelia showed a 
substantial degree of restoration of endocrine differentiation competence, suggesting that 
Cdc42 is not cell-autonomously required for endocrine cell-fate allocation per se, but rather 
that Cdc42 normally functions cell non-autonomously to position and orient progenitor cells 
within micro-environments that are conducive for endocrine differentiation (that is, in this case, 
away from repressive mesenchymal components) (Fig. 1.9G-N). Thus, there appears to be a 
functional relationship between a cell’s ability to incorporate into a properly polarized epithelial 
tube, and its ability to efficiently engage an endocrine differentiation program. Consistent with 
this notion, genetic interference with regulators of other morphogenetic pathways, such as 
planar cell polarity, causes reductions in the number of Neurog3-expressing cells that are born 
from the epithelium (specific effects on Neurog3HI and Neurog3LO states were not described) 
[85]. Together, these studies suggest that progenitor growth and differentiation programs do 
depend strongly upon, at least in part, the activity of regulators of tissue and cell polarity and 
morphogenesis. While the detailed mechanistic underpinnings that cause, for instance, 
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defective endocrine-lineage development in these cases remain unclear, the picture emerging 
is that insights into how endocrine progenitors and committed endocrine precursors are 
efficiently generated and maintained may be gleaned from characterizing, with increased 
spatiotemporal resolution, how cytoskeletal dynamics, cell polarity, actomyosin contractility, 
and/or the trafficking and distribution of receptors such as Notch, all are interconnected to  
 
Figure 1.9. Cell polarization and tubulogenesis mediate endocrine differentiation competence. (A-F) Genetic 
inactivation of the Rho-GTPase Cdc42 results in a failure in epithelial cell polarization and tubulogenesis, a loss of 
endocrine cells, Neurog3-expressing cells, Sox9
+
 trunk cells, and an increase in acinar differentiation (Cpa1
+
 cells). 
(A-D’) Control and Cdc42-deficient pancreata were explanted at E11.5 and cultured on filters for 7 days in the 
presence or absence of mesenchyme, and harvested and labeled with Ecad, insulin, and glucagon. (A,B) In control 
explants with mesenchyme, endocrine cells are generated in normal numbers. In Cdc42-deficeint explants with 
mesenchyme (A’,B’), endocrine cell generation is reduced. In the absence of mesenchyme (C,C’,D,D’), both control 
and Cdc42-deficeint explants readily generate large numbers of endocrine cells. This figure was adapted from [25].   
 
provide functional links between cell and tissue morphogenesis processes and cell-fate 
determination [211]. 
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Epithelial Morphogenesis during Development 
Across metazoans, epithelial morphogenesis is a fundamental component of organ formation 
and function [87,88]. Sheets of embryonic epithelial cells undergo complex and coordinated 
movements during development to create diverse multicellular structures such as tubes, 
capsules, clefted branches, ingressions or egressions, and folds. There are many types of cell 
behaviors, both individualized and collective, that lead to the formation of such structures. 
These include, but are not limited to, directed cell movements and rearrangements, cell 
delamination and extrusion, proliferation, cell contractility, differential cell adhesion, and 
programmed cell death [87,88]. Over the past few decades the molecular mechanisms driving 
cell behaviors such as these have been intensively researched and in many respects have 
become quite well understood, especially for those mechanisms that are well conserved across 
species. The purpose of this brief introductory section on epithelial morphogenesis is to delve 
deeper into specific aspects of: 1) the morphological structure and cytoarchitectural 
organization of epithelia and 2) the molecular mechanisms controlling epithelial cell and tissue 
morphogenesis. With respect to the latter, we focus this introduction on actomyosin 
contractility and RhoGTPase signaling, which are most relevant to the themes of research 
reported in this dissertation. 
Architectural properties of epithelial cells 
An epithelium is defined as ‘a laterally coherent sheet of cells with distinct apical-basal polarity’ 
[88]. The apical surface of internal epithelia, such as those observed in tubular organs, faces the 
luminal space of an epithelial tube. The basolateral domain is subdivided into a basal surface 
that contacts, and mediates adhesion to, the extracellular matrix or basement membrane, and 
a lateral domain involved in cell-cell adhesion. Epithelial cells within an epithelial sheet are 
connected by adherens junctions and tight junctions that link them together. Adherens 
junctions are composed of cadherin proteins, such as E-cadherin (Ecad), that initiate and 
maintain intercellular contacts through trans-interactions with cadherins on opposing 
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basolateral cell surfaces [89,90]. Adherens junctions also involve catenin proteins, such as  
[91,92] and  [93] and p120-catenin [94,95], which together play important roles in stabilizing 
adherens junctions and in linking them to the actin cytoskeleton [89,90]. Adherens junctions 
are localized circumferentially on the basolateral surface of epithelial cells, where they function 
in initializing and stabilizing cell-cell adhesions, regulating actin cytoskeletal dynamics, and 
mediating intracellular signaling and transcriptional regulation. Tight junctions are comprised 
primarily of claudin and occluden proteins, which are important in preventing the passage of 
membrane constituents between apical and basolateral membrane compartments, and in 
sealing the epithelium to gate the paracellular passage of ions and solutes across the apical and 
basal axis [89,96]. They are localized sub-apically (that is, just above the apical domain proper), 
and below the basolateral adherens junctions. Tight junction complexes, like adherens 
junctions, are connected to the filamentous actin (F-actin) cytoskeleton via various scaffold-like 
proteins. One of the most well studied families of such scaffold constituents represents the ZO 
(Zona Occludens) proteins. ZO-1, ZO-2 and ZO-3 are proposed to have both overlapping and 
non-redundant functions, and are found in close association with tight junction complexes and 
the juxtaposed circumferential bundles of cortical F-actin 
[89,97,98,99,100,101,102,103,104,105]. 
A core multi-protein complex component that is critical for the establishment and regulation of 
epithelial cell and tissue architecture is the F-actin cytoskeleton. The dynamic regulation of the 
F-actin cytoskeleton plays many important roles in numerous cell and tissue morphogenesis 
processes including, but not limited to, cell adhesion, cell migration, and cell division [106]. 
There are numerous actin-binding proteins that function to regulate F-actin assembly and 
organization in diverse cellular contexts. Typical configurations of the F-actin network structure 
are found in different regions of the cell, and individual F-actin based substrates are temporally 
regulated to mediate various cellular behaviors [107,108]. For each process, the F-actin 
cytoskeleton utilizes a distinct molecular composition and structure, which reflects that specific 
properties of these networks can be tuned towards mediating particular types of cell 
morphological transitions [106]. Widely documented examples include cellular protrusions 
important for directed cell migration and epithelial delamination, cortical F-actin bundles that 
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mediate the segregation of daughter cells during cytokinesis, and sub-apical bundles of F-actin 
that regulate epithelial cell shape change through processes such as apical constriction.  
Rho-ROCK-myosin regulation of epithelial cell shape  
Morphogenetic movements (such as the ones described above) in epithelia involve alterations 
in the relative sizes and shapes of apical, basolateral, and basal cell surfaces [109]. The shape 
and size of the polarized surfaces of epithelial cells are established and maintained, in large 
part, by Rho-GTPases that control the organization and dynamics of the actin cytoskeleton. The 
cell-shape changes that drive morphogenesis depend on, and can also in turn feed back on, the 
activity of Rho-GTPases. The net effect(s) of Rho-GTPase signaling in a given cell depends on a 
variety of complex and context-dependent factors, but the idea is that the relative sizes, 
shapes, and adhesive properties of the compartmentalized apical and basal domains of a cell 
can be modified to drive transient switches between relatively stable ‘states’ of epithelial cell 
morphology. In this manner, epithelial cells can be configured into columnar shapes (cells taller 
than they are wide), cuboidal shapes (cells as tall as they are wide), and squamous shapes (cells 
wider than they are tall) [89]. At the level of a multicellular tissue, localized or collective 
alterations to cell shape result in various types of tissue deformations. For instance, constriction 
of a cell’s apical domain and a concomitant expansion of the basal domain will produce wedge 
or bottle-like shapes, which can be coordinated broadly across a field of epithelial cells to effect 
tissue folding or invagination [109,110]. These types of dynamic cellular deformations are 
associated with, and proposed to be driven by, Rho-pathway mediated regulation of force-
generating actomyosin networks within the cell [109,111,112]. 
Myosin and actomyosin contractility 
Contractile forces in cells results in large part from interactions between the F-actin 
cytoskeleton and the force generating molecular motor myosin II. Myosin is a large multi-
subunit complex comprising a pair of heavy-chain motor domains, and two pairs of light chains. 
Myosin proteins oligomerize to form minifilaments in association with F-actin, and when such F-
actin filaments are oriented in an anti-parallel manner with respect to each other, the 
molecular motor activity of myosin can move them in opposite directions, generating force. 
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This process is called actomyosin contraction [112]. Actomyosin contraction at the apical 
surface of epithelial cells represents a major effector of cell-shape change, and just as the actin 
cytoskeleton itself is arranged in specific ways to influence a wide variety of cell behaviors, the 
actomyosin network can be arranged and regulated in various ways to effect specific alterations 
in cell and tissue morphology [112]. In apical constriction, for instance, contractile forces 
generated by the actin-myosin cytoskeleton are exerted on the apical circumference of the cell, 
and these forces are in turn transmitted though sites of cell-cell adhesion. In the vertebrate 
neural tube, apical constriction is associated with a contraction of circumferential ‘belts’ of 
subapical cortical actomyosin [113,114], which results in the folding of the neural epithelium 
(Fig. 1.10A-C). Here, effectors of actomyosin contractility such as Shroom3 bind to subapical F-
actin bundles, and recruit modulators of actomyosin contractility such as Rho-associated coiled-
coil kinase (ROCK), to increase circumferential tension and constrict the apical domain of cells 
within the epithelial sheet [112,115, 116,117,118,119,120]. Apical constriction is also 
associated with extrusion of apoptotic cells from epithelia, epithelial cell delamination/EMT 
[121,122,123,124,125], and wound healing [126,127], indicating that apical constriction is a 
widely utilized mechanism that molds epithelial cells and tissues in various ways (Fig. 1.10C-E). 
Actomyosin contractility is, along with many other aspects of epithelial morphogenesis potently 
influenced by regulators of cell polarity. One such regulator is the small GTPase RhoA, which 
functions as an important upstream regulator of a number of molecules in a signaling pathway 
that converges both on actomyosin contractility and actin remodeling dynamics [112,128]. For 
instance, RhoA signaling is shown in Drosophila to be required for efficient apical constriction 
[132,133], actin stress fiber formation in cultured cells [136], and contractile ring formation 
during cell division [137,138]. RhoA modulates myosin activity in large part through regulating 
its phosphorylation state [129,130]. RhoA activates ROCK, which stimulates myosin activity and 
actomyosin contractility through two mechanisms. ROCK inhibits dephosphorylation of myosin 
regulatory light chain, and also directly phosphorylates myosin regulatory light chain [131]. 
Activation of ROCK by RhoA in this manner has been shown to mediate apical constriction in 
several vertebrate and invertebrate systems [112]. Moreover, RhoA also regulates the activity 
of actin-filament nucleators such as the Diaphanous (Dia)-related formin proteins, which 
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facilitate the formation of new actin filaments [134]. It is though that a close cooperation 
between Dia and ROCK activities downstream of Rho provides for a major level of control over 
the form and function of the actin cytoskeleton and actomyosin machine. While there are many  
 
Figure 1.10. The RhoA-ROCK-Myosin pathway regulates apical constriction and cell migration. (A) Contractile 
networks involved in apical constriction are comprised of F-actin (red) and myosin (orange), and can be organized 
into subapical contractile bundles and/or a two dimensional network underlying the apical membrane cortex. (B) 
Narrowing of the apical cell surface is driven by actomyosin contractions (green arrows). Cell-cell contacts at 
adherens junctions allow actomyosin contractions to shape tissues by folding (C), cell extrusion/delamination (D), 
or intercalation (E) [112], in addition to others. (F) High levels of Rho can block cell migration by enhancing 
actomyosin contractility and stress fiber formation through ROCK. (G) Lower levels of Rho permit migration by 
promoting the activity of the formin protein mDia, leading edge protrusivity, and upregulation of Rac (which is 
normally inhibited by high Rho activity). Note that Rac feeds back to inhibit ROCK, consistent with a mutual 
antagonism between Rho and Rac activities. (H,I) ROCK limits leading edge protrusivity in migrating cells 
(depending on the cell type, white arrowheads), and is required for cell rear retraction during directional 
movements (white arrows). This figure was adapted from [112,140,151]. 
other known roles for RhoA in regulating processes such as endosome trafficking, adhesion, and 
migration [135], the power of RhoA-ROCK in stimulating, and responding to, actomyosin 
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contractility and actin filament assembly, clearly places the RhoA-ROCK-myosin pathway as a 
predominant mediator of cell-shape change. 
Rho-ROCK-myosin control of cell migration 
Cells migrate by polarizing in the direction of cell migration, extending protrusions at the 
leading edge of the cell, making adhesions to the ECM to stabilize protrusions and allow 
forward movement, and by finally dissembling adhesions and retracting the rear of the cell 
from the substrate surface [139]. Actin nucleation and polymerization drive membrane 
protrusion at the leading edge, and in association with integrin-mediated cell adhesion and 
actomyosin contractility, the cell body generates tension to pull the cell forward [140]. This 
sequence of events is controlled by a myriad of signaling molecules, but it has become 
increasingly appreciated that the Rho-GTPases Cdc42, Rac, and Rho play important roles in 
directing different and context-dependent aspects of the cell migration process [141,142]. 
Briefly, Cdc42 functions to establish and orient cell polarity through the Par6/aPKC pathway 
[143,144], Rac regulates membrane protrusion in the front of the cell by stimulating activation 
of the WAVE-Arp2/3 pathway [145], and Rho appears to be important for cell adhesion, cell 
contraction, and stress fiber formation through regulating ROCK-myosin [141]. Rho and Rac 
activities are known to antagonize one another in the cell, and the relative activities of these 
molecular regulators have been proposed to effect ‘switch-like’ transitions to drive or inhibit 
cell migration [140]. While the factors controlling upstream the activation of Rho-GTPases, and 
the molecular signaling cascades that lie downstream of Rho-GTPases, are miscellaneous and 
complex, the coordinated activities of Cdc42, Rac and Rho play a central role in cell motility, 
from neurite extension, to filopodia and lamellipodia formation, to cancer cell invasion 
[146,147]. For the purposes of this introductory section, I will focus primarily on those aspects 
of cell migration that are controlled by ROCK-myosin pathway activity, because it is most 
related to the studies that I will present in Chapter V. 
Cell motility can be determined by the balance between the relative activities of the actin-
nucleator mDia and the kinase ROCK [140]. mDia and ROCK act downstream of Rho to mediate 
remodeling of the actin cytoskeleton: mDia stimulates actin-filament nucleation and 
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polymerization, whereas ROCK activates myosin to induce cross-linking with the F-actin 
cytoskeleton, regulate actomyosin contractility, and modulate cell adhesion (Fig. 1.10E,F). ROCK 
also functions in remodeling of the actin cytoskeleton by indirectly inhibiting, through LIM 
kinases, the function of the actin-severing protein cofilin [146]. Many of ROCK’s downstream 
target substrates are proposed to be involved in cell migration, and the specific role(s) for ROCK 
depends on the relative contributions of numerous pathway activities operating within a given 
cell type or during a given cellular process. For instance, ROCK activity can influence cell 
migration by limiting membrane protrusion at the leading edge of the cell, presumably through 
a function for ROCK in inhibiting Rac pathway activity [148,149] (Fig. 1.10E-H). A negative 
modulatory role for ROCK in cell migration was indeed shown to be important during 
delamination of neural crest cells [150], cell migration during wound healing [141,151], and the 
migration of fibroblasts [152]. ROCK activity is also vital for retraction of the rear of the cell 
during migration. Studies on trans-endothelial migration in monocytes and neutrophils have 
shown that Rho-ROCK is dispensable for cell attachment, spreading and crawling, but is 
essential for rear-surface retraction [153,154]. The effect of ROCK inhibition on perturbing rear 
retraction leads to highly abnormal elongation of the cell body along the axis of migration. 
Interestingly, defective rear retraction in ROCK-inhibited cells is not the result of reduced 
actomyosin contractility, but relates to the function of ROCK in disassembling integrin-mediated 
adhesions at the cell rear [153]. Finally, studies in tumor cells have shown that different types 
of cell migration can be influenced by ROCK, in coordination with other regulators of cell 
migration such as Rac. Tumor cells in 3D matrix show two types of movement: Rac-dependent 
mesenchymal movement and Rho/Rho-kinase-dependent amoeboid movement [154]. 
Inhibition of ROCK converts amoeboid morphology to mesenchymal morphology in a Rac-
dependent manner, and silencing of Rac converts mesenchymal morphology back to an 
amoeboid state in a ROCK-dependent manner [147,154]. Together, these studies outline a 
number of typical functions for the ROCK-myosin pathway in regulating several critical aspects 
of cell migration, and highlight the notion that any effect of inhibiting or activating these 
molecules depends greatly on the cellular context. Notably, most studies on ROCK-myosin 
pathway activity have been performed in motile cells, with much less being known about how 
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these morphogenetic determinants influence, for example, cell delamination from an 
epithelium. This latter concept is a central focus of my research into the regulation of 
endocrine-cell specification and commitment. It relates directly to the delamination of nascent 
endocrine cells from the epithelium, and also to how the cell-biological processes that drive 
delamination are connected in turn to the deployment of Neurog3-dependent feedback 
mechanisms that non-autonomously regulate the growth, differentiation, and morphogenesis 
of epithelium progenitors from which new endocrine cells are born. 
 
Dissertation Overview 
If and how organ-specific progenitor populations are assembled, maintained, and regulated 
within niche environments to coordinate cell differentiation, growth, and morphogenesis 
processes during organ formation remains a largely unexplored yet central question in 
developmental biology. The challenges in addressing this question can largely be attributed to 
the fact that organ-specific progenitor populations exist, in many cases, only transiently during 
embryogenesis, and because they are regulated within extremely dynamic multicellular 
environments. Here, we use our proposed “Niche Framework” as a model to elucidate the 
biological form and mechanistic function of the niche that guides the genesis of the duct and 
endocrine pancreas from a pool of bipotent epithelial progenitors during development. These 
studies should greatly increase our understanding of how the therapeutically relevant 
hormone-secreting endocrine cells of the pancreas are formed. More importantly, however, 
insofar as any stem or progenitor cell niche, as a biological entity, represents a fundamental 
‘unit’ of development, evolution, and regeneration [12], our studies should improve our 
understanding of how large and complex organs form and how they evolve. In addition, these 
studies should provide novel insight into how we might gain control over the cell biological 
processes that direct cell fate or progenitor maintenance programs, for use toward the artificial 
manufacture of organ-specific cell types, or even multi-cell-type tissues, to study and treat 
human disease. Our overarching hypothesis is that the signals controlling progenitor 
maintenance and cell fate allocation during pancreas development are both deployed within a 
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discrete and likely highly organized epithelium, and linked with the epithelial morphogenesis 
program. 
In Chapter II, I present my parameterization of endocrine-progenitor growth and differentiation 
dynamics during the pancreatic secondary transition as a necessary step in establishing a new 
descriptive foundation for how progenitor maintenance is balanced quantitatively with 
endocrine cell differentiation. We characterize the relative distributions of Sox9 and Neurog3 
producing cell states as a function of developmental time, and perform a series of EdU pulse-
chase analyses to build a model that accounts for the developmental dynamics of the stage-
specific flux of cells from the epithelial progenitor pool into the Neurog3-positive endocrine-
committed state. We establish a new metric termed “endocrine yield”, which can be used to 
define in spatiotemporal terms the relative magnitudes of endocrine flux that are occurring 
from the progenitor epithelium at any given stage. Finally, we use acute clonal-lineage tracing 
experiments to infer the cellular mechanisms, such as ACD or direct delamination, through 
which individual progenitors give rise to the endocrine lineage.  
In Chapter III, I present how my studies led to experimental models that address the conditional 
control of progression of Sox9+ progenitor cells into the endocrine lineage, as a basis to study 
how the process of endocrine differentiation non-cell-autonomously feeds back onto the trunk 
epithelium to regulate endocrine progenitor growth, differentiation, and morphogenesis during 
pancreatogenesis. We hypothesize that the obligate transcriptional co-regulator of Notch 
signaling, RBPJ, functions to regulate the balance between progenitor-cell maintenance and 
endocrine-cell differentiation during the secondary transition. A conditional genetic system 
comprised of a Sox9CreER transgene [30] and a floxed allele for RBPJ [86] was used to test this 
hypothesis. I then discuss our observations and interpretations of the experiments, their 
limitations, and the justification behind my proposal to discontinue these investigations. I also 
present an alternative experimental model for the conditional control of endocrine 
differentiation via the ectopic expression of Neurog3, and a Neurog3BAC-CreER model designed to 
interrogate even more deeply our newly proposed Neurog3LO condition. I discuss the potential 
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utility of these tools related to both the aims of this dissertation as well as the future goals that 
have emerged.    
In Chapter IV, I address the hypothesis that endocrine-progenitor population growth, 
differentiation, and morphogenesis programs are coordinated by a discrete niche that guides 
the formation of the duct and endocrine pancreas. A three-dimensional (3D), spatiotemporally 
defined map of pancreas epithelium-remodeling patterns is developed, from which I discerned 
those characteristics of the pancreatic epithelium that are associated with its being the source 
of differentiating endocrine cells throughout secondary transition. I present the genetic and 
pharmacological interference tests that were designed to target Neurog3 and Notch, 
respectively, to lead to a model for how the formation of the duct and endocrine lineages are 
coordinated by feedback-control mechanisms operating within an ‘epithelial plexus state’ 
wherein endocrine progenitors are continually assembled  and maintained, and their 
differentiation toward the endocrine lineage is regulated. These studies are the first to identify 
and begin to functionally characterize the pancreatic plexus-state epithelium as a candidate 
endocrine-progenitor niche.  
Chapter V addresses the hypothesis that the signals controlling progenitor maintenance and 
cell fate allocation during pancreas development are deployed within a highly organized plexus 
epithelium, and are linked with the epithelial morphogenesis program of the plexus itself. We 
define the morphological and cyto-architectural properties of the plexus, and correlate changes 
in cell shape with cell-fate transitions. My findings suggest strongly that the morphogenetic 
program of the plexus instructs the earliest known step in the commitment of an endocrine cell 
from within the pancreatic epithelium. I build a model for how ROCK-nmMyoII pathway activity, 
Notch, and Neurog3 gene dosage are interconnected to link epithelial morphogenesis with cell-
fate acquisition in the plexus niche. 
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CHAPTER II 
ENDOCRINE PROGENITOR DYNAMICS DURING THE PANCREATIC SECONDARY TRANSITION 
Introduction 
Organogenesis relies on the proper spatiotemporal regulation and balance of cellular 
differentiation and replicative expansion of tissue-specific progenitors. In the developing mouse 
pancreas, numerous lineage tracing studies have shown that multipotent progenitors of the 
initial organ anlagen (E9.5-E12.5) give rise to all acinar, duct, and endocrine lineages. By E13.5, 
however, acinar potential becomes restricted to epithelial “tip” domains, while duct and 
endocrine lineages become diversified from Sox9-expressing bipotent progenitors residing in an 
epithelial “trunk” domain. While much is known about the transcription factors (such as 
Neurog3) and signaling pathways that maintain progenitors or direct cells toward different 
fates, the quantitative parameters that underlie and define a normal rate of cellular flux 
through various developmental processes, both at the tissue and cellular levels, are not well 
understood. Using gene expression pattern analyses, EdU pulse-chase, and acute mosaic 
lineage tracing, we describe and parameterize the lineage-allocation dynamics of Neurog3+ cells 
as they are born from replicating progenitors in the trunk.  
Materials and Methods 
Mice and Genotyping. Sox9CreER mice were obtained from Maike Sander (UCSD). Primers used 
for genotyping were (5’HRsFr-ccttctcttccagagacttc and 5’HRsH-ctctggtcagagatacctgg; 780 bp) or 
(5’HRseqC- gcgatggatttccgtctctggtgtag and 5’HRseqD-gggtgctggacagaaatgtgtacact; 1080 bp). 
     
Parts of this chapter have been published as Bankaitis ED, Bechard ME, and Wright CV. 2015. Feedback control of 
growth, differentiation, and morphogenesis of pancreatic endocrine progenitors in an epithelial plexus niche. 
Genes and Development 29, 2203-2216 [211]. 
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Immunodetection. Embryonic pancreas was paraformaldehyde-fixed (4%; 4oC, 4-6 hours). For 
cryosectioning, samples were sucrose-equilibrated (30%; 4oC overnight) and OCT-embedded 
(Tissue-Tek). Antibodies used include hamster anti-Muc1 (NeoMarkers, 1:1000), rabbit anti-
Sox9 (Millipore, 1:5000), goat anti-Neurog3 (Gu Lab, 1:40,000), guinea pig anti-Neurog3 (Sander 
Lab, 1:2000), guinea pig anti-Pdx1 (Wright Lab, 1:1000), rat anti-Ecad (AbCam, 1:1000). 
DBZ and EdU administration and quantification. DBZ (Cayman Chemical) was resuspended 
finely in ME4M slow-delivery vehicle (MethocellTM) using a motorized pestle, and injected I.P. 
EdU (Life Technologies) was given I.P. (10 mg/kg). EdU was detected by the Click-iT Plus EdU 
Imaging Kit (Molecular Probes). S-phase indices and percent EdU incorporation were counted 
manually. 
Mosaic lineage tracing. Pregnant dams were injected with a low dose of tamoxifen (0.03 mg) 
re-suspended in corn oil with a final injection volume of 0.1 mL. Embryonic pancreas was 
harvested 36 or 48 hours after injection, and samples were prepared for whole-mount 
immunolabeling as described [166]. Classification of different types of lineage allocation events 
were determined from regions of the pancreas where individual or paired cells were observed 
in relative isolation from other groups of cells (>30 m) and were in direct contact with one 
another. All non-classifiable differentiation events were ignored, as is the cases where cells 
were found in clustered groups with other lineage labeled cells. 
Image Acquisition. Confocal images were from a Zeiss LSM 510 META. Three-Dimensional 
reconstructions were rendered using Imaris Software. 
Quantification and statistical analyses. All sectional analyses covered approximately 30% of the 
dorsal pancreas. For endocrine-yield measurements Sox9+ and Neurog3+ cells were counted 
manually. Statistical analyses were performed using GraphPad software. 
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Results 
Patterns of Neurog3-expression vary during early stages of secondary transition 
To understand how Sox9+ progenitor cells progress through states of Neurog3 positivity during 
the process of endocrine cell birth and during various developmental stages, we analyzed the 
relative numbers and epithelial distribution patterns of Sox9+Neurog3-, Sox9+Neurog3+, and 
Sox9-Neurog3+ cell states by immunodetection. We initially targeted stages E12.5 and E14.5, as 
E12.5 represents the initial stages of secondary transition, and E14.5 is a time point 
representative of the major wave of cellular differentiation at mid-gestation. At E12.5, there 
were abundant Sox9+ cells distributed continuously throughout the epithelium. Within the 
Sox9+ population, there were numerous instances of Neurog3 co-expression. The vast majority 
of the Sox9+Neurog3+ cells expressed relatively low levels of Neurog3 protein, as compared to 
the Sox9- Neurog3HI cells undergoing delamination from the Sox9+ epithelium. Visual inspection 
of typical sections at this stage indicated that the Sox9+Neurog3- cell state was clearly the most 
abundant cell state in the epithelium. The numbers of Sox9+Neurog3+ and Sox9-Neurog3+ cells 
were fewer, but roughly equivalent with respect to one another (Fig. 2.1A-C). At E14.5, the 
Sox9+Neurog3- cell state remained the most prevalent. There was, however, an apparent shift 
in the relative numbers of Sox9+Neurog3+ and Sox9-Nuerog3+ cell states to favor of the Sox9-
Nuerog3+ cell state (Fig. 2.1D-F). Quantifications by manual cell counting confirmed a shift from 
E12.5 to E14.5 in the distribution of Sox9+ and Sox9- Neurog3-producing cell states (41.33 ± 4.93 
% Sox9+Neurog3+ at E12.5 versus 14.67 ± 4.59 % at E14.5), suggesting that Sox9+Neurog3+ cells 
are relatively abundant at early secondary transition, but become progressively eliminated from 
the epithelium as development proceeds. Consistent with this notion, the proportional 
representation of Neurog3+ cells in the Sox9+ epithelium was measurably reduced between 
E12.5 and E14.5 (10.1 ± 2.46 % Sox9+Neurog3+ at E12.5 versus 3.77 ± 1.07 % at E14.5) (Fig. 
2.1I,J). These results suggest that, as the developing pancreas enters the major wave of 
differentiation during secondary transition, fewer Neurog3+ cells are found in the Sox9+ 
epithelium (Fig. 2.1K). 
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Figure 2.1. Dynamic patterns of Neurog3 expression in the trunk domain. (A-F) Split channels from confocal images 
of immunodetection of Neurog3 protein in Sox9
+
 trunk epithelial cells at E12.5 and E14.5.Yellow arrowheads 
indicate Sox9
+
Neurog3
+
 cells, green arrowheads indicate Sox9
-
Neurog3
+
 cells (G,H) Quantification of the total 
Neurog3
+
 population that is also Sox9
+
 (41.33 ± 4.93 %; N = 1,034; n = 3 at E12.5, 14.67 ± 4.59 %; N = 5,101; n = 3 at 
E14.5). (I,J) Quantification of the total Sox9
+
 population that is Neurog3
+
 (10.1 ± 2.46 %; N + 2,400; n = 3 at E12.5; 
3.77 ± 1.07 %; N = 19,057; n = 3 at E14.5). (K) Graphical representation of the proportional distribution of 
Sox9
+
Neurog3
- 
(green), Sox9
+
Neurog3
+ 
(yellow), and Sox9
-
Neurog3
+
 (red) cells states at E12.5 and E14.5, as 
calculated from G-J, when all cell states are summed. Scale bars are 40 m. Error is S.E.M.  
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Cells producing low levels of Neurog3 in the Sox9+ epithelium replicate  
To understand whether or not there could be functionally relevant distinctions between 
Sox9+Neurog3-, Sox9+Neurog3+, and Sox9+Neurog3- cell states, we analyzed and compared 
replication behaviors in each state using thymidine analog incorporation (EdU) and phospho-
histone H3 (pHH3) detection. Timed wild-type matings were set up, and pregnant dams bearing 
E12.5 or E14.5 embryos were pulse injected with EdU, and sacked after one hour. Embryos 
were immediately harvested, the pancreata isolated, fixed, sectioned, and labeled for Sox9, 
Neurog3, and EdU. Analysis of confocal section from these samples showed frequent EdU 
incorporation in the Sox9+ epithelium (Fig. 2.2A).  Quantification of the one-hour EdU 
incorporation index in the total Sox9+ populations at each stage indicated that Sox9+ epithelial 
cells are highly replicative at E12.5 (29.3 ± 1.03 %), and at E14.5, although the EdU 
incorporation index was significantly reduced at E14.5 (22 ± 2.7 %) (Fig. 2.2B). Analyses of the 
EdU incorporation index in Sox9+Neurog3+ cells showed a reduction in the number of cells 
incorporating EdU relative to the Sox9+Neurog3- state at each stage (18 ± 0.0, n =1 at E12.5; 7.9 
± 2.5 % at E14.5) (Fig. 2.2C), suggesting that Sox9+Neurog3+ cells can synthesize DNA, but do so 
less frequently than Sox9+Neurog3- cells. By E14.5, out of all Neurog3+ observed only 1.63 ± 
0.45 % exhibit EdU positivity, indicating that only a small fraction of all cells producing Neurog3 
replicate DNA. Quantification of the distribution of EdU positive cells as a function of all 
Neurog3+ cells exhibiting EdU positivity showed that the vast majority (85.3 ± 1.37 %) of 
Neurog3+ cells replicating DNA are expressing Sox9 (Fig. 2.2D).  These patterns of EdU 
incorporation, which reflect the relative mitotic behaviors between Sox9 and Neurog3+ cell 
states, were confirmed by co-labeling analyses with the mitosis marker pHH3. At E12.5 and 
14.5, we could readily detect, albeit relatively rarely as compared to the Neurog3- epithelial 
populations, instances where Neurog3+ cells were co-labeled with pHH3. These cells were 
consistently closely apposed to the Muc1+ lumen surface, and expressed the epithelial marker 
Ecad, confirming their localization within the epithelium proper (Fig. 2.2E-F, Matt Bechard, 
Wright Lab). Similar to the replication patterns shown by EdU, the numbers of Neurog3+ cells 
positive for pHH3 were reduced from E12.5 to E14.5. Consistent with the notion that it is 
predominantly the Sox9+Neurog3+ population that exhibits proliferative behavior, there was an  
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Figure 2.2. Neurog3
+
Sox9
+
 epithelial populations express low levels of Neurog3 and exhibit proliferative behavior. 
(A) Immunodetection of Sox9, Neurog3, and EdU at 100x magnification (0.6 m optical slice) at E14.5 after 1 hour 
of EdU incorporation. Insets show split channels for a typical EdU
+
Sox9
+
Neurog3
+
 cell state. (B) One hour S-phase 
index in the total Sox9
+
 population at E12.5 and E14.5. (C) One hour S-phase index in the Sox9
+
Neurog3
+
 population 
at E12.5 and E14.5. (D) Proportion of Neurog3
+
EdU
+
 cells that are Sox9
+
 at E14.5.  (E,F) Immunodetection of Muc1, 
Neurog3, and pHH3 at E12.5 and E14.5. Insets show split channels with pHH3 removed. (G,H) Immunodetection of 
ECad, Neurog3, and pHH3 at E12.5 and E14.5. (I)Quantification of pHH3 positivity in total Neurog3
LO
 versus 
Neurog3
HI
 populations. (J) Analysis of mean Neurog3 fluorescence intensities in Neurog3
+
pHH3
+
Muc1
+
 versus 
Neurog3
+
pHH3
-
Muc1
-
 populations. Scale bars are 10 m. Error bars are S.E.M, (*) P=0.0010, (**) P=0.0175.  
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8-fold difference between pHH3-positivity in the epithelium-resident (defined by Muc1 
positivity) Neurog3LO population, and the Neurog3HI population that is undergoing epithelial 
delamination (Fig. 2.2I-J, Matt Bechard, Wright Lab). These results are consistent with previous 
work showing that Neurog3+ cells represent a largely post-mitotic and endocrine committed 
population of cells. However, these results also indicate a previously unappreciated mitotic 
potential in the Sox9+Neurog3LO condition, which is most readily apparent at early stages of 
secondary transition. 
These preliminary analyses on the expression patterns and mitotic properties of the 
Sox9+Neurog3-, Sox9+Neurog3+, and Sox9-Neurog3+ led us to conclude that there are likely to be 
a diversity of cell states existing within the trunk domain during secondary transition. 
Moreover, these cell states appear to have different replicative properties. We provided novel 
and direct evidence that cells expressing low levels of Neurog3 in the Sox9+ epithelium can 
replicate their DNA under normal developmental conditions. We also provided evidence that 
these cycling Neurog3+ cells are enriched at early stages of secondary transition, suggesting 
that a staging period of endocrine-biased progenitor amplification might presage the major 
lineage commitment stages observed later in gestation. While the behaviors observed within 
the Sox9+Neurog3+ cell state were highly suggestive of a mitotic, possibly stable, and endocrine-
biased progenitor intermediate, due to the relatively rare nature of these cells, especially as 
secondary transition progressed, we concluded that new tools and approaches were needed to 
study this prospectively novel progenitor population. Studies in this direction were carried 
forward in detail by Dr. Matt Bechard in the lab. The subsequent analyses of endocrine 
progenitor dynamics presented here will now shift focus toward understanding the dynamics of 
the endocrine commitment step in endocrine birth during the major mid-gestational wave of 
differentiation, and how endocrine commitment is balanced with growth and maintenance of 
the Sox9+ progenitor pool during secondary transition. 
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In vivo endocrine-progenitor dynamics and establishment of the Neurog3 to Sox9 ratio 
In order to quantify and parameterize the balance between progenitor maintenance and 
endocrine differentiation during secondary transition, we devised a method, based on the ratio 
of [differentiating Neurog3+ cells]:[Sox9+ epithelial cells], to quantify the relative flux from the 
Sox9+ trunk towards the Neurog3+ endocrine lineage. Sox9 expression is lost upon upregulation 
of Neurog3 [30,31]. The transient upregulation of Neurog3, in turn, indicates commitment to a  
 
Figure 2.3. The ratio of Neurog3
+
 to Sox9
+
 cells reflects the balance between endocrine differentiation and 
progenitor growth. (A) Lineage diagram showing the progression, from replicating Sox9
+
 progenitor status, through 
sequential Neurog3
+
 states during endocrine-lineage commitment.  Neurog3 and Sox9 co-expression in the 
epithelium (Sox9
+
Neurog3
+
) defines the initial Neurog3
+ 
state, followed by high levels of Neurog3 during 
delamination (Sox9
-
Neurog3
HI
), and finally Neurog3 down-regulation (Sox9
-
Neurog3
LO
) in committed endocrine 
cells. (B-D) Derivation of endocrine yield, a quantitative descriptor of endocrine-lineage flux from the epithelium, 
based on a measured ratio of Neurog3
+
 and Sox9
+
 cell states.  (B) Theoretical segment of the trunk-epithelium with 
a representative distribution of Sox9
+
 and Neurog3
+ 
cell states.  (C) The Neurog3:Sox9 ratio observed at a given 
sampling time is determined by the temporal relationship between the Sox9
+
 cell-cycle period (growth parameter) 
and the duration of the Neurog3-positive period of endocrine commitment (differentiation parameter). (D) Provided 
comparable time-frames for these two parameters, endocrine yield can be determined by converting the 
Neurog3:Sox9 ratio into a fractional representation reflecting the number of cells maintaining replicative  Sox9
+
 cell 
status, versus  differentiating Neurog3
+
 status, in a defined epithelial segment at a given time. This figure was 
adapted from [211]. 
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post-mitotic endocrine-precursor state [16,83] (Fig. 2.3A). The  Neurog3:Sox9 observed at a 
given time, therefore, is largely determined by the temporal relationship between 1) the 
average cell-cycle period of the Sox9+ population (epithelial growth/maintenance), and 2) the 
average duration of the Neurog3+ period of endocrine commitment (differentiation) (Fig. 
2.3B,C). Provided the time frames for these parameters are comparable, the Neurog3:Sox9 
ratio reflects the magnitude of endocrine differentiation (endocrine flux) from the trunk. To 
validate the Neurog3:Sox9 ratio, we adapted EdU pulse-chase methods [155] to measure and 
relate progenitor-replication and endocrine-differentiation parameters in vivo (Fig. 2.3D). 
Dividing Sox9+ populations progress continuously through an estimated 12-hour cell-cycle period 
When Sox9+ cells enter mitosis, we invariably observe sub-cellular segregation of Sox9 
immunoreactivity away from condensed, DAPI+ DNA. These Sox9+ mitotic figures (MF) are EdU+ 
in cells that have recently undergone S-phase (Fig. 2.4A-C). To quantify the average cell-cycle 
period, we timed the appearance and disappearance of pulse-administered EdU within the 
DAPI+ DNA of Sox9+ progenitors as they passed though rounds of mitosis (Fig. 2.4G) [156]. 
Because EdU bioavailability after single-pulse administration is short (distribution half-life 1.4 ± 
1.7 min., elimination half-life 24 ± 2.9 min. at 100 mg/kg, [157]), and because the MF state 
represents a short, transient event during the cell-cycle, this method estimates cell-cycle 
periods at a population level.   
In the Sox9+ epithelium, S-phase indices determined after one-hour EdU-pulse are similar at 
E14.5, E16.5, and E18.5 (22 ± 2.7%, 16 ± 3.2%, and 16 ± 1.8%, respectively) (Fig. 2.4D-F). We 
chose stage E14.5 for a 24-hour EdU pulse-chase analysis of the Sox9+ cell-cycle period.  All 
Sox9+ MF were EdU- one hour after EdU pulse, (Fig. 2.4H), indicating that cells incorporating 
EdU at S-phase had not yet entered M-phase. At 2 hours, the percentage of Sox9+EdU+ MF 
remained unchanged, as did the S-phase index in the Sox9+ population, consistent with a ≤ 1 
hour bioavailability of EdU under these conditions. Between 2-3 hours after EdU pulse, 
essentially all of the detected Sox9+ MF became EdU+ (75.3 ± 2.7% at 2 hrs, 98.3 ± 2.5% at 3 
hrs), consistent with an asynchronously cycling Sox9+ population incorporating EdU at different 
periods along the duration of S-phase, then proceeding over time into mitosis. EdU saturation 
49 
 
in the Sox9+ MF was maintained for approximately 5 hours, before decreasing essentially to 0% 
between the 8-13 hour period (6.3 ± 2.5% at 8 hrs, 0 ± 0% at 12 hrs, 1.7 ± 2.6% at 13 hrs), 
consistent with the EdU+Sox9+ population completing M-phase of the cell cycle. Subsequent 
time points (13-15 hrs) showed rapid and saturating re-entry of EdU+ DNA in Sox9+ MF. After 
this population passed through mitosis (indicated by a second reduction in EdU-positivity in 
Sox9+ MF), a third M-phase was detected at 24 hours. At late time points, EdU saturation of the 
Sox9+ MF population was shorter in duration, reflecting an expected DNA replication-
dependent dilution of EdU-signal. These results demonstrate that EdU pulse-chase reproducibly 
detects a labeled portion of the Sox9+ population moving through three consecutive and largely 
coherent cell-cycle periods with average ~11.3 ± 0.68 hr time intervals.  
Endocrine-committing populations take an average of 12 hours to move through the Neurog3+ 
state 
To determine the average duration of the Neurog3+ period of endocrine commitment, we used 
EdU pulse-chase to monitor EdU+ DNA, from initial incorporation in the replicating Neurog3–
Sox9+ progenitors, through marker-defined, chronological stages of endocrine commitment 
(Fig. 2.5A-A’’) [56]. These include the initial trunk-resident Sox9+Neurog3+ state, the post-
delamination Sox9–Neurog3HI state, and the late Sox9–Neurog3LO state [30,31,32]. The baseline 
EdU+ index in all Neurog3+ states at one hour EdU pulse was ~1%, consistent with their largely 
post-mitotic status. At two hours EdU pulse, the percentage of Sox9+Neurog3+EdU+ cells 
remained unchanged (Fig. 2.5F), indicating that Sox9+Neurog3– cells incorporating EdU at S-
phase had not yet progressed into the initial Sox9+Neurog3+ state. At three hours we observed 
an accumulation of EdU+ DNA in the Sox9+Neurog3+ population. At 6 hours, the EdU+ index in 
Sox9+Neurog3+ cells reached 22 ± 2.7%; as expected, because this quantity reflects the baseline 
EdU+ index in Neurog3–Sox9+ progenitors from which Neurog3+ cells arise. Similar accumulation 
of EdU in the Sox9–Neurog3HI state reached 22% at 10 hours, followed by the late Sox9–
Neurog3LO state at 15 hrs (Fig. 2.5B,C). Finally, at 17 hours, EdU+ DNA was detected in 
Pdx1HINeurog3– cells, which represent a state (likely -cell, the principle cell type produced at 
this stage) arising after downregulation of Neurog3 [52,55] (Fig. 2.5D,E; Fig. 2.6A-F). By 
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measuring the time difference (t) between the curves demarcating early and late Neurog3+ 
state (between Sox9+Neurog3+ and Sox9–Neurog3LO), bounded within the range defining the 
minimum and maximum baselines for EdU-incorporation in the Neurog3–Sox9+ and  
 
Figure 2.4. EdU pulse-chase analysis measures average cell-cycle period in Sox9
+
 cells.  (A) Individual Sox9
+
EdU
+
 
cells captured before and during mitosis (left to right; Sox9
+
 cell not in mitosis, mitotic figures (MF) in prophase, 
metaphase, anaphase, and cytokinesis). Scale bar 10 m. (B,C) MF observed in representative 20x field at E14.5, 3 
hours post-EdU injection.  Sox9
+
EdU
+
 MF (yellow arrowheads), Sox9
–
EdU
+
 MF (cyan arrowheads), MF after DNA 
segregation into daughters (doublet arrowheads). Scale bars 50 m. (D-F) One hour S-phase indices are similar 
from E14.5-E18.5. Scale bar 50 m. (G) Diagram of EdU pulse-chase in replicating Sox9
+
 populations. Sox9
+
 cells 
undergoing S-phase are labeled by EdU. EdU
+
Sox9
+
 populations (white) undergo and complete mitosis (t = 5 hrs), 
before undergoing subsequent round of mitosis (t = 12-15 hrs). Rounds of mitosis can be tracked by monitoring 
51 
 
waves of EdU-positivity in the Sox9
+
 MF states (green and white bar over time). t’s are determined from intervals 
between waves of EdU+ MF.  (H) 24 hour EdU pulse-chase analysis of cell-cycle period in Sox9
+
 populations, with 
t’s represented in dashed light red line. (I) Calculation of avg. t from pulse-chase measurements in H.  Error bars 
are S.E.M. This figure was adapted from [211]. 
 
Figure 2.5. EdU pulse-chase measures duration of the Nuerog3
+
 period of endocrine commitment. (A-A’’) Pulsed-
EdU is incorporated in Sox9
+
 cells at S-phase, and chased (EdU
+
 DNA in white) through marker-defined stages of 
Neurog3-positivity. (B,C) EdU captured in cells of various Neurog3
+
 states. Early Sox9
+
Neurog3
+
 cells (yellow 
arrowheads), Sox9
–
Neurog3
HI
 cells (red arrowheads), late Sox9
–
Neurog3
LO
 cells (white arrowheads). (D,E) EdU in 
Neurog3
–
Pdx1
HI
 cells (blue arrowheads). (F) Time-course for EdU pulse-chase analysis of the Neurog3
+
 period. 
Graph indicates percentage of EdU
+
 cells in Sox9
+
Neurog3
+
 (yellow line), Sox9
–
Neurog3
HI
 (red line), or Sox9
–
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Neurog3
LO
 (orange line) states at time points indicated. Blue dashed line shows one-hour EdU-incorporation 
baseline for Sox9
+
Neurog3
–
 cells (22 ± 2.7%). Black dashed line, one-hour EdU-incorporation baseline for 
Sox9
+
Neurog3
+
 cells (8.5 ± 2.8%).  Blue shading with arrows indicates the period when EdU
+
 DNA becomes 
increasingly observed Neurog3
–
Pdx1
HI
 populations (indicating end of Neurog3
+
 period). Grey shaded area, the 
domain and range of data points used to estimate the Neurog3
+
 period. (G) Calculation of t (brown dashed lines in 
F) from the lines demarcating Sox9
+
Neurog3
+
 and Sox9
–
Neurog3
LO
 cell states. Error bars, standard deviations (N=3 
pancreata). (H-H’’) Derivation of endocrine yield as a quantitative measure of the relative magnitude of endocrine 
differentiation from the trunk domain. This figure was adapted from [211]. 
Sox9+Neurog3LO cell states (Fig. 2.5F, grey shaded area, Sox9+Neurog3+ ≤ y ≥ Neurog3–Sox9+), 
these data indicate an  average duration of~12.3 +/- 1.03 hrs (Fig. 2.5G) for the Neurog3+ 
period of endocrine commitment (Fig. 2.7).   
These analyses indicate that the Sox9+ cell-cycle period and the duration of the Neurog3+ period 
of endocrine commitment are similar (11.3 ± 0.68 hrs and 12.3 +/- 1.03 hrs, respectively). 
Therefore, the Neurog3:Sox9 ratio estimates quantitatively the relative magnitude of endocrine 
differentiation occurring from the trunk at a given sampling time. For simplicity, we convert 
Neurog3:Sox9 hereafter to the fractional term “endocrine yield” (given as total Neurog3+ 
cells/total Sox9+ cells) (Fig. 2.5H-H’’). 
 
Figure 2.6. Neuorg3 is down-regulated before acquisition of Pdx1
HI
 status.  (A-F) Immuno-detection of Neurog3 and 
Pdx1 in cryosections at indicated stages.  The vast majority of Neurog3
+
 cells co-express low levels of Pdx1 (white 
arrowheads).  Low levels of Pdx1 are also observed in the Neurog3
-
 epithelium (yellow arrowheads in C,F). Pdx1
HI
 
cells do not co-express Neurog3 (blue arrowheads).  Scale bars are 20 m. This figure was adapted from [211]. 
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Figure 2.7. Absolute numbers of Sox9
+
 mitotic figures and Neurog3
+
 cell states evaluated during EdU pulse-chase 
time-course analyses. “n” indicates the number of pancreata sampled for each time point. This figure was adapted 
from [211]. 
Endocrine yield is robust throughout the secondary transition 
Previous measurements from whole pancreas mRNA, or from limited quantifications of 
Neurog3+ cell numbers, suggest that endocrine birth peaks around E14.5-E15.5, and reduces 
thereafter [55,78,158]. However, these measurements do not take into account the direct 
relationship between cells undergoing endocrine-lineage commitment (Neurog3+) versus 
maintenance and growth as Sox9+ progenitors. To address this, we quantified endocrine yield in 
sections representing ~33% of the dorsal pancreas, from E14.5-18.5 stages, as a bulk measure 
of endocrine differentiation dynamics. We detected essentially a constant endocrine yield 
throughout E14.5-17.5 stages; this trend reversed, relatively sharply, only at E18.5 (Fig. 2.8A-I). 
At all time points, we detected no significant change in the relative number of early 
(Neurog3+Sox9+) versus late (Neurog3+Sox9–) endocrine committing cell-states, indicating that 
new endocrine cells are being generated at all stages (Fig. 2.8J). These results show that Sox9+ 
trunk populations continuously allocate a large fraction of their progeny toward the endocrine 
lineage over essentially the entire mid-to-late gestational period. 
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Figure 2.8. Endocrine yield is robust at all stages of the secondary transition. (A-H) Representative images (E14-
15.5) of Sox9
+
 and Neurog3
+
 populations at stages indicated.  Later stage (E16-17.5) images focus on epithelium 
where Neurog3
+
 cells are being born in large numbers. Scale bars are 50 m. (I) Bulk endocrine yield determined by 
sectional analysis of secondary transition stages. 33% of n = 3 dorsal pancreas analyzed at each stage. Error bars 
are S.E.M, (*) p=0.1161, (**) p=0.0249. Student’s t-test. (J) Distribution of early (Sox9
+
Neurog3
LO
) and late (Sox9
-
Neurog3
+
) cell states among all Neurog3
+
 cells at indicated stages.  Error bars are S.E.M for n = 3 pancreata at each 
stage, 30% of total pancreas analyzed. No statistical difference was detected at any stage (p = 0.5912, one-way 
Anova). This figure was adapted from [211]. 
 
Evidence for asymmetric and terminal differentiation from individual trunk progenitors in vivo 
Next, we wanted to understand how endocrine lineage allocation and progenitor maintenance 
might be regulated at the level of individual differentiation events. Our EdU-pulse chase data 
suggested that acquisition of the Neurog3+ state occurs shortly (2-4 hrs) after EdU 
incorporation in Sox9+ progenitors, suggesting the endocrine commitment occurs in close 
association with cell division. One interesting observation that we made was that, at 6 and 10 
hour after EdU pulse-chase, we frequently observed EdU+Sox9+Neurog3+ and EdU+Sox9-
Neurog3+ cells, respectively, differentiating as Neurog3+ neighboring cell-pairs. This suggested 
that one cellular mechanism for endocrine lineage allocation is to send both daughters, via 
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symmetric terminal differentiation, into the endocrine lineage after division (Fig. 2.9A-F). 
Consistent with this notion, we observed that the peak representation of EdU in the 
Sox9+Neurog3+ state at 10 hr, and the Sox9-Neurog3+ state at 17 hr, post pulse-chase 
approached double the baseline incorporation index observed in the Sox9+Neurog3- progenitor 
population from which these cells arise (40% for Sox9+Neurog3+ at 6 hours, and 35% for Sox9-
Neurog3+ at 10 hours versus 22% of Sox9+Neurog3- progenitors at 1 hour; Fig. 2.9G).  This 
quantitative relationship (% EdU in Neurog3+ populations is ~2x > % baseline EdU in Sox9+ 
progenitors) provides additional evidence that a prevalent lineage allocation behavior for Sox9+ 
progenitor cells is to generate more than one Neurog3+ daughter cell after division.   
We next utilized an independent mosaic lineage tracing system to trace, in acute time frames, 
individual Sox9+ progenitors as they allocate Neurog3+ progeny. Using this method, we could 
provide evidence that neighboring pairs of Neurog3+ cells were indeed being derived from 
symmetric, terminal lineage allocation from a common Sox9+ trunk progenitor. We crossed 
Rosa26.RYFP mice [159] with mice bearing a Sox9CreER(T2) BAC-transgene [15], administered low 
doses of Tamoxifen (0.03 mg) to pregnant dams at E12.5 or E14.5, and harvested 
Sox9CreER(T2);Rosa26RYFP/+ embryos 36-48 hours later. Samples were immuno-labeled for Sox9, 
Neurog3 and YFP, and confocal Z-stack volumes were acquired in regions of highly mosaic 
labeling patterns (Fig. 2.9H-I). Despite significant variations in the labeling frequency within and 
between samples, we observed evidence for three prevalent behaviors in YFP-labeled cells.  
The majority of YFP+ cells were maintained in the Sox9+ epithelium as dividing, Neurog3- 
populations (not shown). We also observed frequent Neurog3+YFP+ cells that were 
differentiating in isolation from other YFP+ cells, suggesting that Sox9+ cells can give rise to 
Neurog3-expressing progeny without undergoing a recent division event. We also frequently 
observed Neurog3+YFP+ cells differentiating next to individual Neurog3-YFP+ cells, suggesting 
that a cell had divided, and only one of the daughter cells had turned on Neurog3. Finally, we 
also observed frequent YFP+Neurog3+ cells differentiating as neighboring cell pairs. Analysis of 
the percentage of total Neurog3+YFP+ cells differentiating as neighboring cell-pairs suggests that 
a substantial portion (~60%, N=26 at E14.5, N = 157 at E16.5) of endocrine cells are allocated 
through symmetric terminal differentiation, while the remainder is allocated via direct  
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Figure 2.9. Acute mosaic lineage tracing confirms prevalent asymmetric and terminal differentiation behavior in 
replicating Neurog3
+
 populations. (A-F) Detection of paired EdU
+
Neurog3
+
 progeny during EdU pulse-chase time-
course. (G) Quantification of the peak EdU-labeling index attained in the Sox9
+
Neurog3
+
 and Sox9
-
Neurog3
+
 cell 
states during EdU pulse-chase time-course. Green dashed line indicates the theoretical peak EdU-labeling index 
expected for an “isolated and direct terminal differentiation” model. Blue dashed line indicates the theoretical peak 
EdU-labeling index expected for a “paired terminal differentiation” model. (H) Genetic lineage tracing system and 
tamoxifen administration strategy for acute analysis of “isolated” and “paired” terminal differentiation of Neurog3
+
 
cells. (I) Diagrammatic representation of possible lineage tracing outcomes supporting direct terminal 
differentiation, asymmetric terminal differentiation (ACD), and paired terminal differentiation models of endocrine 
cell birth. (J-O) Typical acute mosaic lineage labeling patterns discerned in 3D volumes of pancreatic epithelium 
labeled with Neurog3. YFP, and Sox9 (Sox9 not shown).  (P) Quantification of the incidence of isolated and paired 
differentiation events at time points representative of the secondary transition (E14.5 and E16.5, respectively).  
57 
 
differentiation or asymmetric cell division. While there are a number of important caveats to 
these interpretations (namely, we do not know exactly when in reference to a cell division 
event a given cell became reporter+), our collective observations suggest that while the 
individual lineage allocation behaviors of Sox9+ trunk progenitors appear to vary, two prevalent 
modes of endocrine lineage allocation occur during endocrine cell birth. These include a 
terminal, symmetric differentiation of both daughter cells, and asymmetric allocation of only 
one daughter cell, toward the Neurog3+ state, in close association with a cell division event.   
 
Discussion 
The genetic regulation of endocrine differentiation by the transcription factor Neurog3 and the 
signaling mechanisms (such as Notch) that balance differentiation with pancreatic progenitor 
maintenance have long been established. To date, however, there is little to know 
understanding of the physiological parameters that underlie the regulated progression of 
pancreatic progenitors into the endocrine lineage during the secondary transition. As a result, 
there are major gaps in our understanding of the diversity of possibly functionally distinct 
progenitor states existing in the epithelium, how cell-type heterogeneity and organization 
develop over time, and how in quantitative terms the flux toward differentiated lineages is 
balanced with an appropriate growth of the pancreatic progenitor pool. We describe a novel 
replicating cell state that expresses low levels of the endocrine lineage determinant Neurog3, 
that is enriched during early stages (E12.5) of trunk domain formation, and that represents a 
candidate endocrine-biased and replicating progenitor pool. Subsequently (E14.5 and after), 
endocrine lineage commitment is continually robust and surprisingly long-lived in the trunk, 
with an estimated one-quarter to one-third fraction of progenitors being allocated to the 
endocrine lineage (Neurog3HI) every twelve hours. This endocrine lineage flux is balanced with 
an estimated 12-13 hour cell cycle in the Sox9+ cells that remain behind in the epithelium. 
Finally, we provide evidence that individual Sox9+ progenitors grow and differentiate through 
various cellular mechanisms; these include symmetric renewing divisions, asymmetric divisions, 
and symmetric terminal differentiation behaviors. These findings begin to parameterize the  
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Figure 2.10. Model for in vivo endocrine progenitor dynamics during the pancreatic secondary transition. (A) 
Lineage diagram on population averages of temporal parameters for progenitor replication and endocrine lineage 
allocation. Red line indicates the period of time between a progenitor cell’s last division event and activation of 
Neurog3. This period appears to be short (2-6 hrs) in the majority of cells traced in our analyses. However, the 
appreciable mitotic index in Neurog3
LO
 cells (especially at E12.5) is suggestive of an inverse relationship between 
cell cycle rate and likelihood for Neurog3 activation. (B) Model for endocrine progenitor dynamics as a function of 
time. Various cell states analyzed and quantified are shown. Separate time-frames are indicated by black line and 
labeled accordingly. Each time frame is an independent “snapshot” of the prevalent progenitor behaviors 
representing prevalent progenitor behaviors occurring over a roughly ~12 hr time-frame. 
59 
 
dynamic flux of endocrine cells from the trunk epithelium during the major wave of cellular 
differentiation in the pancreas (Fig. 2.10). 
Our observations that Neurog3+ cells in the Sox9+ epithelium incorporate thymidine analogues 
at S-phase, and exhibit mitotic behavior as indicated pHH3 co-localization, puts forth several 
possibilities with respect to how the process of endocrine lineage allocation may progress 
during development. The observation that at E12.5 nearly half of the Neurog3+ population is 
found in the Sox9+ epithelium in a Neurog3LO expressing state, suggests that at early stages of 
secondary transition, there may be maintained within the epithelium a replicating and “pre-
endocrine-committed” Neurog3-expressing cell state. This idea is consistent with lineage 
tracing experiments utilizing a Nueorg3Cre BAC transgene, which showed that a small but 
significant number of Nuerog3-expressing can adopt non-endocrine lineages during normal 
organogenesis [68]. Interestingly, this plasticity in the Neurog3-expressing lineage depends 
greatly on a cell’s ability to upregulate Neurog3 to high levels [69], suggesting that there may 
be intrinsic or extrinsic mechanisms that regulate the progression of cells through OFF-LO-HI 
states of Neurog3 expression. The notion that the Neurog3LO state maintains replicative 
potential suggests that they may represent a mitotic progenitor state that is amplifying an 
endocrine biased progenitor pool during early stages of pancreas formation. It remains possible 
that the analyses presented here, which focus on detection of Neurog3 protein in snapshot 
time frames, might in fact under-represent the size of this proposed endocrine-biased 
progenitor population. For instance, limitations in our ability to detect very low amounts of 
protein by immunodetection, or the idea that Neurog3 protein levels may oscillate in this pre-
committed condition, might be addressed with the use of more sensitive lineage tracing tools 
and transciptional reporter alleles. Indeed, oscillations in Notch pathway effectors such as Hes7 
[160] and Hes1 [161] are known to be important for regulating differentiation and progenitor 
maintenance in a number of biological systems, and in many respects act through repression of 
differentiation factors such a Neurogenin [162]. 
Previous analyses on the dynamics of endocrine lineage allocation during secondary transition 
have suggested that there exists a definitive peak in endocrine differentiation around E14.5-
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E15.5 [55,78,158]. The analyses that have been performed, however, were not rigorously 
quantified, or have not been normalized in a way that allows for specific conclusions to be 
made as to when the highest absolute numbers of cells are being born, or when the highest 
period of flux from the epithelial progenitor pool occurs. We have established and validated a 
simple metric that estimates the proportion of epithelial progenitors adopting the endocrine 
committed state at a given sampling time. This metric, the Neurog3-to-Sox9 ratio, normalizes 
the number of endocrine cell being born to the number being left behind in the Sox9+ 
epithelium, and in this manner can be used to quantify differentiation dynamics with increased 
precision, both in spatial and temporal terms. Here we have found that the magnitude of 
endocrine differentiation from the trunk domain is relatively constant over the course of 
secondary transition, and does not become reduced until E18.5. The idea that the trunk domain 
can stably and continually allocate a large fraction of its cellular mass toward the endocrine 
lineage could reflect that there are mechanisms in place that maintain a precisely balanced 
optimum flux of endocrine progenitors from the progenitor pool within this tissue. As such, 
future investigations should attempt to elucidate the feedback and/or feed-forward regulatory 
mechanisms that define this quantitative balance, and how they contribute to the regulation of 
organ size and cellular composition. 
Cell labeling and lineage tracing approaches represent powerful approaches in studying the 
cellular mechanisms through which progenitor populations give rise to differentiated progeny, 
yet each method comes with its own advantages and limitations. With regards to Cre and 
CreER-based lineage tracing, for instance, the uncertainty regarding when an individual cell has 
activated a lineage label makes it difficult to interpret how a given cell moves through a 
process, which in the case of endocrine lineage allocation, appears to occur through various 
means. The use of reporter based knock-in alleles has overcome these difficulties to some 
extent, especially where a given developmental processes can be monitored in real-time in 
vitro. Relating parameters measured via in vitro live imaging to those occurring in vivo, 
however, remains a major limitation to this type of analysis. Finally, EdU pulse-chase analyses 
have been used to monitor the replication and cell-cycle properties of progenitor populations, 
both in vivo and in vitro, but are limited in their ability to quantify the timing and specific 
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behaviors underlying cellular differentiation behaviors due to the non-specificity of thymidine 
analog labeling (i.e. any replicating cell population will become labeled), and the requirement 
that scoring of labeled populations be done in fixed tissues. Thus, in order to gain quantitative 
insights into how progenitor growth and differentiation behaviors are balanced during organ 
formation in vivo, it is necessary to utilize and cross-reference different cell-tracing approaches 
in parallel. We have leveraged the high temporal resolution enabled by a short bioavailability of 
EdU [157], a known injection time, and a set of directly detected and marker defined states that 
arise during progenitor replication and endocrine commitment to carry  out a population-based 
analysis of endocrine differentiation and progenitor growth dynamics during secondary 
transition. We estimate approximately 12 hours for both the cell-cycle period and Neurog3 
expression period in vivo, and a time frame of roughly 17 hours for an average cell to undergo 
its last S-phase in the epithelium and then to acquire differentiated endocrine cell status. 
Consistent with recent reporter-based single-cell live-imaging analyses in explants [163], the 
rapid EdU acquisition in Neurog3+ populations indicates that a large portion of endocrine-
committing cells acquire Neurog3-immunoreactivity shortly after a division event. The single-
cell live-imaging experiments carried out previously in explants did, however, report an average 
cycling time of 24 hours (instead of 12 hours in our case), which we would propose is likely due 
to reduced replication rates for progenitor cells in explanted culture systems. Indeed, our 
unpublished observations suggest that the increase in organ size observed in explants in culture 
does not match that which is observed in the same time frame in vivo. Our estimate of the time 
it takes to give rise to hormone producing endocrine cells are also in line, but perhaps more 
precisely temporally resolved, with what has been shown using Neurog3 reporter and 
Neurog3CreER alleles in vivo [164,165]. Our mosaic lineage tracing analyses are well in line with 
previous live imaging analyses in explants, which have shown that endocrine cells are born 
through a prevalent symmetric terminal differentiation process, asymmetric differentiation 
after division, and a less well characterized direct differentiation that does not appear to 
involve a cell fate acquisition during, or in close association with, a cell division event. These 
same studies also provided evidence for a rare population of Neurog3-expressing cells that are 
capable of undergoing cell division [163]. Thus, a bigger picture is emerging from these various 
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analyses that suggest that there are likely to be many complex mechanisms in place to guide 
the progression of cells from an undifferentiated progenitor state through to a differentiated 
endocrine cell. We propose that future studies on the genetic and signaling-based regulation of 
endocrine differentiation should undertake a cautious consideration that the outcome of a 
given experimental manipulation may reflect cell-type and context-specific effects depending 
on the developmental state of a cell within the progenitor epithelium. 
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CHAPTER III 
EXPERIMENTAL MODELS FOR CONDTIONAL CONTROL OF ENDOCRINE DIFFERENTIATION 
Introduction 
While the genetic and signaling mechanisms that balance progenitor maintenance and cell fate 
allocation during development are relatively well studied, how progenitor growth, 
differentiation, and morphogenesis processes are coordinated during organ formation remain 
obscure. This gap in our knowledge can be attributed to the challenges inherent in investigating 
how cell autonomously controlled processes non-autonomously influence various cell behaviors 
within a field of cells. Our goal is to develop experimental system(s) where the progression of 
cells into the Neurog3-expressing endocrine lineage (a cell autonomous process) can be 
conditionally and precisely manipulated, as a means to address larger questions about how the 
process of endocrine differentiation itself influences (cell non-autonomously) morphogenesis, 
cellular differentiation, and progenitor maintenance programs within the trunk. Here, we 
interrogate the cell-autonomous and non-autonomous functions of RBPJ in limiting endocrine 
differentiation from the trunk domain using conditional mosaic ablation of RBPJ with Sox9CreER. 
We report our findings and discuss technical limitations that preclude use of this genetic system 
for our research aims. We design and test an alternative genetic strategy for mosaic and 
inducible ectopic Neurog3 expression, and present data showing the utility of this model for 
studying the nature and scale of Neurog3-dependent non cell-autonomous feedback within the 
trunk domain. Finally, we present our design and manufacture of a Neurog3BAC-CreER construct 
for controlled manipulations on the previously proposed Neurog3LO endocrine-biased 
intermediate progenitor state. In sum, we propose new approaches and generate new tools 
that should be useful for studies on the molecular and genetic mechanisms controlling 
progression through the cell autonomous process of endocrine cell birth, and also on the 
underlying mechanisms linking this process to progenitor growth, differentiation, and 
morphogenesis processes through non-autonomous feedback communication. 
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Materials and Methods 
Mice and Genotyping. Sox9CreER mice were obtained from Maike Sander (UCSD). Primers used 
for genotyping were (5’HRsFr-ccttctcttccagagacttc and 5’HRsH-ctctggtcagagatacctgg; 780 bp) or 
(5’HRseqC- gcgatggatttccgtctctggtgtag and 5’HRseqD-gggtgctggacagaaatgtgtacact; 1080 bp). 
RBPJ floxed mice were a kind gift from Tasuko Honjo (Kyoto University). Primers used for 
genotyping were RBPJNeo-gcaatccatcttgttcaatggcc, RBPJF1-gcgtgcctccccgcatcta, RBPJwt1-
gttcttaacctgttggtcggaacc, RBPJwt2- gcttgaggcttgatgttctgtattgc as described [191]. The 
Rosa26.lox.STOP.lox.rtTA.ires.GFP line was a kind gift from Mark Magnuson (Vanderbilt). 
Primers used for genotyping were (Rosa3-cgaggcggatacaagcaata, Rosa5-gagttctctgctgcctcctg, 
and RosaRTTA-aagaccgcgaagagtttgtc; Rosa3 & 5 = (wt) 322 bp, Rosa3 & RTTA = (knock-in) 215 
bp). The Rosa26.Neurog3.CFP allele was also a kind gift from Mark Magnuson, and was 
genotyped with (Rosa26.S1-AGACTTATCTACCTCATAGGTG and CFPF-CAGCACGACTTCTTCAAG; 
1209bp). 
Immunodetection. Embryonic pancreas was paraformaldehyde-fixed (4%, 4oC, 4-6 hours). For 
cryosectioning, samples were sucrose-equilibrated (30%; 4oC overnight) and OCT-embedded 
(Tissue-Tek). Thin (10 m) and thick (35 m) cryosections were obtained on a LEICA CM3050S 
cryostat.  Antibodies used include hamster anti-Muc1 (NeoMarkers, 1:1000), rabbit anti-Sox9 
(Millipore, 1:5000), goat anti-Neurog3 (Gu lab, 1:40,000), guinea pig anti-Neurog3 (1:2000), 
goat anti-RBPJk D-19 (Santa Cruz, titrated), mouse anti-RBPJk E-7 (Santa Cruz, titrated), rabbit 
anti-RBPJk (Protein Tech, titrated), DBA (Vector Labs, 1:500), guinea pig anti-PP (Linco, 1:500), 
rabbit anti-glucagon (Linco, 1:500), guinea pig anti-insulin (Dako, 1:1000), chicken anti-GFP 
(Aves, 1:2000). 
Image Acquisition. Confocal images were from a Zeiss LSM 510 META. Images were also 
acquired on a ZIESS Observer.Z1 apotome. 
Tamoxifen and Doxycycline administration. Doxycycline was dissolved in water (5.0 mg/mL) and 
administered intraperitoneally at 10.0 g/g body weight. Embryos were harvested and fixed 12 
hours after Dox injection. Tamoxifen was dissolved in pharmaceutical grade corn oil (Welch, 
Holme & Clark Co. Inc.) at 30 mg/mL, and 3.0 mg administered at each time point. 
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BAC transgene generation. pBACe3.6 RPCI-32-121F10 BAC bearing Neurog3 genomic sequence 
was obtained from BAC-PAC resources. Plasmid PL451 [203] was modified by insertion of PuroR-
TK upstream of NeoR using BamHI and Nhe1 sites to generate PL451.PuroR-ΔTK-em7-neoR. The 
5’ homology region against the Neurog3 locus was a 40 bp region located immediately 
upstream of the Neurog3 start codon (5’HR: 5’-
GCTGGCACACACACACCTTCCATTTTTTCCCAACCGCAGG-3’) [68]. This 5’HR was synthesized into 
the forward primer used to amplify the CreER open reading frame (ORF) (Forward primer 
5’HR1ay5: 5’–ctaaggggcccgctggcacacacacaccttccattttttcccaaccgcaggatgtccaatttactgaccgtacacc-
3’; Reverse primer 5’HR1brevy5: 5’-ctagagtcgaccagacatgataagatacattg-3’). This 5’HR was 
digested with Apa1 and SalI, and ligated into PL451.PuroR-ΔTK-em7-neoR to generate 
PL451.5’HR-CreER.PuroR-ΔTK-em7-neoR. A 3’HR targeting 436 bp of Neurog3 coding sequence, 
starting from the ATG, was amplified:  
(3’HR2a:GCGGCCGCATGGCGCCTCATCCCTTGGATGCGCTCACCATCCAAGTGTCCCCAGAGACACAAC
AACCTTTTCCCGGAGCCTCGGACCACGAAGTGCTCAGTTCCAATTCCACCCCACCTAGCCCCACTCTCATA
CCTAGGGACTGCTCCGAAGCAGAAGTGGGTGACTGCCGAGGGACCTCGAGGAAGCTCCGCGCCCGACG
CGGAGGGCGCAACAGGCCCAAGAGCGAGTTGGCACTCAGCAAACAGCGAAGAAGCCGGCGCAAGAAG
GCCAATGATCGGGAGCGCAATCGCATGCACAACCTCAACTCGGCGCTGGATGCGCTGCGCGGTGTCCTG
CCCACCTTCCCGGATGACGCCAAACTTACAAAGATCGAGACCCTGCGCTTCGCCCACAACTACATCTGGG
CACTGACTCAGACGCTGCGCATAGCGGA) 
This 3’HR was ligated into PL451.5’HR-CreER.PuroR-ΔTK-em7-neoR with Not1 to yield 
PL451.5’HR-CreER-3’HR.PuroR-ΔTK-em7-neoR. PL451.5’HR-CreER-3’HR.PuroR-ΔTK-em7-neoR was 
then linearized with Apa1 and SacII, gel purified, and electroporated into recombination 
competent E. coli carrying the RPCI-32-121F10 BAC molecule. Recombinants were selected for 
with amplicillin and kanamycin. This modified BAC (F10.5’HR-CreER-3’HR.PuroR-ΔTK-em7-neoR) 
contains a Lox2272 site 3’ of the NeoR cassette. To generate a BAC transgene capable of 
undergoing RMCE, we placed a Lox71 site ~1.6 kb upstream of the original location of the 
Neurog3 start codon. 5’ and 3’HRs were constructed: 
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(5’HRlox71:CAGGAAGGTCTACCCTTGCCTGCAGATTCAATTTCTCTGCAGTAGGGAAGGAATTCCCTCCT
CACTCTCGATCATTTTAGGGATAGTGTTATGCCCCCACCCAATCCTACCACCTCCCCTCCTGCTGAGTGCC
AAGCAAGCCATCCTCTGCCCAGGGGATTTTGTAGTGCTCCCTCCTCTTCCTTGCAGCCCAGGCGGCCAGT
GGTCATCATAGAGTCAAGTCACACACCTACCCCGACCCTGACTCTACGCCTTCAGCCTCCCAGCCAGGGT
ATGGTCCCTTCTACAATATCCAGGAGCTTCGGAGTTAGAGAACGTACTAGAAAGCTTAGAGTTACTGCC
AAGAATCTTTAACTCCCAGCCATAGCTTCCTCCCATGCACATCCTGACTAGAAAGCTGGGGGGGGGGGG
AGGGAGGGAGGGAGGGCAGGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGATCAGC
GGAAGCCACAACCCCTCACCCTGAG)  
(3’HRlox71:TGACCGGAAACAGAAGACCACGGGGTGTCAGGGACAAGAAGGGCGGGTCTGCAGGGAA
GAAAGGACAATGTCTTAAGGCTCACAGGAAAGATTTCCAGATAGCTTAAGATAACCTCTTAAGAGGGAC
AAACTAGAAGTCTCCCTGCCCTGGGCTCACCCACAGTTCAGGAGTGATGGGGAGGGAGGGGGCGGGA
AGGAGTAGGACTAGGTGAAGCTGCTAGTCCTCTCTGGTCTGTGATTGGACAGGGGCACTAAAGGGGGC
AGAAAGTAGATCTGCTTTTCTCCCAGGGCCTGCACACGGAGGCATTGAAAAGACAAAAAAGGCTAGCA
GAGAACAAGTCCCTCCTTGACCTTTCCCTATCACCTGCCTCTCGGGTCAGGCCTTCCCGATAGCATCCATA
GTGGGGCGGGGCGTGATGAGATGCCCCCTCTGCACTCTCTCTACAACCACCCTCGCCTCCGGAATAGAA
CCCAATGTCTCGGATGAGGACTATGGTGGG)  
And each inserted 5’ (with Sal1 and EcoRV) and 3’ (with Spe1 and Not1) of the galk ORF in 
pGALK. Homologous recombination into F10.5’HR-CreER-3’HR.PuroR-ΔTK-em7-neoR in E. coli 
with galk selection was performed, and recombinants verified by PCR and sequencing to 
generate GK-F10.5’HR-CreER-3’HR.PuroR-ΔTK-em7-neoR. To introduce Lox71 by galk 
replacement, Lox71 sequence was annealed, digested with Spe1 and EcoRV, an inserted to 
replace the galk ORF in pGALK. This construct was electroporated into recombination 
competent E. coli bearing GK-F10.5’HR-CreER-3’HR.PuroR-ΔTK-em7-neoR, and the resulting 
bacteria were galk-counterselected, grown and proper recombinants PCR and sequencing 
verified. This molecule is denoted Lox71-(F10.5’HR-CreER-3’HR.PuroR-ΔTK-em7-neoR)-Lox2272, 
or hereafter Neurog3BAC-CreER. 
Preparation of BAC DNA for electroporation into mouse ES cells. Modified Neurog3BAC-CreER was 
purified using a QIAGEN Large-Construct Kit, linearized and separated from the BAC backbone 
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with Mlu1 and Pme1, and sent off to the Vanderbilt Transgenic ES Cell Core via established 
standards. 
Single copy screening and qPCR: Single copy transgene estimation was performed using the 
standard curve method as described [201]. All PCR was run on a Bio-Rad CFX96 with SsoFast 
EvaGreen Supermix (Bio-Rad). Primers used were (PTK copy – F1 5’- CCACGCTACTGCGGGTTTAT-
3’) and (PTK copy – R1 5’- CAGTTGCGTGGTGGTGGTT-3’) designed to amplify DNA internal 
within the PuroR ORF. 
 
Results 
Targeted inactivation of RBPJ with Sox9CreER 
Canonical Notch signaling is proposed to act as a major determinant and feedback-effector of 
binary fate decisions in the developing pancreas, as it is in numerous other developing systems 
[34,183,184,185,186,187,188]. The transcription factor RBPJ is an obligatory cofactor for Notch 
mediated repression of pro-differentiation genes such as Neurog3 [34], and a function for RBPJ 
in limiting differentiation in early pancreatic MPC has been long established [37,38,189,190]. To 
date, there has been no specific genetic intervention reported on Notch pathway function in 
the Sox9+ trunk epithelium during secondary transition. To address a function for RBPJ in 
limiting endocrine differentiation from the secondary transition trunk epithelium, we utilized a 
Sox9CreER BAC transgene [15] to affect inducible Cre-mediated recombination of a floxed allele 
for RBPJ [191]. We focused our initial studies on targeting RBPJ ablation in large numbers of 
cells within the epithelium, in order to prospectively analyze a pronounced effect of broad RBPJ 
loss within the tissue.  
To analyze the efficiency of Sox9CreER in recombining floxed loci in response to tamoxifen (TAM), 
we paired Sox9CreER-bearing mice with mates harboring a ROSA26-lox-STOP-lox-EYFP reporter 
allele (R26R-EYFP) [159], and administered persistent and high doses of TAM to the pregnant 
dam. Subsequent tracing of the resulting lineage labeled cells was used to assess the efficiency  
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Figure 3.1. Genetic systems used for conditional inactivation of RBPJ in the trunk. (A) Crossing Sox9
CreER
 and 
Rosa26
EYFP
 allele-bearing mice generates Sox9
CreER
;Rosa26
EYFP/+
 embryos. (B) Tamoxifen-loading in pregnant dams 
causes conditional activation of lineage reporter. Distribution of EYFP
+
 cells in labeled endocrine and ductal lineages 
at E18.5 after tamoxifen administration. (C) Quantification of EYFP-positivity in endocrine and ductal lineages at 
E18.5, as determined by manual cell counting (66% DBA
+
; 50% Endo
+
; n = 1). (D) Design of RBPJ alleles used for 
conditional mosaic inactivation of RBPJ by Sox9
CreER
.  Control and experimental embryonic genotypes representing 
an allelic series are shown. (E,F) Selected embryos from a cross between RBPJ
+/-
 mating pairs, where the RBPJ null 
allele was generated from the RBPJ
floxed
 allele using germline recombination with E2ACre [199]. The extraembryonic 
tissues are apparent at E9.5, but lack embryonic tissues in the most severe manifestation of the RBPJ null 
phenotype. This figure was adapted from [30,191]. 
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of CreER-mediated gene targeting in this system (Fig. 3.1A). For mice injected with 3 mg of TAM 
at E12.5 and E13.5, followed by an additional 2 mg dose at E15.5 (these doses were empirically 
determined as the most TAM a female could receive without termination of the pregnancy), 
there was a broad activation of lineage label throughout the pancreas at E18.5 (Fig. 3.1B). EYFP 
marked a large portion of the endocrine lineage, as marked by a cocktail of antibodies (EndoC-
TAIL) that bind to insulin, glucagon, and pancreatic polypeptide (PP). EYFP also marked a large 
portion of the ductal epithelium as demarcated by the lectin-binding protein DBA [192]. 
Quantification of the proportion of the DBA+ duct and EndoC-TAIL+ endocrine compartments 
labeled by EYFP showed that over 60% of the duct cell population, and approaching 50% of the 
endocrine cell population, had undergone CreER-mediated activation of R26R-EYFP. We also 
observed that EYFP lineage reporter was activated in the acinar compartment of the pancreas, 
consistent with the notion that Sox9CreER is not entirely specific for the trunk epithelium under 
these conditions. Notably, Sox9 protein is readily detectable, albeit at lower levels, in the pro-
acinar tip domains at early stages of secondary transition [15]. These results are in line with 
previous studies suggesting that the bulk of the endocrine lineage is generated during the 
pancreatic secondary transition, and supports the notion that Sox9CreER can be a useful tool to 
inactivate RBPJ broadly within the trunk domain. 
To inactivate RBPJ within the Sox9-expressing trunk domain, we mated Sox9CreER;RBPJfl/+ mice 
with RBPJfl/fl mice. Successful recombination of the RBPJ floxed allele results in a deletion of 
exons 6 and 7, which encode the DNA-binding domain of RBPJ, and generates a functional null 
allele [191]. We injected pregnant dams with 3 mg of TAM at E12.5 and E13.5, and analyzed the 
pancreas for loss of RBPJ protein by direct immunodetection at E15.5. Unfortunately, we were 
unable to obtain convincing nuclear signal for RBPJ on positive controls or experimental 
samples, with any of the immunodetection methods used in the lab, using three separate 
antibodies directed against RBPJ (data not shown) (See Fig. 3.9 for antibodies used). As another 
method to verify recombination of the RBPJ floxed allele, we isolated whole E15.5 pancreas and 
extracted and prepared DNA to attempt to detect allelic recombination by genotyping analysis. 
Genotyping primer sets that could detect and differentiate the intact the wild type allele, the 
intact floxed allele, and the recombined floxed allele were used to amplify PCR fragments from 
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whole pancreas DNA (See Fig. 4.9 for primers used). Tail DNA from wild type, RBPJfl/fl, and 
RBPJ+/-mice in which the RBPJ floxed allele had been converted to an RBPJ null allele by using 
the germline deleter E2A.Cre (RBPJ+/-) [199], were used as controls. While PCR amplicons 
representing wt and RBPJ floxed alleles were readily detected, we obtained no convincing 
evidence that there was recombination of the RBPJ floxed allele in our experimental mice. We 
ruled out the use of qRT-PCR or western blot as additional approaches to detecting a change in 
RBPJ expression, because RBPJ is a ubiquitously expressed gene [193], and we therefore did not 
expect to be able to detect a reduction in signal over what would be an already high basal 
signal. Finally, we ruled out the likelihood that we could detect a bias in the lineage allocation 
of RBPJ-mutant cells via lineage tracing, because the activation of EYFP lineage label is not 
linked to recombination of the RBPJ-floxed allele in a given cell. We had already, in 
collaboration with the Gu Lab, demonstrated that non-parallel recombination of non-linked 
genetic elements limits Cre-LoxP reporter systems as precise indicators of conditional genetic 
manipulations [194]. We next reasoned that the best way to proceed forward with the tools at 
hand would be to try and sensitize the genetic system to Cre-mediated recombination. To do 
this, we used a genetic condition in which one copy of the RBPJ floxed allele had been 
converted to a null condition (RBPJfl/-), thereby increasing the probability that the remaining 
RBPJ floxed allele would be recombined to generate a null genotype in response to TAM 
administration (Fig. 3.1D). This Sox9CreER;RBPJfl/- genetic condition could then be analyzed in 
parallel with Sox9CreER;RBPJfl/fl, and Sox9CreER;RBPJfl/+ animals in order to assess a phenotypic 
spectrum. Matings of RBPJfl/fl mice with E2ACre mice gave first generation pups in which the 
RBPJ floxed allele had been converted to a null allele based on genotyping analysis (data not 
shown). After breeding out E2ACre we crossed RBPJ+/- to RBPJ+/- mice to assess embryonic 
lethality before E10.5, which is the known consequence of complete RBPJ deficiency in mice 
[204]. Out of 30 E9.5 embryos generated from four separate matings, 6 exhibited severe 
growth retardation, and 8 showed complete embryonic absorption (Fig. 3.1E-F), consistent with 
the generation of a functional null allele for RBPJ. These alleles were used to generate an allelic 
series comprised of Sox9CreER;RBPJfl/+, Sox9CreER;RBPJfl/fl, and Sox9CreER;RBPJfl/- mice. For analysis 
of a potential phenotype, we decided to focus on measuring changes in the ratio of Neurog3+ to 
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Sox9+ cells, alterations to the relative mass of duct and endocrine lineages, and effects on the 
gross morphology of in response to TAM exposure during development. 
Sox9CreER;RBPJfl/fl and Sox9CreER;RBPJfl/- mice have altered ratios of Neurog3+ and Sox9+ cells after 
TAM administration 
To assess and compare the consequences of TAM administration on the ratio of Neurog3+ and 
Sox9+ cells in Sox9CreER;RBPJfl/+, Sox9CreER;RBPJfl/fl, and Sox9CreER;RBPJfl/- embryos, we crossed 
Sox9CreER;RBPJfl/+ mice with RBPJfl/- mice, and administered TAM to the pregnant dam (Fig. 
3.2.A). Sectional analysis of E15.5 pancreas from Sox9CreER;RBPJfl/+ and Sox9CreER;RBPJfl/fl animals 
immunolabeled with Neurog3 and Sox9 showed an apparent increase in the number of  
 
Figure 3.2. The ratio of Neurog3
+
 and Sox9
+
 cells is altered in Sox9
CreER
;RBPJ
fl/fl
 and Sox9
CreER
;RBPJ
fl/NULL
 embryos after 
TAM administration. (A) Diagram for tamoxifen administration and analysis at E15.5. (B-E) Single and merged 
channels showing Sox9 and Neurog3 immunodetection at E15.5 in Sox9
CreER
;RBPJ
fl/+
 and Sox9
CreER
;RBPJ
fl/fl 
genotypes. 
(F) Diagram for tamoxifen administration and analysis of the RBPJ allelic series at E18.5. (G) Quantification of the 
Neurog3:Sox9 ratio (fractional representation) in Sox9
CreER
;RBPJ
fl/+
, Sox9
CreER
;RBPJ
fl/fl
, and Sox9
CreER
;RBPJ
fl/- 
pancreata 
at various stages of secondary transition. Error bars are S.E.M. P values calculated by Student’s t. 
Neurog3+ cells relative to Sox9+ cells (Fig. 3.2.B-E). Quantification of the change in (total 
Neurog3+/total Sox9+) at E14.5 (Sox9CreER;RBPJfl/+ = 0.285 ± 0.01, Sox9CreER;RBPJfl/fl = 0.42 ± 0.04) 
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and E16.5 5 (Sox9CreER;RBPJfl/+ = 0.25 ± 0.02, Sox9CreER;RBPJfl/fl = 0.40 ± 0.03) showed an 
approximate 25% increase in the number of Neurog3+ cells relative to Sox9+ cells. 
Quantification of (total Neurog3+/total Sox9+) at E18.5, with the addition of the Sox9CreER;RBPJfl/- 
genotype, showed a correlative increase in (total Neurog3+/total Sox9+) as a function of 
whether Sox9CreER-bearing embryos were RBPJfl/+ (~0.08 ± 0.0, n = 1), RBPJfl/fl (~0.16 ± 0.023, n = 
2), or RBPJfl/- (~0.195 ± 0.02, n = 2) (Fig. 3.2.F,G). The statistical significance of these changes 
could not be definitively made with the number of samples analyzed. These alterations in (total 
Neurog3+/total Sox9+) did not appear to be due to increased cell death, because 
immunodetection of cleaved-caspase 3 did not label appreciable cell numbers in the 
experimental or control samples (Fig. 3.3). These results suggest that, relative to control, there 
is are alterations the relative numbers of Neurog3+ and Sox9+ cells in pancreata bearing 
conditional alleles for RBPJ and Sox9CreER, and that have been injected with high and persistent 
doses of TAM. 
 
Figure 3.3. Cell death is unchanged in Sox9
CreER
:RBPJ
fl/fl
 embryos exposed to TAM. Embryonic pancreata at E15.5 
treated with 2 x 3 mg tamoxifen at E12.5 and E14.5, and labeled with DAPI, Sox9, and cleaved caspase-3 (n = 1). 
 
Alterations to epithelial morphology in Sox9CreER;RBPJfl/fl and Sox9CreER;RBPJfl/- mice injected with 
TAM 
A previous study showed that increased endocrine differentiation caused by pharmacological 
inhibition of Notch resulted in thinning of Muc1+ epithelial lumens [72]. Because we were 
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observing changes to (total Neurog3+/total Sox9+) that were suggestive of increased endocrine 
differentiation, we hypothesized that this would result in alterations to epithelial morphology 
similar to what had been previously reported. We obtained thick frozen sections from E15.5 
Sox9CreER;RBPJfl/+ and Sox9CreER;RBPJfl/fl embryonic pancreas that had been exposed to TAM in 
utero, labeled them with Muc1, and rendered composite images of the whole dorsal pancreas. 
At E15.5, we observed no apparent difference in the gross anatomical morphology of the 
epithelium (Fig. 3.5A,B). Epithelial branch patterns appeared to be normal, and there was 
abundant and grossly normal web-like plexus epithelium in both conditions. There was no 
apparent thinning in the diameters of the epithelial lumens, as had been shown under 
conditions where Notch is pharmacologically inhibited in vitro [72]. There were also no 
apparent changes in the size or gross morphology of the pancreas as a whole (data not shown) 
at this stage. Inspection of the gross tissue morphology of the pancreas at E16.5, as shown 
using an anti-mouse secondary antibody that gives high background signal to reveal the general 
features of tissue architecture, showed alterations in the morphology of acinar clusters relative 
to control (Fig. 3.5C). The lumens of most, but not all, of the acinar clusters in Sox9CreER;RBPJfl/- 
pancreata appeared to be enlarged or dilated relative to control (n = 1). At E18.5, however, 
even in the Sox9CreER;RBPJfl/-  condition there appeared to be little if any overt change to the 
gross morphology of the pancreas. In only one Sox9CreER;RBPJfl/- pancreas out of numerous 
inspected (n > 3), there appeared to be some reduction in the size, and change in the  gross 
morphology, of the pancreas (Fig. 5D). While, these data present instances where minor 
alterations in the morphology of the pancreas were documented, we conclude that there are 
no overt, reproducible phenotypes with respect to pancreas gross morphology observed in our 
experimental model.   
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Figure 3.4. Analysis of gross pancreatic epithelial morphology in Sox9
CreER
:RBPJ
f/f
 embryos exposed to TAM. (A-B) 
Composite 10x images of E15.5 Sox9
CreER
;RBPJ
fl/+
 and Sox9
CreER
;RBPJ
fl/fl 
pancreata treated with 2 x 3 mg tamoxifen at 
E12.5 and E14.5, and labeled in 30 m thick sections with Muc1. (C) Background signal from Cy2-conjugated 
antibody used to highlight the gross architecture of the pancreatic epithelium at E16.5. Panels show RBPJ
fl/-
 and 
Sox9
CreER
;RBPJ
fl/-
 genotypes treated with 2 x 3 mg tamoxifen at E12.5 and E14.5, and an additional 2 mg at E15.5. 
White arrowheads point to dilated acinar lumens. (D) Illuminated stereomicroscopic images of RBPJ
fl/-
 and 
Sox9
CreER
;RBPJ
fl/-
 pancreata (dashed black line) treated with 2 x 3 mg tamoxifen at E12.5 and E14.5, and an 
additional 2 mg at E15.5. 
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Altered duct and endocrine cell mass in Sox9CreER;RBPJfl/fl and Sox9CreER;RBPJfl/- mice injected with 
TAM 
Lastly, we investigate whether or not the increased (total Neurog3+/total Sox9+) observed 
during multiple stages of development in Sox9CreER;RBPJfl/+ and Sox9CreER;RBPJfl/- mice injected 
with TAM resulted in a change in the final relative sizes of the duct and endocrine pancreas. To 
do this, we sectioned E18.5 pancreas, labeled them with the EndoC-TAIL and DBA, and then 
measured and compared the relative pixel areas for the duct and endocrine tissues using 
ImageJ software. Sox9CreER;RBPJfl/- embryos exposed to TAM showed an increase in the size of 
the endocrine pancreas relative to the duct (Fig. 3.6A). This increase was relatively minor 
(Sox9CreER;RBPJfl/+ = 60 ± 4.62% endocrine, Sox9CreER;RBPJfl/- = 79.67 ± 6.08% endocrine), but was  
 
Figure 3.5. Relative duct versus endocrine area is altered in Sox9
CreER
:RBPJ
f/-
 embryos injected with tamoxifen. (A, B) 
Composite 10x images of E18.5 Sox9
CreER
;RBPJ
fl/+
 and Sox9CreER;RBPJ
fl/NULL 
pancreata treated with 2 x 3 mg 
tamoxifen at E12.5 and E14.5, and an additional 2 mg at E15.5. Samples were sectioned, and labeled with DBA, 
DAPI and the endocrine-cocktail of antibodies. (C) Quantification of relative pixel area determined from samples in 
A & B; 30% of entire pancreas analyzed by serial section.  Error bars are S.E.M. P values calculated by Student’s t.  
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significant (P= 0.022) when averaged across several samples. We did not normalize these 
measurements in a way that would allow for a conclusion to be made on whether the absolute 
sizes of the duct or endocrine pancreas were changed. We conclude that administration of TAM 
in Sox9CreER;RBPJfl/- pancreata is associated with an increased relative size of the endocrine 
versus the duct pancreatic lineages. 
Conditional genetic ablation of RBPJ with Sox9CreER is not a suitable model for studying Notch 
and other endocrine-differentiation-dependent feedback influences on the trunk domain 
The above experiments lead us to conclude that conditional genetic ablation of RBPJ with 
Sox9CreER is not a suitable model for studying 1) studying the cell autonomous role of RBPJ in 
limiting endocrine differentiation, or 2) assessing non-cell autonomous endocrine-
differentiation-dependent feedback influences on progenitor growth, differentiation, and 
morphogenesis in the trunk domain. In this model system, we could not definitively confirm 
that Sox9CreER was causing genetic inactivation of RBPJ, we had no ability to directly trace the 
consequences of RBPJ loss in a cell or in populations of cells, and we had only minor and 
difficult-to-interpret changes in endocrine differentiation patterns during development. Thus, 
this was an insufficient experimental model given the questions we were trying to address. 
With these justifications, we discontinued this project, and sought other means to conditionally 
control endocrine differentiation during pancreas development.  
Inducible ectopic Neurog3 expression to study endocrine-differentiation-dependent feedback on 
trunk progenitors 
We reasoned that an alternative strategy for controlling endocrine differentiation from the 
trunk would be to ectopically express Neurog3, in a spatiotemporally controlled fashion, within 
the Sox9+ trunk. To do this, we developed a three allele system that permits 1) conditional 
mosaic activation of Neurog3 induction-competence via Sox9CreER, 2) indelible and direct lineage 
tracing of control (uninduced) and experimental (Neurog3-induced) cells, and 3) and controlled 
ectopic expression of Neurog3. The first element of this three allele system (hereafter  
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Figure 3.6. Ectopic Neurog3 expression for controlled manipulation of endocrine flux from the trunk domain. (A) 
Sox9
CreER
-based specificity determinant for targeting CreER-mediated recombination of lol.STOP.lox alleles knocked 
into the Rosa26 locus. (B) Tamoxifen-inducible driver allele for doxycyline-mediated overexpression of tet-
responsive alleles knocked in to the Rosa26 locus. (C) Doxycycline-inducible system for controlled ectopic expression 
of Neurog3. (D,E) Proposed genetic backgrounds for analyses on the non-cell autonomous effects of ectopic 
Neurog3 expression on gene expression patterning, progenitor growth and differentiation, and epithelial 
morphogenesis in the trunk domain. The relative numbers of cells targeted for ectopic Neurog3-induction is 
controlled by the administered dose and timing of tamoxifen administration. This figure was adapted from 
schematics made in the M. Magnuson Lab. 
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Neurog3OE) is represented by the specificity determinant Sox9CreER (Fig.  3.7A). As previously 
shown (Chapter II and Fig. 3.1B), administration of low or high doses of TAM recombines 
Rosa26.lox.STOP.lox alleles (such as R26R) in highly mosaic or broadly scattered populations of 
Sox9+ cells in the trunk. Different doses of TAM can be used to control the patterning of cells 
with recombined alleles within the Sox9+ epithelium. The second element of Neurog3OE is 
represented by a TAM-inducible Rosa26.lox.STOP.lox.rtTA.ires.GFP allele, which allows for 
conditional expression of a reverse tetracycline trans-activator (rtTA) [195] (which 
transcriptionally activates gene targets regulated by tetracycline responsive elements (TetO)) 
and tracing of recombined cells with a genetically coupled GFP fluorophore (Fig. 3.7B). The last 
element of Neurog3OE is represented by a doxycycline responsive, bicistronic 
Rosa26.Neurog3.CFP allele [Mark Magnuson Lab, Vanderbilt, unpublished], which in response 
to doxycyline administration, is designed to express both Neurog3 and CFP proteins from a 
tetracycline responsive promoter (Fig. 3.7C). This proposed Neurog3OE system could 
theoretically enable control over the patterning and timing of ectopic Neurog3 expression in 
the Sox9+ trunk domain, and thus represents a tractable model for mosaic studies on Neurog3-
dependent cell non-autonomous feedback.  
We next proposed that the Neurog3OE system should be bred into two experimental 
backgrounds. The first model consists of Neurog3OE bred into a ‘normal’ genetic background 
(Fig. 3.7D). The second experimental model consists of the Neurog3OE system bred into a 
Neurog3 nullizygous background [59] (Fig. 3.7E). With these experimental models in-hand, we 
propose that information can be gleaned about the nature and scale of the cell non-
autonomous functions for Neurog3 in directing programs of progenitor growth and 
maintenance, gene expression patterning and cell differentiation, and patterns of epithelial 
morphogenesis in the trunk domain. 
Neurog3OE allows for tight control over endocrine differentiation from the trunk 
We next carried out preliminary tests on the efficacy of the Neurog3OE system as a model to 
conditionally control the entrance of Sox9+ epithelial cells into the endocrine lineage via ectopic 
Neurog3 expression. We bred the Neurog3OE system into a normal genetic background, and 
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populated the epithelium with Neurog3 induction-competent cells via TAM injection at E13.5 
and E14.5. We next compared the effects of doxycyline administration on Neurog3 induction in 
GFP-expressing cells in Neurog3OE pancreata, and using a Sox9CreER;ROSA26-lox-STOP-lox-ires-
GFP condition, which does not carry the Rosa26.Neurog3.CFP allele, as control. We injected 
doxycycline into pregnant dams at E15.5, and because we had previously shown that Sox9+  
 
Figure 3.7. Proof of efficacy of the Neurog3 ectopic expression system. (A) Experimental timeline for tamoxifen and 
doxycycline administration and analysis of resulting tissues in embryos harboring the Neurog3
OE
 system. (B-E) 
Analysis of the overlap between EGFP lineage label (coming from the tamoxifen-inducible driver allele) and 
Neurog3 protein in the presence or absence of doxycycline. Note the lack of overlap between EGFP and Neurog3 in 
the absence of doxycycline, and the near-full overlap in the presence of doxycycline. Muc1 and Sox9 are provided as 
markers for the trunk epithelium. 
epithelial cells normally activate Neurog3 and undergo differentiation over an estimated 12 
hour period (Chapter II), analyzed embryonic pancreata 12 hours later (Fig. 3.8A). In control 
animals, we observed broad activation of GFP in the Sox9-expressing epithelium, indicating that 
Sox9CreER had faithfully recombined and activated the ROSA26-lox-STOP-lox-ires-GFP allele in 
response to TAM administration. The vast majority of these GFP+ cells were not Neurog3 
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protein-positive (~10%, n = 1) at the twelve hour time point, consistent with the idea that only 
some Sox9-expressing cells activating GFP will “choose” to turn on Neurog3 within a given 
period of time (Fig. 3.8B,C). Most GFP cells were found in the epithelium and were Sox9+. In 
contrast, in pancreata bearing Neurog3OE, we observed a near complete coincidence (90%, n = 
1) of GFP and Neurog3 protein expression. This result indicates that Neurog3 protein is 
faithfully induced in response to Dox-administration in cells that have undergone activation of 
the ROSA26-lox-STOP-lox-ires-GFP allele (Fig. 3.8D,E). Notably, these same cells were not 
positive for Sox9, indicating that similar to the normal endocrine differentiation process, Sox9 
expression had been faithfully downregulated as a result of Neurog3 expression [31,80]. There 
were, as expected, Neurog3+ cells that were not GFP+ in this condition, which is explained by 
the idea that cells that have not activated the Neurog3OE system are still capable of entering 
into the endocrine differentiation program. Finally, analysis of these same expression patterns 
24 hours after Dox-administration showed a much less pronounced overlap between GFP+ cells 
and those expressing Neurog3, suggesting that due to the short half-life of Dox in vivo (~ 170 
min. [196]), cells that had previously ectopically expressed Neurog3 had since downregulated 
Neurog3 protein (data not shown, n = 1). Collectively, these data suggest that Neurog3OE 
represents a faithful genetic system with which to control an ostensibly similar-to-normal 
process of Neurog3 activation and endocrine differentiation from the pancreatic epithelium. 
Neurog3CreER BAC transgene for tracing and manipulation of the Neurog3LO state 
As an additional entry point into understanding the molecular and cellular mechanisms that 
function to balance endocrine differentiation and progenitor maintenance, we endeavored to 
generate new tools to study the proposed Neurog3LO endocrine-biased state outlined in 
Chapter II. We reasoned that one useful avenue would be to generate a Neurog3CreER BAC 
transgene, to conditionally lineage trace the progeny of cells expressing low levels of Neurog3. 
Several Neurog3Cre lines have been generated, but these appear to mark mostly cells that have 
progressed into the Neurog3HI state that is associated with endocrine commitment [16,63]. One 
Neurog3Cre BAC transgene, however, has been shown to mark Neurog3-expressing cells of the 
pancreas and intestine that appear to maintain some degree of plastic lineage potency, and can 
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give rise to non-endocrine lineages [68]. We used this same BAC molecule to engineer a 
Neurog3CreER BAC for generation of a new Neurog3BAC-CreER transgenic mouse line (Fig. 3.8A,B). 
This mouse would theoretically maintain the high sensitivity of lineage labeling necessary to 
track the Neurog3LO condition [68], and would also evade phenotypes associated with Neurog3  
 
Figure 3.8. Generation of the Neurog3CreER BAC transgene. (A) Entire modified RP23-121F10 BAC 
harboring CreER(T2) and PuroR.tK.em7.NeoR cassettes inserted in front of the Neurog3 start codon. BAC 
molecule is equipped with lox-cassette-acceptor (LCA) capability to provide for later exchanges of 
experimental constructs into the LCA by RMCE. See materials and methods for details. 
haploinsufficiency [69]. The final BAC construct featured a CreER-PuroR-ΔTK-em7-neoR cassette 
inserted in front of the endogenous Neurog3 start codon. For later flexibility in exchanging 
other cassettes into this same allele via Recombinase Mediated Cassette Exchange (RMCE) in 
mouse embryonic stem cells (ESC), we inserted a Lox71 variant site [202] ~1.6 kb upstream of 
the CreER start codon, and a Lox2272 variant site [202] at the 3’ end of the PuroR-ΔTK-em7-
neoR cassette. The resulting Neurog3CreER BAC molecule was released from the pBACe3.6 
backbone by restriction enzyme digest (the backbone contains exogenous sequences necessary 
for BAC replication in bacteria, and includes unwanted variant loxP sites) and electroporated 
into TL1 [200] mESC (129/Sv background) at the Vanderbilt Transgenic ES Cell Core. The 
resulting mESC were selected by puromycin to isolate stable transgene integrations, mESC 
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colonies were grown, and DNA was prepped for a two-part screen to isolate single copy 
transgene insertions. It was vital that the transgene only be contained within the genome as a 
single copy, so that later exchange by RMCE could be predictably accomplished without 
undesirable recombinant products. The first round of screening was designed to use genomic 
PCR to screen for regions of the Neurog3CreER BAC, including the CreER open reading frame 
(ORF), selection cassettes, and 5’ and 3’ junctions between inserted and endogenous DNA (see 
materials and methods), to verify successful insertion of the BAC. Genomic PCR was also used 
to find and to exclude mESC clones that had incorporated pBACe3.6 backbone DNA during 
electroporation. From this first screen were identified 14 out of 67 colonies screened that were 
qualified candidates for ‘correct’ transgenic insertions, without pBAC backbone insertions. For 
the next part of the screen, these 14 candidates were submitted to qPCR screening in order find 
single copy insertion events. Briefly, primers directed against the Puromycin ORF were 
generated. Then, qRTPCR was run on 2.5, 10, 20, 40 and 200 ng of DNA from a TL1 mouse line 
carrying ROSA26PuroTk as a single copy of PuroR-ΔTK-em7-neoR to obtain a line of best fit for a 
standard ct curve reflecting increasing copy number. 20 ng of DNA from candidate single copy-
bearing mESC clones was run in triplicate alongside this standard curve. Of the 14 clones tested, 
2 clones showed estimated copy numbers of 1.0 (clone f5) and 1.6 (clone c10). Clones f5 and 
c10 were expanded, and subsequently prepped and injected into C57BL/6 blastocysts to 
generate chimeras. Two female and one male chimera were isolated. The two females were 
less than 10% TL1 as judged by brown coat color, while the male was ~50% TL1. Mating the 
chimeras with C57BL/6 mice showed no germline transmission of the 129/Sv (TL1) background 
with Neurog3CreER. In sum, while animals were not successfully generated from these attempts, 
we have generated an RMCE-compatible Neurog3BAC-CreER for use in lineage tracing studies, and 
for generating additional mouse lines with experimental constructs inserted into the Neurog3 
locus in a BAC by RMCE.  
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Discussion 
Challenges and limitations of CreER-mediated deletion of RBPJ as a tool to control endocrine 
differentiation from the pancreatic epithelium 
Our goals in achieving Sox9CreER-mediated inactivation of RBPJ in the trunk were two-fold. First, 
we aimed to gain the first insight into a proposed cell-autonomous function for RBPJ in limiting 
Neurog3 activation and endocrine differentiation within the Sox9+ trunk. Second, we sought to 
use this conditional system as a tool to manipulate the magnitude of endocrine differentiation 
occurring from the trunk, as a basis to gain insights into the non-cell-autonomous regulation of 
growth, differentiation, and morphogenesis processes that occur in the trunk response to 
endocrine differentiation-dependent feedback. Due to a number of limitations in this 
experimental system, we were unable to achieve either of our goals. One main limitation in this 
model system was that we could not reliably detect, by any methods attempted, loss of RBPJ 
protein in Sox9-expressing progenitors. We propose that better methodologies and/or reagents 
will likely be needed in order to quantify and track the behaviors of RBPJ-deficient cells, at 
cellular resolution, in order to make definitive conclusions on the fate of RBPJ-deficient Sox9+ 
progenitor cells. A second limitation in this model system is that the lineage tracing methods, 
which in an ideal case would allow one to infer the fate of RBPJ-deficient cells by following EYFP 
positive lineage labeled cells, are flawed. We recently published a report, in collaboration with 
and led by the Gu Lab [194], which demonstrated that Cre-mediated activation of reporter 
alleles does not accurately predict recombination of another floxed allele in an individual cell. 
The degree of overlap between lineage-reporter activation and gene-inactivation appear to 
depend on a number of factors, including the levels of Cre-recombinase expressed in a given 
cell, the distance between loxP sites at a given floxed locus, the number of floxed loci that must 
be successfully targeted to achieve full genetic inactivation of a target gene, and perhaps even 
chromosome-localization effects that restrict the access of Cre-recombinase to a given floxed 
locus [194]. In the Sox9CreER;RBPJ-floxed system, we can invoke two of these factors  as 
potentially detrimental to the efficacy of our lineage tracing capability. First, CreER-based 
systems are thought to be less efficient than Cre-based systems at recombining floxed alleles, 
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and the amount of Cre-recombinase translocated to the nucleus upon TAM-administration 
represents one important determinant of recombination frequency [194]. While we were 
successfully able to “hit” the lineage reporter allele in an appreciable number of Sox9-
expressing cells through administration of high and persistent does of TAM (~50%), we expect 
there to be, even in an ideal case, as much as a 50% non-overlap between EYFP+ cells that 
retain at least one intact floxed allele, and EYFP+ cells that have undergone successful 
recombination.  Second, the loxP sites that flank exons 6 and 7 in the RBPJ floxed allele are 
more widely spaced (~ 2.3 kb) [191], when compared to the Lox-STOP-Lox sequence in the 
lineage reporter allele (~ 1.9 kb) [194,195]. We suspect that a 400 bp increase in spacing 
between the loxP sites of the RBPJ floxed allele and the lineage reporter allele could contribute 
to the degree of non-parallel recombination in our system. Thus, multiple features of the 
Sox9CreER;RBPJ-floxed system call into question whether or not this model can be successfully 
utilized to target and analyze RBPJ function in the trunk domain. 
The proposal that there may be an inefficient, or perhaps even non-existent, recombination of 
RBPJ in our system begs an important question. That is, how does one explain the observed 
changes in (total Neurog3+/total Sox9+), and the observed changes in relative endocrine versus 
duct compartment sizes which occur in the different genotypes in response to TAM 
administration? First, under the assumption that there is at least some deletion of RBPJ in 
response to TAM, and that RBPJ does in fact function to limit endocrine differentiation in Sox9-
expressing cells, it could be the case that our genotyping methods used to detect recombined 
floxed alleles are not sensitive enough to detect a small number of recombination events. 
Indeed, the changes observed in our experimental animals a relatively minor. The ~25% 
increase in Neurog3+ cell numbers relative to Sox9+ cells is consistent with a 1 in 10 
recombination rate for any given cell. The measured increase in endocrine ‘mass’ relative to the 
duct in Sox9CreER;RBPJfl/fl animals at E18.5 could reflect the sum of these infrequent 
recombination events that occur over a 5-day period. The notion that the increase in (total 
Neurog3+/total Sox9+)  is augmented at E18.5 (Fig. 3.3G) in the Sox9CreER;RBPJfl/- condition (this 
condition should have hypothetically a higher frequency of RBPJ KO due to the presence of only 
one floxed allele) is consistent with the idea that Sox9CreER is indeed able to recombine RBPJ 
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floxed alleles at some frequency. We propose that it might be useful to FACS isolate endocrine 
islets and DBA+ duct cells from control and experimental animals at E18.5, and then assess the 
relative enrichment of recombined RBPJ floxed alleles in each tissue-fraction by genomic PCR. 
In this manner, it might be possible to show an enrichment of the recombined RBPJ floxed locus 
in the endocrine compartment versus the ductal compartment. We do not propose that these 
experiments convincingly argue for a cell autonomous function for RBPJ in limiting endocrine 
differentiation from the trunk domain during secondary transition. 
Previous studies have shown that increased endocrine differentiation caused by 
pharmacological inhibition of Notch results in thinning of the trunk epithelial lumen [72]. We 
did not observe such changes in our experiments. We suspect that this could be due to either 
an inability to resolve small changes in epithelial lumen morphology using the relatively low-
resolution analyses presented here. Conversely, there could be compensatory growth 
processes that become activated in the trunk in response to increased endocrine lineage 
differentiation. In this regard, it has been previously shown that the initial numbers of MPC 
allocated to the pancreas-specified bud determine the final size of the pancreas [17], suggesting 
that there are not compensatory growth mechanisms intrinsic to the pancreas growth program. 
However, these experiments [17] targeted primary MPC, and do not rule out that interventions 
in secondary transition progenitors might elicit compensatory growth at later-stages. We also 
documented observations that acinar lumens become enlarged or dilated in response to TAM 
exposure. This could be the result of RBPJ-loss in the acinar cells themselves (Sox9 is expressed 
at low levels in these cells) [31,80], or could be due to non-autonomous influences of RBPJ-loss 
in the trunk. A previous study showed that over-expression of a dominant negative form of the 
obligatory Notch transcriptional co-activator mastermind-like1 [46], or genetic deletion of the 
Notch-signal processing enzymes presinilin1/2 [197], caused Notch-pathway-deficient cells to 
adopt acinar status. Thus it is possible then that cells inactivating RBPJ adopt a pro-acinar fate, 
which leads to increasing numbers of cells moving into the acinar clusters, which then grow 
larger and become dilated as a result. If this altered cell-fate allocation depleted Sox9-
expressing cells from the epithelium, without also depleting cells undergoing endocrine 
differentiation, it could explain how the relative sizes of the duct and endocrine pancreas 
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become skewed toward the endocrine compartment by late gestation. We suggest that gaining 
an understanding of the biology underlying  these phenotypes will be much easier to 
accomplish in an experimental model that is more robust and not as hampered by the 
limitations and caveats intrinsic to the Sox9CreER;RBPJfl/fl system. 
The Neurog3OE system to study the cell-non-autonomous effects of endocrine differentiation on 
trunk progenitor function 
We find the Neurog3OE system to be an attractive model for studying the non-autonomous 
effects of endocrine cell birth on the function and behavior of progenitor cells in the trunk 
epithelium, as it overcomes essentially all of the shortcomings of the Sox9CreER;RBPJfl/fl system. 
This is especially true given the fact that cells experimentally induced to ectopically express 
Neurog3 move through a differentiation sequence that, in terms of timing and progress 
through different states of Neurog3 and Sox9-positivity, appears to be quite similar to that 
which is observed normally (Chapter II). Manipulations using Neurog3OE should be informative 
in an otherwise “normal” genetic background. Such an experimental genotype allows for 
analysis of the consequences of ‘over-production’ of Neurog3+ cells from the trunk domain. For 
instance, one can assess the acute consequences of large-scale and abrupt endocrine lineage 
production on the patterning of Neurog3 expression and endocrine differentiation within the 
trunk. We hypothesize that the controlled induction of large amounts of induced (and GFP-
labeled) endocrine cells from the trunk will have a pronounced inhibitory effect on the numbers 
of un-induced (GFP-negative) cells entering into the Neurog3+ state. The power of the 
Neurog3OE system should also become evident when it is bred into different genetic 
backgrounds. Breeding Neurog3OE into the Neurog3 nullizygous condition, for instance, would 
readily allow for two important levels of analysis. First, one could assess the acute 
consequences of broad induction of Neurog3 expressing cells on the altered state of the 
Neurog3-deficeint epithelium. These include documented alterations to the morphology of the 
epithelium, and alterations to Neurog3 and Hes1 gene expression patterning within the 
epithelium [72]. At a second level of analysis, one can activate Neurog3 induction-competence 
in a highly mosaic or clonal fashion, and then assess the local effects that Neurog3 producing 
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cells have on, for instance, Hes1-expression in neighboring cells within the epithelium. In sum, 
the Neurog3OE system could represent a powerful tool for studying the spatiotemporally 
defined and quantized influences that differentiating endocrine cells have in regulating the 
growth, morphogenesis, and differentiation properties of the epithelial progenitors. 
Neurog3CreER BAC transgenic line for studying the behavior of the Neurog3LO condition 
A previous study showed that Neurog3-expressing cells of the intestinal tract and pancreas 
exhibit a remarkable degree of plasticity with regards to their lineage potency [68]. All 
enteroendocrine cells in the intestine [68], and all endocrine cells of the pancreas are born from 
Neurog3+ cells [63]. However, a small fraction of Neurog3-expressing cells in the intestine can 
give rise to goblet and paneth cells [68], in the stomach to acid-producing cells [68], and in the 
pancreas to duct and acinar cells [63]. These studies suggest that a Neurog3LO state in the 
pancreas could represent an important, and possibly stable, replicating intermediate progenitor 
cell that feeds the production of committed endocrine precursors during secondary transition. 
We have used the same BAC fragment used in the studies documenting the plastic lineage 
allocation behavior of Neurog3-expressing cells to generate our Neurog3BAC-CreER construct. This 
BAC molecule contains a large portion of the accessory genomic sequence comprised by the 5’ 
and 3’ DNA flanking the Neurog3 locus, which has been shown to contain distal enhancer as 
well as promoter-proximal elements regulating Neurog3 [59,198]. We suspect that the 
selection of this particular BAC molecule will improve the fidelity and sensitivity of lineage 
tracing in a manner that will benefit studies geared toward studying the Neurog3LO condition. 
We propose that initial studies should focus on lineage tracing Neurog3LO cells to assess 
whether they are maintained in the trunk epithelium for long periods of time, whether they can 
undergo several rounds of division, whether they are unipotent for hormone+ endocrine 
subtypes [16], and whether they exhibit a preferred mode of endocrine lineage allocation (via 
asymmetric division or terminal differentiation, for example) [163].  
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CHAPTER IV 
FEEDBACK CONTROL OF GROWTH, DIFFERENTIATION, AND MORPHOGENESIS OF PANCREATIC 
ENDOCRINE PROGENITORS IN AN EPITHELIAL-PLEXUS NICHE 
 
Introduction 
In the mammalian pancreas, endocrine cells undergo lineage allocation upon emergence from a 
bipotent duct/endocrine progenitor pool, which resides in the “trunk epithelium”. Major 
questions remain regarding how niche environments are organized within this epithelium, to 
coordinate endocrine differentiation with programs of epithelial growth, maturation and 
morphogenesis. We used tissue-reconstruction approaches to analyze how endocrine 
progenitors, and their differentiating progeny, are assembled within the trunk as it undergoes 
remodeling from an irregular plexus of tubules to form the eventual mature, branched ductal 
arbor. The bulk of endocrine progenitors are maintained in an epithelial ‘plexus state’, which is 
a transient intermediate during epithelial maturation, and within which endocrine-cell 
differentiation is continually robust and surprisingly long-lived. Within the plexus, local 
feedback effects derived from the differentiating and delaminating endocrine cells non-
autonomously regulate the flux of endocrine-cell birth, as well as proliferative growth of the 
bipotent cell population, using Notch-dependent and independent influences, respectively. 
These feedback effects, in turn, maintain the plexus state to ensure prolonged allocation of 
endocrine cells late into gestation. These findings begin to define a niche-like environment 
guiding the genesis of the endocrine pancreas, and advance current models for how 
differentiation is coordinated with the growth and morphogenesis of the developing pancreatic 
epithelium. 
     
This chapter have been published as Bankaitis ED, Bechard ME, and Wright CV. 2015. Feedback control of growth, 
differentiation, and morphogenesis of pancreatic endocrine progenitors in an epithelial plexus niche. Genes and 
Development 29, 2203-2216 [211]. 
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Material and Methods 
Mice. Neurog3EGFP knock-in mice from Guoqiang Gu (Vanderbilt University) were genotyped as 
described [59]. Neurog3EGFP/+ and Neurog3EGFP/EGFP embryos were phenotyped by EGFP 
fluorescence and lack of endocrine cells, or genotyped with primers ngn3-1 5’-
ATACTCTGGTCCCCCGTG-3’, ngn3-2 5’-TGTTTGCTGAGTGCCAACTC-3’, and EGFP 5’-
GAACTTGTGGCCGTTTACGT-3’ [59]. Wild-type mice were of mixed genotype. All protocols were 
approved by Vanderbilt University IACUC.  
Immunodetection. Embryonic pancreas was paraformaldehyde-fixed (4%; 4oC, 4-6 hours). For 
cryosectioning, samples were sucrose-equilibrated (30%; 4oC overnight) and OCT-embedded 
(Tissue-Tek). Thick cryo-sections (30-45 m) were obtained on a Leica CM3050 S. For whole-
mounts, pancreata were manually divided into core and peripheral regions, and processed as 
described [166]. Antibodies used include hamster anti-Muc1 (NeoMarkers 1:1000), DBA (Vector 
Labs, 1:400), rabbit anti-CK19 (B. Stanger, U. Penn, 1:2000), rabbit anti-Sox9 (Millipore, 1:5000), 
goat anti-Neurog3 (Gu Lab, 1:40,000), guinea pig anti-Neurog3 (Sander Lab, 1:2000), guinea pig 
anti-Pdx1 (Wright Lab, 1:1000), rat anti-Ecad (AbCam, 1:1000), guinea pig anti-insulin (Dako, 
1:1000), chicken anti-GFP (Aves, 1:2000), rabbit anti-amylase (Sigma, 1:1000), guinea pig anti-
Hes1 (T. Sudo, Toray Industries, Japan, 1:4000).   
qRTPCR. Total RNA was TRIzol-isolated from dorsal pancreata and cDNA synthesized with iScript 
cDNA Synthesis Kit (Bio-Rad) for PCR in a Bio-Rad CFX96 with SsoFast EvaGreen Supermix (Bio-
Rad).  Expression level was normalized to GAPDH by the Ct method. Primers include GAPDH 
1F 5’-ACTTTGGCATTGTGGAAGG-3’, GAPDH 1R 5’-GGATGCAGGGATGATGTTCT-3’, Hes1 RTf 5’-
TAGCCCACCTCTCTCTTCTGA-3’, Hes1 RTr 5’-CAGTGCATGGTCAGTCACTTAAT-3’, Sox9 RT2for 5’-
CTCCCCCTTTTCTTTGTTGTTT-3’, Sox9 RT2rev 5’-TCTGAAACCTCTCATTTGTCCA-3’. 
DBZ and EdU administration and quantification. DBZ (Cayman Chemical) was resuspended 
finely in ME4M slow-delivery vehicle (MethocellTM) using a motorized pestle, and injected I.P. 
EdU (Life Technologies) was given I.P. (10 mg/kg). EdU was detected by the Click-iT Plus EdU 
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Imaging Kit (Molecular Probes). S-phase indices and percent EdU incorporation were counted 
manually. 
Image Acquisition and 3D reconstructions. Confocal images were from a Zeiss LSM 510 META 
(details in figure legends), and 3D reconstructions were rendered using Imaris Software. 
Quantification and Statistical Analyses. Muc1+ plexus and duct areas were traced manually as 
indicated in the figure legends. Pixel areas were obtained using ImageJ. All sectional analyses 
covered approx. 30% of the dorsal pancreas. For endocrine-yield measurements within plexus, 
duct, and DB states, the morphology types were based on the Muc1 lumen structure. Sox9+ and 
Neurog3+ cells were counted manually. Muc1+ lumen that was not unambiguously scorable as 
plexus, duct, or DB was not analyzed. For Hes1-immunofluorescence, mean pixel intensity was 
determined using ImageJ.  For Sox9 immunofluorescence, mean pixel intensity was determined 
using Imaris image-analysis software (Dots function, 4 m nuclear sphere). Statistical analyses 
were performed using Graph Pad software. 
 
Results 
Neurog3+ populations show non-random localization patterns within the trunk 
To address if nascent endocrine cells arise preferentially in different locations within the 
secondary transition trunk, we evaluated the localization of Neurog3+ cells relative to the 
Muc1+ epithelial lumen. Because the bulk of the endocrine mass at birth lies relatively interiorly 
(data not shown), we compared core and peripheral regions to assess whether the later 
endocrine-mass distribution reflects an earlier bias in the location of newly born endocrine 
cells. As previously described, Neurog3+ cells at E15.5 were broadly distributed in a salt-and-
pepper pattern across the Muc1+ lumen, both in the core and periphery, and were absent in 
Muc1+Amylase+ pro-acinar tips (Fig. 4.1A,C) [14]. At E17.5, significant portions of epithelium 
showed a reduction or lack of Neurog3+ cells (Fig. 4.1B,D). Diminished Neurog3+ cell numbers 
were evident in the core, especially where lumen diameters were large, and in the periphery 
where lumens joined with amylase+ tips. There remained however, frequent instances along 
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the lumen where the density of Neurog3+ cells was comparable to the E15.5 stage. These data 
outline a non-random localization pattern of endocrine commitment from the trunk, and 
suggest that endocrine-cell birth might be coordinated with specific epithelial morphogenetic 
states. 
 
Figure 4.1.  Neurog3
+
 populations show non-random localization patterns within the trunk.  (A-D) Epifluorescence 
images of core and peripheral regions, in 10 m cryosections showing Muc1, Neurog3, amylase. (A,C) Neurog3
+
 
cells distributed over Muc1
+
 lumen surface. (B,D) Regions of lumen where Neurog3
+
 cells are reduced in number.  
Blue arrowheads in B, enlarged lumen in the core; blue arrowheads in D, lumen interconnecting amylase
+
 tips. Scale 
bars 50 m. This figure was adapted from [211]. 
 
Plexus expansion and plexus-to-duct transformation in the organ core 
As a first step toward analyzing relationships between endocrine differentiation and epithelial 
morphogenesis, we used a whole-mount and thick-section-based approach to categorize 
epithelial states (derived via lumen morphology) existing as the trunk remodels from the initial 
plexus to the arborized ductal system (Fig. 4.2A). At E14.5-15.5, consistent with a previous 
report [24], the majority of the core was composed of a complex, web-like plexus (Fig. 4.2B). 
Within the plexus, intersecting segments of epithelium varied in length and diameter (Fig.  
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Figure 4.2. Epithelial morphogenesis comprises plexus remodeling in the core and epithelial branching in the 
periphery. (A) Composite 10x images of 45 m thick cryosectioned dorsal pancreas at E16.75. Green and red 
dashed lines bound the core and periphery, respectively.  (B-D) Muc1-labeled 35 m thick cryosections showing 
typical progression through plexus expansion and duct-transformation in the core. (E-G) Epithelial branching in the 
periphery.  White dashed line, outer organ boundary.  (G-L) Confocal z-stacks show features of plexus (H,K), duct 
(I,L), and DB (J,M) states. Core (green dashed line in I-J); periphery (red dashed line). Small, unclefted DBs in the 
core (blue arrowheads), clefted DBs in the periphery (yellow arrowheads in H), lobes of DBs (blue dashed line), 
Muc1
+
 lumen of pro-acinar tips (white arrowheads in J), and connecting lumen (red arrowheads in J). (K-M) Line 
traces of lumen from H-J. Individual segments of plexus (dotted light blue lines) and core duct-states (red dashed 
line). Note the increase in lumen diameter, and the continuous directionality across representative 40x field, of the 
duct-state in L relative to the plexus in K. Green arrowheads: unlabeled cell-fields (epithelial & parenchymal) 
bounded by Muc1 signal.  (N,O) Traced representations of the processes of plexus-to-duct transformation in the 
core, and epithelial branching in the periphery. Scale bars 20 m in B,E,H-J; 50 m in C,F; 100 m in A,D,G. This 
figure was adapted from [211]. 
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Figure 4.3. Formation of the core-duct and ductal-branch states during late gestation.  (A,B) Plexus-to-duct 
transformation (from Fig. 2I,L) showing plexus (blue dashed line in A) connected to duct (yellow dashed line in B). 
Sox9 in plexus and duct-states (C is sectional inset from B). (D,E) Analysis of nuclear position and shape in plexus 
versus core duct states. (F) Quantification of mean fluorescence intensities in Sox9
+
 populations from plexus and 
duct states at E17.5 (G,J) Epifluorescence images of 30-40 m-thick cryosections showing central (red dashed line) 
and interlobular ducts (green dashed line) at E17.5. (H,I,K,L) Fluorescence detection of DBA
+
, Muc1
+
, and CK19
+
 
epithelium at 40x magnification in ~35 m confocal z-stacks.  DBA marks the central (yellow arrow), interlobular 
(yellow arrowhead), and intralobular ducts (blue arrow).  (L) CK19 marks the same, in addition to DBA
-
 intercalating 
ducts (blue arrowhead).  Scale bars are 15 m in A-C, 100 m in G,K; 20 m in H,I,K,L. This figure was adapted from 
[211]. 
4.2H). In traced representations, cell fields bounded by the Muc1+ lumen (represented as 
“holes” in the plexus web) varied in size and shape, but showed a uniform heterogeneity across 
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the core (Fig. 4.2K). There was no evidence of an extensive arborized ductal structure at these 
stages. We found little evidence of multi-branched epithelia interconnecting pro-acinar tips, 
except at the outer edges of the plexus.  Most pro-acinar tips (demarcated by a bulb-like 
morphology and intense Muc1-positivity) appeared as small, individual tips interspersed 
throughout the plexus. We conclude that the principal epithelial state in the core from E14-15.5 
is plexus.    
At E16.5, there was an expansion of the plexus state concomitant with the increase in organ 
size. This was accompanied by a transformation of the plexus into ductal states representing 
the beginnings of an arborized ductal system. Ductal states in the core were discernible by their 
increased lumen diameter and extended, continuous directional orientation compared to the 
web-like plexus (Fig. 4.2C,D). This “plexus-to-duct transformation” occurred asynchronously 
across the organ, and was evident first with appearance of the central duct (E16.5). Cells in the 
core ductal state showed measurably reduced Sox9 immunoreactivity, and a flattening of cells 
and their nuclei (Fig. 4.3A-F), consistent with an acquisition of a ductal phenotype [82]. At E17-
18.5, connecting interlobular ducts were observed to form, oriented toward the periphery (Fig. 
4.3G-I). This process remained incomplete even late into the secondary transition, and 
abundant plexus remained in scattered locations at E18.5 (Fig. 4.3). These analyses show that 
trunk morphogenesis in the core is dominated by an initial phase of growth and expansion in a 
plexus state, followed by plexus-to-duct transformation to generate the core of the ductal 
arbor (Fig. 4.2N).   
Epithelial branch remodeling in the organ periphery 
In contrast to the organ core, a pervasive epithelial branching process was evident in the 
periphery (Fig. 4.2A,E-G).  From E14.5-E18.5, pro-acinar tips exhibited a variety of clefted 
morphologies, and appeared to grow and multiply progressively to generate lobes of 
interconnected ductal branches (hereafter “DB”) linking multiple tips (Fig. 4.2J,M). Intervening 
DB-segments multiplied and lengthened over time, at late stages forming CK19+DBA+ 
intralobular ducts and distal CK19+DBA– intercalating ducts (Fig. 4.3J-L) [167].  DBs were most 
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Figure 4.4. Dynamics of plexus-to-duct transformation in the core.  Measurement of relative pixel area for Muc1
+
 
plexus over the combined plexus and duct-state pixel area in the core. Measurements were taken from serial 30-40 
m thick sections covering whole dorsal pancreata.   Measurements exclude Muc1
+
 ductal branches and pro-acinar 
tips. Measurements were taken using ImageJ software. Error bars are S.E.M, n = 3 for each time point. This figure 
was adapted from [211]. 
 
advanced in peripheral regions devoid of plexus, but less so in regions within or approaching 
the plexus. Taken together, we detect two disparate patterns of trunk morphogenesis during 
the secondary transition. There is a long-lived plexus expansion followed by plexus-to-duct 
transformation in the core, contrasted to pervasive epithelial branching in the periphery (Fig. 
4.2N,O). These observations on the spatiotemporal and morphological features of plexus, duct, 
and branched (DB) epithelial states provide a basis to map correlations between endocrine-
lineage flux and states of epithelial morphology.  
Endocrine differentiation is enriched in the plexus  
To ascertain if Neurog3+ populations have specific localization patterns within the remodeling 
epithelium, we compared endocrine yield (as determined by the ratio of Neurog3-to-Sox9+ 
cells; see Chapter II) between plexus, duct, and DB states from E14.5-E18.5. Epithelial cells in 
plexus, duct, and DB states showed similar Sox9 immuno-reactivity (Fig. 4.5A-F). Low Sox9 
signal was observed in pro-acinar tip cells, which were excluded from our analysis. From E14.5-
E18.5 endocrine yield was highest in the plexus, and significantly lower or absent in ducts and 
DBs (Fig. 4.6A-H). Endocrine yields measured selectively from samples of plexus consistently 
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exceeded those measured from bulk sectional analyses, indicating that endocrine yield is 
enriched in the plexus (Fig. 4.6I). At E18.5, there were scattered yet extensive remainders of 
plexus, which were invariably associated with large numbers of Neurog3+ cells, indicating that a 
high level of endocrine differentiation is consistently maintained in the plexus, independent of 
stage (Fig. 4.7A-D). Sharp boundaries demarcating high and low endocrine yields were  
 
Figure 4.5. Sox9
+
 populations mark plexus, duct, and ductal-branch states.  (A-F) Whole mount z-stack 
reconstructions of Sox9 and Muc1-labeled epithelium in peripheral segments of wild-type dorsal pancreas at E14.5 
and E17.5.   Blue, red, and green boundaries demarcate plexus, duct, and ductal-branch states, respectively.  (C,F) 
Pro-acinar tips are demarcated by intense Muc1 signal, a bulb-like morphology that becomes clefted and elongated 
over time, and a low nuclear Sox9 signal that diminishes over time. Scale bars are 20 m. This figure was adapted 
from [211]. 
commonly observed at the interface between plexus and duct or DB states, respectively, 
suggesting a rapid cessation of endocrine-cell birth concomitant with loss of plexus 
morphology. These data put forth the view that endocrine differentiation is robust and 
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enriched within the plexus during the entire secondary transition, and is rapidly downregulated 
upon plexus-to-duct transformation in the core, or engagement of epithelial branching in the 
periphery.   
 
Figure 4.6. Endocrine differentiation is enriched in the plexus-state. (A-H)  Representative images of Neurog3
+
 cells 
in relation to plexus (blue dashed box), duct (red dashed box), and DB (green dashed box) states. Scale bars 20 m. 
(I) Comparison of endocrine yield in plexus, duct, and DB states. Each point represents endocrine yield summed 
from individual 35-50 m thick 40x z-stacks. E14.5-E18.5 plexus vs DB, p < 0.0001.  E17.5 and E18.5 plexus vs duct, 
p < 0.0001. E16.5 plexus vs duct p = 0.0019. Error bars are S.E.M, Student’s t-test. Bulk endocrine yield determined 
in A (black dashed line). This figure was adapted from [211]. 
 
Notch-responsive endocrine progenitors are enriched in the plexus 
Consistent with a proposed model for lateral Notch-pathway activation by Neurog3-expressing 
cells [32,168,169], genetic ablation of Neurog3, as reported previously [72], caused loss of Hes1 
(a Notch transcriptional-effector) signal in Sox9+ epithelial cells, suggesting that Notch-pathway 
activity is Neurog3-dependent, and engaged locally in the plexus-state (Fig. 4.8A-D). Consistent 
with this notion, immunodetection of the Hes1 showed relatively pervasive expression in the 
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plexus compared to regions of fully-resolved core ducts and peripheral DBs, suggesting that 
Notch-responding cells are enriched within the plexus (Fig. 4.9A,B). Because Notch-Hes1 
signaling blocks endocrine differentiation, we hypothesized that Sox9+ populations in the plexus  
 
Figure 4.7. Endocrine differentiation in the plexus-state persists late into secondary transition. (A-D) Muc1, 
Neurog3, and Sox9 whole-mount immunolabeling of core and peripheral regions of dorsal pancreas exhibiting 
plexus (blue dashed line), ductal-branch (green dashed line), and duct (red dashed line) states at E18.5. Note 
reduced Sox9 levels in duct compared to plexus in B.  Scale bars are 20 m. This figure was adapted from [211]. 
would show an increased endocrine-differentiation response, compared to duct and DB states, 
under conditions where Notch is inhibited. To test this, we compared endocrine yield in E17.5 
embryos from pregnant dams injected each day for two days with the gamma-secretase 
inhibitor DBZ, which blocks Notch signaling [170,171]. Similar to a previous report showing 
dose-dependent reductions in Hes1 and Sox9 expression in Notch-inhibited pancreatic explants 
[32], increasing DBZ doses elicited reproducible, progressive reductions in pancreatic Hes1 and 
Sox9 expression measured by qRT-PCR. Hes1 decreased at a lower DBZ dose (0.15 ± 0.06 and 
0.09 ± 0.07, at 12 and 20 mol/kg DBZ relative to control, respectively) as compared to Sox9 
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(0.88 ± 0.18 and 0.43 ± 0.18, 12 and 20 mol/kg DBZ relative to control) (Fig. 4.9H). We chose 
the 12 mol/kg DBZ condition for analysis of endocrine yield, due to the minimal effect 
registered on Sox9. Endocrine yield from the plexus was robustly increased in response to DBZ  
 
Figure 4.8. Epithelial Hes1-expression is lost under Neurog3-deficient conditions. (A-D) Frozen section 
analysis of the ratios of Hes1+ and Sox9+ populations in the trunk domain of control and Neurog3-
deficient animals. (D) Blue arrowheads indicate clusters of Hes1+ cells in the Neurog3EGFP/EGFP samples. 
This figure was adapted from [211]. 
(Fig. 4.9C-F), and consistently approached a near three-fold increase relative to the vehicle-
treated condition. Assuming the absence of a proliferation effect on Sox9+ cells, this increase 
indicates that approximately half of the plexus population (endocrine yield = 1 indicates 1:1 
Neurog3:Sox9) defaults to the endocrine lineage under these conditions (Fig. 4.9G). In contrast, 
Sox9+ cells in duct and DB states showed marginal and variable responses to DBZ, indicating 
that Sox9+ cells in these states are largely refractory to endocrine differentiation. These 
expression data and inhibition studies suggest that the plexus-state is enriched for a Notch-
responsive Sox9+ progenitor pool that is poised to adopt the endocrine lineage under normal 
conditions. 
Sox9+ cell replication is uncoupled from Neurog3-dependent Notch-inhibition of endocrine 
differentiation 
Notch signaling has been linked to the regulation of mitogenic cell-cycle progression 
[41,172,173]. We analyzed whether the Notch function in maintaining the undifferentiated 
progenitor state is coupled with the maintenance of proliferative growth in Sox9+ cells. We 
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Figure 4.9. Notch-responsive progenitors are enriched in the plexus-state.  (A) Detection of Hes1 relative to the 
Muc1
+
 duct-state (yellow arrowheads), plexus-state (blue arrowheads), and DBs (green arrowheads). Scale bar 50 
m. (B) Mean nuclear intensity of Hes1 signal in individual Sox9
+
 cells. N=102 plexus, N=91 DB (*) (p < 0.0001), 
N=52 duct (p < 0.0001) from three separate z-stack volumes. Error bars: S.E.M, Student’s t-test. (C-F) 
Representative images of Muc1 and Neurog3 in plexus and duct-states under vehicle or DBZ treatment. Blue 
arrowheads delineate plexus in C,D; yellow arrowheads indicate the surface of ductal states in E,F; dashed magenta 
lines delineate locations where Neurog3-rich plexus intersects with the duct state. Scale bar 20 m. (G) Endocrine 
yield in plexus, duct, and DB states under vehicle or DBZ treatment. Each point represents endocrine yields summed 
from individual 40x z-stack volumes (~35-50 m thick). N=11, N=12, N=15 for plexus, duct, and DB in vehicle 
control. N=16, N=11, N=15 for plexus, duct, and DB in DBZ-treated group. n=3 for both conditions. Error bars are 
S.E.M, (**) p < 0.0001, (***) p=0.0149, (****) p=0.0013, Student’s t-test. (H) Normalized gene expression for Sox9 
and Hes1 under control, Neurog3-deficient, and DBZ-treated conditions. Error bars are S.E.M, n ≥ 3 for each 
condition, (*) p=0.0373. (I,J) One-hour EdU indices in Sox9
+
 populations under control or DBZ treatment. Error bars 
S.E.M., n = 3. This figure was adapted from [211]. 
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evaluated EdU uptake in embryonic pancreata taken from DBZ-treated dams.  For both 12 and 
20 mol/kg doses, we observed no change in the proportion of Sox9+ cells replicating DNA after 
two days DBZ administration (Fig. 4.9I,J). Because these DBZ doses reduced Notch activity by an 
amount similar to or beyond that caused by Neurog3-deficiency (Fig. 4.9H), we conclude that 
bulk epithelial proliferation behaviors are not significantly affected by reduced Notch activity 
under these conditions.  
Neurog3-deficiency causes reduced Sox9+ progenitor replication and precocious remodeling of 
the plexus 
To evaluate cell-non-autonomous functions for Neurog3 in regulating the growth of the 
epithelial progenitor pool, we compared cell replication behaviors in Neurog3EGFP/+ and 
Neurog3EGFP/EGFP pancreata. Analysis of S-phase indices indicated a 50% decrease in EdU-
labeling of Sox9+ progenitors when Neurog3 is lost. This decrease was evident at E13.5, when 
the vast majority of the trunk is in the plexus-state, and also at E16.5 when plexus-to-duct 
transformation begins in the organ core (Fig. 4.10A-C). This reduction in EdU-labeling was not a 
general feature of all pancreatic epithelial cells. S-phase indices in pro-acinar cells were 
unchanged, and because they represent the major cell type during mid-to-late gestation, no 
gross organ hypoplasia was evident at any stage (Fig. 4.11A-C, and data not shown). These 
results demonstrate a previously unreported function for Neurog3 in supporting robust 
replication in the Sox9+ trunk that is, based on the DBZ treatment results above, largely 
independent of Notch-pathway activity. 
Given the reduction in progenitor replication observed under Neurog3 deficiency, we assessed 
potential defects in maintenance of the plexus by comparing the time-course for Neurog3-
deficient plexus remodeling into duct and DB states. Analyses at E14.5 confirmed previously 
reported increases in lumen diameters, and moderate decreases in peripheral branching [72] 
(Fig. 4.10D,E). Surprisingly, we also found frequent DB-like structures emerging in peripheral 
locations normally comprised of plexus at this stage, indicating a precocious remodeling of 
plexus morphology into non-plexus states under Neurog3-deficient conditions. At E16.0, a time 
point just before the plexus normally undergoes transformation into core-duct and peripheral-
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DB states, we observed multiple regions where plexus-morphology was diminished or 
completely lost relative to control (Fig. 4.10G-M). Consistent with this, the relative area of 
plexus compared to duct-like-states was significantly decreased at E14.5, 16.5 and 18.5 in 
Neurog3 null tissue (Fig. 4.10F). These results indicate that Neurog3 functions not only to 
determine a normal plexus morphology, but also to maintain and propagate the plexus by 
limiting its remodeling into non-plexus states. 
 
Figure 4.10. Neurog3 deficiency causes reduced cell replication and precocious loss of the plexus-state. (A,B) S-
phase indices in Sox9
+
 cells from Neurog3
EGPF/+
 and Neurog3
EGFP/EGFP
 samples. (C) Quantification of A & B (E16.5), 
plus measurements at E13.5. Error bars are S.E.M, n=2 E13.5 (*) p=0.0277, n=3 E16.5 (**) p=0.0048 with 30% of 
dorsal pancreas scored; Student’s t-test. (D,E) Dorsal pancreas from E14.5 Neurog3
EGFP/+
 and Neurog3
EGFP/EGFP
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samples at E14.5. Red arrowheads, regions where plexus is lost in the Neurog3
EGFP/EGFP
 compared to control. Green 
arrowheads, core locations where plexus becomes dysmorphic in the Neurog3
EGFP/EGFP
 animal compared to control. 
(F) Quantification of plexus-to-duct transformation in core Neurog3
EGFP/+
 and Neurog3
EGFP/EGFP
 pancreata. Error bars 
are S.E.M, n=3 all stages, (*) p<0.01, (**) p=0.119. The entire dorsal pancreas core was analyzed in serial thick 
sections (40 m). (G) Analysis of precocious loss of plexus at E16.0. (G) Regions a, b and c in cartoon correspond to 
images in H-M. (H-M) Muc1 and insulin immune-detection in similar locations in Neurog3
EGFP/+
 and Neurog3
EGFP/EGFP
 
littermates. Scale bars: A,B 20 m; D,E 50 m; H-M 40 m. This figure was adapted from [211]. 
 
Figure 4.11. S-phase indices in acinar cells are unchanged in Neurog3-deficient pancreata.  (A) Representative 20x 
image of EdU incorporation at 1 hour post-injection in amylase
+
 acinar clusters of Neurog3
EGFP/+
 and 
Neurog3
EGFP/EGFP
 dorsal pancreas.  (B) Quantification of the EdU-incorporation index. Scale bars are 50 m.  Error 
bars are S.E.M.  N = 1673 Neurog3
EGFP/+
 and N = 1436 Neurog3
EGFP/EGFP
 amylase
+
 cells counted from five sections 
spanning n = 2 dorsal pancreas for each genotype. This figure was adapted from [211]. 
 
Late-stage autonomous epithelial remodeling in the Neurog3-deficient plexus 
While a limited amount of precocious remodeling and alteration of the Neurog3-null plexus 
morphology was observed at mid-gestation, there was no grossly aberrant phenotype at late 
gestation, suggesting that the mechanisms guiding epithelial remodeling could eventually over-
ride the earlier defect. Consistent with this, Muc1 and insulin (to label the endocrine-cell mass 
105 
 
derived from the epithelium) detection in equivalent organ regions from E14.5-17.5 showed a 
progressive normalization of the Neurog3-null epithelium (Fig. 4.12A-F). Specifically, the  
 
Figure 4.12. Late-stage corrective remodeling in Neurog3-deficient epithelium. Muc1 and insulin labeling in 40 m 
thick sections showing representative core (A-L) and peripheral (M & N) regions of Neurog3
EGFP/+ 
and 
Neurog3
EGFP/EGFP 
pancreata at stages indicated. Scale bars are 30m in A,D,G-L; 20 m in B,E; 50 m in C,F; 100 m 
in M,N. This figure was adapted from [211]. 
expansive enlargements of Neurog3EGFP/EGFP plexus lumens seen at E14.5 underwent remodeling 
toward a morphology largely indistinguishable from control by E17.5. Furthermore, the 
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previously reported moderate reduction in peripheral branching in Neurog3-nulls [72] were 
also corrected (Fig. 4.12M,N). The plexus morphology at E12.5 was similar between 
Neurog3EGFP/+ and Neurog3EGFP/EGFP (data not shown), indicating that the perturbed morphology 
of the Neurog3-deficient plexus manifests most severely during the peak of endocrine (-cell) 
birth [57]. These analyses show a late-stage process of autonomous epithelial remodeling 
occurs in the absence of Neurog3-dependent differentiation, delamination, and Notch-
regulated processes. 
 
Discussion 
Understanding how niche environments direct progenitor activities is fundamental to 
uncovering the basic principles underlying complex organ formation and function, and 
predisposition to disease. In studying endocrine-progenitor activity during the secondary 
transition of pancreatic organogenesis, we discovered that endocrine progenitors are largely 
constrained within an epithelial plexus-state. Although the plexus is transient, it is maintained 
through all stages of the secondary transition, and is as productive at generating endocrine cells 
during late gestation as it is at earlier stages. Genetic and pharmacological interference tests 
indicate that endocrine-progenitor expansion, differentiation and morphogenesis processes are 
coordinated by local feedback effects within the plexus. These effects derive largely from 
differentiating Neurog3+ cells, but can be uncoupled on the basis of Neurog3-dependent 
differentiation/delamination functions supporting progenitor replication, and Notch-dependent 
functions in maintaining an undifferentiated progenitor state. Together, these feedback 
interactions serve to propagate the plexus, and the large numbers of endocrine progenitor cells 
maintained therein, late into gestation. Ultimately, as the plexus remodels into duct and DB 
states, endocrine differentiation and progenitor maintenance behaviors are reduced then lost. 
We propose that the epithelial plexus functions as a niche environment, where endocrine 
progenitors are assembled and maintained, and where local differentiation-dependent 
feedback interactions are deployed to direct the genesis of the endocrine pancreas (Fig. 4.13). 
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Figure 4.13.  Feedback control of endocrine progenitor growth, differentiation, and morphogenesis in the plexus 
niche.  (A)  Diagrammatic representation of the principle morphogenetic processes comprising trunk epithelial 
morphogenesis during 2
O
 transition. Regions of the organ enriched for Notch-responsive endocrine progenitors are 
demarcated in blue, whereas regions reduced or absent in this respect are orange.  (B) Diagrammatic 
representation of the local feedback interactions operating in the plexus-state. This figure was adapted from [211]. 
  
Distinct processes of plexus-to-duct remodeling and epithelial branching in the trunk  
Our characterization of pancreatic epithelial remodeling indicates distinct modes of 
morphogenesis in largely separate zones of the organ. In the core, plexus expansion and growth 
from E12.5-E15.5, accompanied by plexus-to-duct transformation from E16.5-E18.5, represents 
the principal mode by which ductal tissues analogous to the trunk and main limbs of a tree are 
generated. In the periphery, however, an “epithelial branching” mode remodels the epithelium, 
apparently by a clefting and outgrowth process, to eventually generate tightly-packed 
peripheral lobules of interconnected DB structures. This dual-mode program, especially the 
major contribution from plexus expansion and resolution, diverges greatly from the classical 
and more stereotypically defined branching morphogenesis involved in the growth of other 
endodermal organs [26,174,175].   
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Because the plexus-remodeling process occurs asynchronously across the organ, it will be 
important to determine what influences (cellular or otherwise) cause some plexus regions to 
undertake expansion while remaining unresolved (and in a high endocrine-yield state), while 
others begin transformation toward the mature duct-like states. We do not find evidence, at 
any stage of plexus resolution, which would suggest that remodeling is accomplished through 
breakage and regression of epithelial segments, as reported for vascular plexus remodeling 
[176]. Rather, we observe an apparent progressive consolidation of epithelial plexus segments 
that effectively reduces the complexity of, and eventually eliminates, the plexus-web, to 
generate the final ductal tree. Our analysis of Neurog3-/- pancreata allows us to rule out a 
model whereby plexus remodeling is primarily driven by epithelial-cell departure 
(delamination) of Neurog3+ endocrine precursors. While Neurog3-dependent processes are 
clearly important for regulating and propagating a “normal” plexus state, the observation of the 
late-stage corrective remodeling demonstrates that the epithelial remodeling program, albeit 
with substantial delay, eventually enforces a relatively normal morphogenesis even in the 
absence of Neurog3. Therefore, in normal tissue, we propose that the function of Neurog3 in 
maintaining and propagating the progenitor-rich plexus is balanced with an opposing, and 
apparently self-organizing epithelial morphogenesis process, that eliminates the plexus 
intermediate in favor of the typical ductal structures of the mature epithelium. It remains to be 
determined how other known regulators of pancreatic epithelial morphogenesis and growth, 
especially those derived from epithelium-extrinsic sources such as the mesenchyme 
[177,178,179] and vasculature [24,72], contribute to localized epithelial remodeling patterns 
during plexus growth, plexus-to-duct transformation, and epithelial branch specification and 
outgrowth. We propose that the detailed analysis of the dual-mode morphogenesis program 
reported here should enable future connection of such extrinsic cues to specific epithelial-
remodeling outcomes. 
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Notch and endocrine-differentiation-mediated feedback effects regulate distinct endocrine-
progenitor behaviors 
Our finding that Hes1 expression is maintained locally within the plexus, even at late gestational 
stages, leads to interesting questions regarding how duct vs. endocrine cell-fate allocation 
might be dynamically influenced by Notch activity. Our data showing that Hes1, similar to 
Neurog3, is enriched in the plexus, and that Notch inhibition by DBZ increases the portion of 
the plexus cell population activating Neurog3, fit a model whereby Notch-based signals derived 
locally from Neurog3+ cells maintain epithelial cells in an undifferentiated and Notch-responsive 
state.  Ultimately, Sox9+ cells of the duct-state epithelium – that is, in the core ducts and 
peripheral DB – downregulate Hes1 and Sox9, and become a poor source of Neurog3+ cells, 
both normally and under Notch-inhibited conditions, consistent with the idea that non-plexus-
state cells have truly entered a ductal differentiation program. Our observations thus begin to 
outline spatial variations in the level of Notch pathway activity, and the differentiation response 
to perturbing Notch, which are correlated with distinct states of epithelial morphology arising 
during organogenesis. Identifying markers that distinguish states of pro-duct specification 
versus undifferentiated bipotent-progenitor will likely aid in defining the non-cell-autonomous 
cues that instruct duct specification or maintain the bipotent pool, perhaps as obligatory 
features of developmental coordination in the plexus. 
We observe profound reductions in progenitor replication under conditions where Neurog3 is 
inactivated, but not when Notch signal processing is inhibited. While spatiotemporally more 
precise Notch perturbation may uncover roles in regulating the replicative amplification of 
endocrine progenitors in mice, our results raise the possibility that a delamination function for 
Neurog3 may determine replication rates in the epithelial population.  Indeed, studies in 
Drosophila demonstrate that cell delamination limits tissue overcrowding and promotes 
epithelial growth [127], suggesting that biomechanical mechanisms and/or pathways regulating 
cell-shape or density-dependent growth [180] could be critical determinants of pancreatic 
progenitor growth and replication. 
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Intrinsic versus feedback-based regulation of endocrine lineage allocation, progenitor 
maintenance, and plexus morphogenesis during the secondary transition 
In contrast to growth-compensation programs in the liver, the pancreatic growth program is 
regulated intrinsically by the number of MPC initially allocated to the pancreatic anlagen [17]. 
We speculate that an internally regulated, feedback-rich process of plexus morphogenesis, 
from its initial establishment to maturation as a ductal arbor, could explain how endocrine 
lineage output is “pre-determined” by founder MPC number. Our data are consistent with a 
highly processive plexus state from which endocrine cells are continuously born. Endocrine 
yield is robust within the plexus at all stages, but is rapidly reduced upon its transformation into 
non-plexus states. The initial number of MPC allocated to the initial plexus-state could influence 
how long the plexus is maintained, and thereby prolong or shorten the period of endocrine-
lineage allocation. Of relevance is the effect of ectopic Nkx6.1 expression in pancreatic MPC. 
During stages concomitant with plexus formation, Nkx6.1 antagonizes the pro-tip gene Ptf1a, 
diverting MPC toward bipotent trunk progenitors [43]. This transcriptional-antagonism effect 
on tissue-compartment allocation is Notch-regulated, providing a potential link between the 
timing and/or levels of Notch in the Nkx6.1+ MPC during initial plexus formation and the final 
endocrine-cell output [169,181]. Current translational objectives regarding the differentiation 
of pluripotent cells toward the endocrine cell fate in vitro could benefit from investigating how 
the size of the “initiating plexus” and duration of its maintenance impact the final size and 
composition of the endocrine pancreas, and if these parameters can be controlled by 
modulation of Notch, Nkx6.1, and Ptf1a.  
Our data put forward the possibility that endocrine-differentiation dynamics, in terms of the 
rate of endocrine flux and/or the specific type of endocrine cells produced, could be guided by 
epithelium-intrinsic morphogenetic influences. Of particular interest to endocrine sub-type 
specification, a previous study [57] showed that competence windows for the differentiation of 
endocrine-cell sub-types are regulated by factors intrinsic to the pancreatic epithelium. Such 
windows of competence could be connected to specific tissue-level or cell-biological alterations 
associated with plexus formation, expansion, and remodeling phases. [The -cell competence 
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window could correlate with initial plexus formation (E9.5-E12.5), -cell birth more with the 
mid-gestation plexus-expansion phase (E12.5-E15.5), and the later production of /PP cells 
with plexus-to-duct transformation (E16.5-E18.5)]. We envisage the future testing of the idea 
that specific, and perhaps relatively subtle perturbations to the plexus morphogenesis program 
might alter the epithelial environment in ways that influence the number and type of endocrine 
cells born. 
Linked programs of endocrine progenitor maintenance, differentiation, and morphogenesis 
Emerging reports suggest that some aspects of endocrine-progenitor differentiation and 
proliferative expansion are dependent on molecular determinants of cell and tissue 
morphology. For instance, a requirement for Cdc42-mediated apicobasal polarization has 
already been linked to the generation of an endocrine-differentiation-competent progenitor 
pool [71], and could thus be considered as a central contributor to the generation of the plexus. 
Additionally, ablation of Strad13, a RhoA-ROCK-nmMyoII negative regulator, reduces the size 
and replicative activity of pancreatic MPC [182], and defects in planar cell polarity are 
associated with reduced Neurog3+ cell numbers [85]. While the detailed mechanistic 
underpinnings causing defective endocrine-lineage development in these cases remain unclear, 
the picture emerging is that insights into how endocrine progenitors and committed endocrine 
precursors are efficiently maintained and generated, respectively, may be gleaned from 
characterizing, with increased spatiotemporal resolution, how cytoskeletal dynamics, cell 
polarity, actomyosin contractility, and/or the trafficking and distribution of receptors such as 
Notch, functionally link cell and tissue morphogenesis processes with cell-fate determination. 
 
Acknowledgements 
We thank Tetsuo Sudo (Toray Industries) for the gift of Hes1 antibody, the Vanderbilt Cell 
Imaging Shared Resource for training and access to equipment and image-processing software. 
Imaging scholarships were from the VUMC DDRC, DRTC and VICC [supported by NIH grants 
CA68485, DK20593, DK58404, DK59637]. We thank Anna Means, Guoqiang Gu, and members 
112 
 
of the Wright/Gu labs for discussions. This study was supported by the National Institutes of 
Health (1UO1DK089570-01).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
113 
 
CHAPTER V 
A ROCK-nmMYOII, NOTCH, AND NEUROG3 GENE DOSAGE CIRCUIT LINK EPITHELIAL 
MORPHOGENESIS AND CELL FATE IN THE PANCREATIC ENDOCRINE PROGENITOR NICHE 
 
Introduction 
How cell differentiation and morphogenesis are coordinated during organogenesis remains a 
central question in biology. During pancreas development, endocrine cells are allocated from a 
bipotent duct/endocrine progenitor pool located within an epithelial “plexus state”. We find 
that upregulation of the endocrine lineage determinant Neurog3 occurs in the plexus upstream 
of Neurog3 protein function and concomitant with initiation of cell-delamination, suggesting 
that endocrine commitment is directed by a epithelium-intrinsic morphogenetic program. 
Progression through delamination is characterized by initial apical-narrowing and focalization, 
and increased migratory activity at the basal cell surface, with the latter being Neurog3-
dependent. Mechanistically, the ROCK-nmMyoII pathway mediates Neurog3-independent and 
dependent steps in delamination to guide endocrine cell birth. NmMyoII is necessary for apical 
narrowing and basal migratory activity, and its inhibition results in an early block in Neurog3 
upregulation. ROCK activity gates the transition from low to high Neurog3 expression by 
limiting apical narrowing and basal migratory activity, and its inhibition can rescue defects in 
Neurog3 upregulation observed in Neurog3-hypomorphs. Finally, Neurog3 gene dosage, 
ROCK/nmMyoII, and Notch pathways comprise a self-organizing feedback circuit that optimizes 
endocrine lineage commitment from the plexus state. These studies demonstrate linked 
programs of differentiation and morphogenesis in the plexus, and provide insights into 
principles underlying the formation of complex organs. 
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Material and Methods 
Mice 
Neurog3EGFP knock-in and Neurog3Flox mice were from Guoqiang Gu (Vanderbilt University). 
Ngn3EGFP/EGFP embryos were phenotyped by EGFP fluorescence and lack of endocrine cells. Wild-
type mice were of mixed genotype. The Neurog3RG line was generated as described [Matt 
Bechard, Wright Lab, submitted). All protocols were approved by Vanderbilt University IACUC. 
Genotyping primers for the EGFP allele were ngn3-1 5’-ATACTCTGGTCCCCCGTG-3’, ngn3-2 5’-
TGTTTGCTGAGTGCCAACTC-3’, and EGFP  5’-GAACTTGTGGCCGTTTACGT-3’ [59]. Genotyping 
primers for Neurog3 floxed allele were 5’HRsFr-ccttctcttccagagacttc and 5’HRsH-
ctctggtcagagatacctgg, or 722: 5′-CTATCCACTGCTGCTTGTCACTG-3′, 723: 5′-
TGTGTCTCTGGGGACACTTGGAT-3′, jv45: 5′-TTCCGGTTATTCAACTTGCACC-3′ [52]. The nmMyoIIC-
GFP line was a kind gift from Dr. Adelstein [212], and nmMyoIIC-GFP+ embryos were 
phenotyped under a fluorescence microscope. 
Immunodetection 
Embryonic pancreas paraformaldehyde fixed (4%, 4oC for 4-6 hours).  For cryosectioning, 
samples were sucrose-equilibrated (30%, 4oC overnight), and embedded in OCT (Tissue-Tek, 
Sakura).  Thick sections were obtained on a Leica CM3050 S in the range of 30-40 m; thin 
sections at 10 m. Protein detection reagents used include chicken anti-GFP (Aves), hamster 
anti-Muc1 (NeoMarkers), rabbit anti-Sox9 (Millipore), goat anti-Neurog3 (Gu lab), DAPI (Life 
Technologies), mouse anti-Ecad (AbCam), rabbit anti-gamma-tubulin (AbCam), rabbit anti-Prox1 
(AngioBio Co), guinea pig anti-Pdx1 (Wright Lab), phalloidin (Molecular Probes), rabbit anti-ZO1 
(AbCam), rabbit anti-aPKC (Santa Cruz), rabbit anti-phospho-nmMyoII (AbCam), rabbit anti-
nmMyoIIa (Covance), rabbit anti-nmMyoIIb (Cell Signaling).   
Image Acquisition and Data Collection 
Confocal images were obtained using Zeiss LSM 510 META upright scope or a Zeiss Apotome. Z-
stack volumes were acquired in the 20-30 m range at 40X magnifications. 3D reconstructions 
were rendered using Imaris software.  
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Quantification and Statistical Analyses 
Method to distinguish plexus from non-plexus states was performed as described [211].  
Fluorescence intensity measurements were performed by mean pixel intensity using ImageJ. 
Sox9 and Ngn3 ratios were determined by manual counting. Measurements of all 
morphological structures and nuclear densities were acquired using line or polygon-trace 
functions in IMARIS.     
Explants and Drug Treatments 
Explants were manually dissected and culture at the air liquid interface on transwell permeable 
supports (Costar, 3422). Incubator conditions were 37oC and 5% CO2. S(-) Blebbistatin (Abcam), 
Y27632 (Selleckchem), and DBZ (Cayman Chemical) were administered in the culture medium 
(10% FBS, 1% Pen/Strep, 1% L-glut). After harvesting, explants were fixed for 2 hours in 4% 
paraformaldehyde. 
EdU incorporation studies 
EdU (Life Technologies) was given I.P. (10 mg/kg). EdU was detected by the Click-iT Plus EdU 
Imaging Kit (Molecular Probes). 
Live Imaging 
Neurog3RG+ pancreata were isolated at E12.5 and phenotyped under a fluorescence 
microscope. These were grown on fibronectin, cultured in DMEM (10% FBS, 37O C, 5% CO2) in 
an incubator overnight to promote attachment to the matrix, and imaged on a LSM 780 two-
photon microscope.  
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Results 
Morphological transitions at the F-actin+ apical cell cortex are associated with cell-fate 
allocation 
In polarized epithelial cells, a prominent feature of the cytoskeleton is a belt of bundled 
filamentous actin (F-actin) that circumscribes the subapical cell cortex [112]. These belt-like 
structures (hereafter F-actinBELT) are closely apposed to tight and adherens junctions, and play 
important roles in mediating cell and tissue remodeling processes such as apical constriction, 
tissue folding, cell intercalation, and delamination or extrusion [210]. To gain insight into 
whether specific cell-shape changes may be involved in mediating duct and endocrine lineage 
allocation, we compared the shape of the F-actinBELT in cells residing within the progenitor-rich 
plexus-state, in cells expressing Neurog3, and in cells within the endocrine-progenitor-poor 
duct-state. In confocal z-stack reconstructions of the plexus, a multicellular meshwork of 
cortical F-actin could be visualized by a relatively intense phalloidin signal closely associated 
with the Muc1+ epithelial apical lumen surface (Fig. 5.1A). This meshwork of F-actin was 
apposed to apical ZO1+ tight junctions, and located apically with respect to the basolateral 
Ecad+ adherens junctions (Fig. 5.2A-H’), as defined for F-actinBELT in numerous epithelia.  
Plotting the measured F-actinBELT aspect ratio against F-actinBELT perimeter from individual cells 
(as a surrogate for apical domain shape (Fig. 5.3A-B)) showed a broad spectrum of apical 
domain shapes in the plexus (Fig. 5.1D). The domain and range of this spectrum was similar in 
the plexus throughout the secondary transition, indicating that the characteristics of the plexus 
at both tissue and cellular levels are maintained during the course of development. In addition, 
we consistently observed at all stages numerous distinct puncta of intense F-actin signal, 
located directly at the lumen, that were associated with the focalized Muc1+aPKC+ apical 
surface-to-lumen contact (hereafter F-actinFOCAL) of delaminating Neurog3-expressing cells, as 
shown using the NeurogEGFP knock-in mouse strain (Fig. 5.1B,C, Fig. 5.4A-D) [58]. Essentially all 
cells reporting high levels of EGFP (EGFPHI) exhibited a measurably narrowed or focalized F-
actinBELT (Fig. 5.1F). In contrast, the F-actinBELT of cells in the duct-state showed measurable 
increases in perimeter and aspect ratio reflecting enlargements of the apical domain (Fig. 5.1G-
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J). Consistent with our previous findings using direct immune-detection of Neurog3, the 
numbers of Neurog3-reporting cells were greatly diminished in ductal states, and accordingly, 
F-actinFOCAL structures were significantly reduced or absent. Comparisons of cell morphologies 
using E-cad as an additional indicator of cell shape suggested similar increases in apical domain 
size in the duct versus plexus (Fig. 5.5A-D), and a cell-flattening phenotype indicative of cell 
differentiation toward a duct-cell-like state [82,211]. These analyses on the morphological 
features of the apical domain in the plexus, Neurog3-expressing, and ductal-states suggest that 
within the plexus, F-actinBELT narrowing and F-actinFOCAL formation are associated with 
endocrine differentiation, while F-actinBELT expansion is associated with duct-cell 
differentiation.   
Apical narrowing and F-actinFOCAL formation mediate endocrine commitment in the plexus 
upstream of Neurog3 protein 
Genetic inactivation of Neurog3 results in a morphologically abnormal plexus state at E14.5 
[72], and a complete absence of EGFPHI cells. To test whether the defect in Neurog3 
upregulation could be the result of defective apical narrowing or F-actinFOCAL formation in this 
condition, we compared the cortical F-actinBELT meshwork in Neurog3EGFP/+ and Neurog3EGFP/EGFP 
epithelia. Indeed, the relatively broad spectrum of F-actinBELT observed in the Neurog3EGFP/+ 
shifted toward a more uniformly circular morphology in the NeurogEGFP/EGFP plexus (Fig. 5.6A-D, 
I). There was no evidence for F-actinFOCAL structures in the Neurog3EGFP/EGFP plexus, suggesting 
that F-actinFOCAL formation does not occur in the Neurog3-deficient plexus at this stage. 
Neurog3-reporter expression was expanded but reduced (EGFPLO) across essentially the whole 
dysmorphic plexus. Consistent with a previous report, we observed a broad expansion of the 
epithelial lumen diameter [72] in the Neurog3-defiecient condition. There was also a 
measureable increase in the number of Sox9+ cells over the Muc1+ lumen surface distance, 
suggesting a cell crowding effect caused by the lack of endocrine cell delamination (Fig. 5.7A,B). 
Collectively, these data are consistent with previously-proposed functions for Neurog3 in non-
autonomously limiting its own expression domain, and in regulating epithelial morphology 
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[80,169], but do not rule out the possibility that the alterations in Neurog3 expression may 
occur as a consequence of dysregulated epithelial morphogenesis. 
 
Figure 5.1. Duct versus endocrine differentiation is associated with apical expansion or narrowing of the F-actin
+
 
epithelial cell cortex. (A) Confocal z-stack (30 m depth) of E14.5 dorsal pancreas showing the plexus web labeled 
with Muc1 and F-actin. Inset shows F-actin channel, with intense cortical F-actin signal marking F-actin
BELT
 
circumscribing the apical domain of individual epithelial cells. Yellow arrowheads show Muc1
+
 F-actin
FOCAL
 
structures. (B) F-actin
FOCAL
 structures mark the apical-lumen contacts of delaminating Ngn3
EGFP/+
 reporter
+
 cells. (C) 
Manual trace of the F-actin
BELT
 meshwork (thin black lines) from A, F-actin
FOCAL
 structures (red dots), and 
representative Neurog3-expressing cells (inset). (D) Dot-plots of cortical F-actin
BELT
 dimensions (aspect 
ratio/perimeter) from individual cells superimposed for control or Neurog3
EGFP/+
 cells in the E14.5 plexus. (E) 
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Superimposed F-actin
BELT
 dot-plots from E14.5 and E17.5 control plexus. (F) Superimposed F-actin
BELT
 dot-plots from 
E14.5 plexus and in Neurog3-expressing
 
cells. (G) Confocal z-stack (30 m depth) of representative plexus and duct-
states at E17.5. Duct state is demarcated by green dashed line. Yellow arrowheads indicate F-actin
FOCAL
 structures. 
(G,H) Zoomed insets from plexus and duct-state in F. Note the expansion of F-actin
BELT
 and dearth of F-actin
FOCAL
 in 
the duct state. (I) Superimposed F-actin
BELT
 dot-plots from E17.5 plexus and duct states. Scale bars are 20 m in A,F, 
5 m in B.  
 
 
 
Figure 5.2. Adherens and tight-junction markers demarcate a multicellular F-actin
BELT
 meshwork. (A) Schematic 
showing the localization of the cortical F-actin
BELT
 with respect to apical-surface (Muc1), tight junction (ZO1), and 
adherens-junction (Ecad). (B-D) Representative en fasse images of Ecad and ZO1 in relation to the F-actin
BELT
 
network. (E-H’) Confocal steps (z-direction, 1.0 m/step) through a plane of representative epithelial cells. Note the 
progression from Ecad (blue) through to intense F-actin signal and ZO1. Scale Bars in B, C, & D are 10 m, and 5 m 
in E-H’. 
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Figure 5.3. F-actin
BELT
 aspect ratio versus perimeter defines the spectrum of F-actin
BELT
 sizes in epithelial 
populations. (A) Schematic of a typical cortical F-actin
BELT
 near apical surface an epithelial cell.  Perimeter (black 
line) demarcates the F-actin
BELT
. (A’) Long axis (red dashed line) and short axis (blue dashed line) defines 
perpendicular axial dimensions of the F-actin
BELT
. (A’’) Aspect ratio is defined by the divisional product of the long 
and short axis. (B) Schematic with examples of the extremes in possible F-actin
BELT
 (white) dimensions (F-actin
BELT
 
traced in yellow dashed line) obtained from measurements as described. Roman numeral I indicates narrowed 
apical cortex. Roman numeral II indicates elongated F-actin
BELT
. Roman numeral III indicates expanded F-actin
BELT
. 
Roman numeral IV indicates expanded and elongated F-actin
BELT
. Grey dashed line demarcates minimum of 
resolution in x and y for accurate measurements by these methods (~2.0 m). F-actin
FOCAL
 perimeter and aspect 
ratio are below minimum resolution or at the origin (red box). Yellow arrowhead marks typical F-actin
FOCAL
 structure 
at the apical surface of a delaminating Neurog3
EGFP/+
 reporting
+
 cell. Scale bars are 20 m. 
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Figure 5.4. Delaminating endocrine cells maintain contact with a narrow apical lumen-surface contact. (A) 
Representative 40x confocal z-stack of E14.5 Ngn3
EGFP/+
 plexus showing apical lumen-surface contact of 
delaminating EGFP-reporting cells. (B-D) Immuno-detection of aPKC and Muc1 showing the localization of each at 
representative Muc1
+
 F-actin
FOCAL
 structures (yellow arrowheads). Scale Bars are 10 m in A-D. 
 
 
Figure 5.5. Ecad immunolabeling shows enlargements in cell shape in the duct-state compared to the plexus. (A,B) 
Confocal z-stack of Muc1 and Ecad markers showing cell morphologies in the plexus at E17.5 (plexus traced by 
yellow dashed line). (C,D) Confocal z-stack of cell dimensions and shapes in the duct at E17.5 (duct traced by green 
dashed line). Scale bars are 10 m. 
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Figure 5.6. Plexus-state morphogenesis is associated with upstream activation of Neurog3. Representative 
Neurog3
EGFP/+
 plexus (A,B) versus Neurog3
EGFP/EGFP
 plexus (C,D) with EGFP
HI
-reporting cells distributed within the 
cortical F-actin
BELT
 meshwork at E14.5. Note the dilations of the Muc1
+
 lumens, alterations to the F-actin
BELT
 
network, and expansion of EGFP
LO
-reporting cells throughout the epithelium of Neurog3
EGFP/EGFP
 compared to 
Neurog3
EGFP/+
 plexus. Representative Neurog3
EGFP/+
 plexus (E,F) versus Neurog3
EGFP/EGFP
 plexus (G,H) with EGFP-
reporting cells distributed within the cortical F-actin
BELT
 meshwork at E17.5. Note the re-activation of EGFP reporter 
to high levels in the Neurog3
EGFP/EGFP
 plexus. (I,J) Superimposed F-actin
BELT
 dot-plots from Neurog3
EGFP/+ 
and 
Neurog3
EGFP/EGFP 
plexus at E14.5 and E17.5, respectively. Note that the abnormalities observed in the 
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Neurog3
EGFP/EGFP 
plexus at E14.5 are largely corrected within the plexus by E17.5. (K) Schematic representation of 
the general patterns of F-actin
BELT
 shape-change as normal epithelial cells transition from the plexus (blue), to the 
duct (orange) or Neurog3-expressing states. Green dashed line demarcates the spectrum of F-actin
BELT
 in the 
Neurog3
EGFP/EGFP
 plexus at E14.5. (L) Schematic representation of the morphological alterations associated with 
states of Neurog3-activation in Neurog3
EGFP/+
 and Neurog3
EGFP/EGFP
 epithelium during the secondary transition. Scale 
bars are 15 m in A-D, 20 m in E-H.  
 
We have recently reported that the abnormal Neurog3EGFP/EGFP epithelium remodels during late 
gestation (E16.5-18.5) to a morphological state essentially indistinguishable from the wild type 
condition [211]. This “corrective epithelial remodeling” process suggests that the pancreatic 
epithelial morphogenesis program can over-ride early morphological defects caused by the 
absence of Neurog3-dependent differentiation, delamination, and Notch-regulated processes. 
The Neurog3EGFP/EGFP condition thus provides a stringent model to assess the activation 
dynamics of Neurog3 in the complete absence of Neurog3 protein, as an initially “abnormal” 
plexus-state undergoes corrective remodeling toward a “normal” plexus-state. Numerous 
inspections of thick-sectioned and Muc1-labeled late-stage (E16.5-onward) embryonic 
pancreata confirmed a pervasive corrective remodeling of the epithelium to generate grossly 
normal plexus, duct, and branched states by E17.5 (Fig. 5.6A-D). In contrast to the increased cell 
densities observed in the plexus at E14.5, the number of Sox9+ cells over Muc1+ lumen surface 
distance was comparable in the plexus between control and mutant samples by E17.5 (Fig. 
5.7A-H). Moreover, the spectrum of F-actinBELT shapes within the corrected plexus was 
essentially indistinguishable from the spectrum observed in stage-matched controls. 
Surprisingly, we observed periodic F-actinFOCAL structures within the corrected plexus which 
demarcated, as in control samples, the narrowed or focalized apical domains of individual 
EGFPHI cells (Fig. 5.6E-H,J). While the relative number of EGFPHI cells in the late-stage 
Neurog3EGFP/EGFP plexus was reduced compared to control, these data indicate an appreciable 
rescue of Neurog3-promoter upregulation, up-stream and in the complete absence of Neurog3 
protein function, within the correctively remodeled Neurog3-deficient epithelium. Rescue of 
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Figure 5.7. Alterations in Sox9
+
 cell-densities in the Neurog3-deficient epithelium are corrected by late gestation. 
(A,B) Measurements on the number of Sox9
+
 nuclei along the length of Muc1
+
 lumen Neurog3
EGFP/+
 versus 
Neurog3
EGFP/EGFP
 epithelium at E14.5 and E17.5, respectively. (C-H) Representative thick sections of Muc1, Sox9 and 
EGFP in duct and plexus states at E17.5. Cyan dashed lines in C and F demarcate the duct from the plexus-state, and 
white trace marks low EGFP expression in the forming endocrine islets. Scale bars are 20 m in C,D,F,G; 10 m in 
E,H. 
Neurog3 upregulation was tightly associated with plexus morphology, because non-plexus 
ductal and branched states, as in control samples, did not exhibit appreciable numbers of 
EGFPHI cells (Fig. 5.8A-D). Taken together these data suggest that there are tight morphological 
and tissue-architectural constraints imposed within the plexus that are necessary to direct the 
initiating step in endocrine commitment, and that deviations from these constraints can 
preclude efficient engagement of the endocrine lineage commitment process (Fig. 5.6K,L). 
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Figure 5.8. Neurog3 is broadly upregulated in cells within the Neurog3-deficeint plexus at late gestation. (A-D) 
Wide-field 10x epifluorescent images of thick-sectioned pancreas (30 m) showing Neurog3-expressing cells in the 
plexus (blue dashed line), duct (white arrowheads), and peripheral ductal-branches (yellow arrowheads) in 
Neurog3
EGFP/+
 and Neurog3
EGFP/EGFP
 epithelium at E18.5. Scale bars are 100 m. 
 
Apical narrowing and increased migratory activity at the basal cell-surface demarcate the 
Neurog3LO-HI transition  
To better understand how specific morphogenetic inputs might mediate endocrine 
commitment within the plexus, we focused on the precise cell-morphological alterations that 
occur as Neurog3-reporter becomes activated (EGFPLO) and then upregulated (EGFPHI) during 
endocrine cell specification and commitment. Using the Neurog3EGFP/+ reporter line, we found at 
E14.5 a rare population of EGFPLO cells (6.5%; n = 95; Fig. 5.10A) that did not exhibit a highly-
narrowed apical domain (as judged by the size of the F-actinBELT relative to the basal surface), 
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nor any evidence for delamination-type migratory behavior at the basal cell surface (Fig. 5.9A-
A’). A significant portion of the total EGFP+ population showed a narrowed apical domain 
(19.3%), and exhibited an EGFPHI state (Fig. 5.9B-B’). The remainder of EGFPHI cells (and the 
largest portion of the total EGFP+ population at 74.2%) exhibited a fully-formed and elongated 
F-actinFOCAL structure, as well as prevalent migratory activity at the basal cell-surface (Fig. 5.9C-
C’; Fig. 5.10A,B). Measurements of mean EGFP intensity in non apically-narrowed, apically 
narrowed, and migrating (cells with protrusions at the basal leading edge) cell-states were 
consistent with a sequence whereby the Neurog3 is rapidly upregulated in association with the 
initiation and then progression of a cell delamination process (Fig. 5.9E; Fig. 5.10C). The 
delamination process was finalized upon rear detachment of the apical surface-to-lumen 
contact (Fig. 5.9D-D’).  To independently confirm these observations, we employed a 
Neurog3BAC transgenic dual-reporter line (hereafter referred to as Neurog3RG), which features 
chromatin-localized H2B-mCherry and membrane-localized GPI-GFP fluorophores, and can be 
used to precisely monitor the cell-morphological transitions occurring during Neurog3-
activation and upregulation (Matt Bechard, Wright Lab, submitted). Focusing on the 
membrane-linked EGFP component of the Neurog3RG reporter, and consistent with the 
Neurog3EGFP line, at both E14.5 and E17.5 only a rare population EGFPRG-LO cells we found (4.7% 
at E14.5, n = 295; 2.3% at E17.5, n = 84), and these exhibited a non apically-narrowed shape 
(Fig. 5.9G,G’; Fig. 5.10D,D’). EGFPRG-HI cells, however, consistently were apically-narrowed (17% 
at E14.5, 17.9% at E17.5), or were associated with an F-actinFOCAL structure and displaying 
prevalent migratory activity at the basal surface (~75%) (Fig. 5.9H-I’). Fully delaminated EGFPRG+ 
endocrine precursors were rounded in morphology, and exhibited full apical-detachment from 
the Muc1+ lumen surface (Fig. 5.9J,J’). Thus, Neurog3EGFP and Neurog3RG reporter lines 
independently confirm that Neurog3 transcriptional upregulation occurs concomitant with an 
initial step in apical-narrowing (Neurog3LO), followed by formation of an F-actinFOCAL structure 
and increased migratory activity at the basal cell surface (Neurog3HI) (Fig. 5.9L).  
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Figure 5.9. Neurog3-independent apical narrowing and Neurog3-dependent basal migration guide endocrine cell 
birth. (A-D’) Neurog3
EGFP/+
 reporter-expressing cells showing step-wise progression from a non-apically-narrowed 
and non-delaminating Neurog3
LO
 state, to an apically-narrowed (yellow dashed line) Neurog3
HI
 state, an F-
actin
FOCAL
-associated migrating (blue dashed line) Neurog3
HI
 state, and finally an apically detached delaminated 
state. (E) Mean fluorescence intensity measurements (arbitrary units) in typical cells in non-apically-narrowed, 
apically-narrowed, or migrating states. (G-J’) Neurog3
RG
 reporter-expressing cells showing similar progression as A-
D’. (K) Mean fluorescence intensity measurements in typical cells in non-apically-narrowed (green), apically-
narrowed (red), or migrating (blue) states. (L,M) Neurog3-expressing cells in the Neurog3
EGFP/+ 
plexus at E14.5 and 
E17.5. (N,O) Neurog3-expressing cells in the Neurog3
EGFP/EGFP 
plexus at E14.5 and E17.5. (P-S) Percentage of 
Neurog3
HI
 cells in non-apically-narrowed, apically-narrowed, and migrating states at E14.5 and E17.5. (T) Mean 
fluorescence intensities from non-apically-narrowed (green), apically-narrowed (red), and migrating (blue) 
Neurog3-reporting states in Neurog3
EGFP/+
 and Neurog3
EGFP/EGFP
 epithelium at E17.5. (U) Schematic showing 
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Neurog3-independedt and Neurog3-dependent steps in the process of Neurog3-upregulation during cell 
delamination from the plexus. Scale bars are 5 m in A-D’ and L-M, 3 m in G-J’. 
 
Endocrine-cell birth proceeds through Neurog3-independent and Neurog3-dependent steps 
Neurog3-deficient cells are incapable of undergoing endocrine differentiation and 
delamination, but during corrective remodeling of the plexus can upregulate Neurog3. To 
understand when during the endocrine commitment process Neurog3 protein function 
becomes required, we analyzed the progression of control (Neurog3EGFP/+) and Neurog3 
protein-deficient (Neurog3EGFP/EGFP) EGPF-producing cells as they moved through the step-wise 
process of apical-narrowing, F-actinFOCAL formation, and basal migration during cell 
delamination. In the E17.5 Neurog3-deficient plexus, most EGFPHI exhibited an apically-
narrowed shape (84.7% versus 18% in control; n = 90) (Fig. 5.9L-S, Fig. 5.11A). A significant 
portion of EGFPHI cells were associated with and apical F-actinFOCAL structure (41.6%), but these 
were reduced in number (41.5% of total EGFPHI cells versus 81.7% in control), and the length of 
the F-actinFOCAL structures was reduced compared to control (Fig. 5.11A-D). Importantly, the F-
actinFOCAL-associated EGFPHI cells did not display prevalent migratory activity at the basal cell 
surface, suggesting that the migratory stages of delamination are dependent on Neurog3 
protein function. Notably, a portion of the EGFPHI population at this stage exhibited a non-
delaminating phenotype (15.3% in Neurog3EGFP/EGFP versus 2.3% in Neurog3EGFP/+; Fig. 5.9S-U), 
which we interpret as cells that have likely previously entered the initial stages of cell 
delamination, have upregulated Neurog3, but have failed to retract the cell rear and then 
returned to an epithelial-resident state upon delamination failure [80,164]. These data support 
a model whereby Neurog3 upregulation is controlled by morphogenetic factors that regulate 
apical narrowing and F-actinFOCAL formation in the plexus, and suggest that later stages of cell 
migration and rear retraction require Neurog3 protein function (Fig. 5.9U). 
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Figure 5.10. Quantification of Neurog3-expressing states using Neurog3 knock-in and BAC-transgenic reporter 
alleles. (A) Quantification of the proportions of non-apically narrowed (green), apically narrowed (red), and 
migrating (blue) Neurog3
EGFP/+
 cells at E14.5. (B) Neurog3
RG+
 cells in a representative z-stack labeled with Muc1 at 
E14.5. Yellow arrowhead marks non-apically narrowed EGFP
LO
 cell, cyan arrowheads mark apically narrowed 
EGFP
HI
 cells, pink arrowheads mark EGFP
HI
 cells associated with fully formed F-actin
FOCAL
 structures. Scale bar is 20 
m. (C,C’) Percentage of non-apically narrowed (green), apically narrowed (red), and F-actin
FOCAL
-associated 
migrating (blue) Neurog3
RG+
 cells at E14.5 and E17.5. (D) Diagram of the principle cell-morphological states 
associated with Neurog3
OFF
, Neurog3
LO
, and Neurog3
HI
 populations, color coded to match A-C’.  
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Figure 5.11. Neurog3-deficeint Neurog3
HI
 cells become apically narrowed and form F-actin
FOCAL
 structures, but do 
not migrate from the epithelium. (A) Proportion of Neurog3
HI
 cells that exhibit a narrowed apical surface versus a 
fully formed F-actin
FOCAL
 structure in Neurog3
EGFP/+
 and Neurog3
EGFP/+ 
plexus at E17.5. (B) Images of Neurog3
HI
 cells 
in Neurog3
EGFP/+
 pancreata undergoing Neurog3 upregulation during apical narrowing and F-actin
FOCAL
-formation. 
Note the migratory protrusions at the basal cell surface (dashed cyan lines). (C) Images of Neurog3
HI
 cells in 
Neurog3
EGFP/EGFP
 pancreata undergoing Neurog3 upregulation during apical narrowing and F-actin
FOCAL
-formation. 
(D) Measurements of the lengths of typical F-actin
FOCAL
 structures associated with Neurog3
HI
 cells in Neurog3
EGFP/+
 
and Neurog3
EGFP/EGFP 
epithelium at E14.5 and E17.5. Green dashed line indicates the distinction between an apically-
narrowed surface (below line; apically narrowed length ~ 0.0 m) versus a fully formed F-actin
FOCAL
 structure (above 
line). Scale bars are 7 m in B,C. 
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Evidence for nmMyoII as a regulator of plexus morphogenesis 
The molecular motor nmMyoII, which is expressed in IIa, IIb, and IIc isoforms in mammals, has 
known functions in acting on F-actin substrates to drive processes such as apical constriction 
and cell delamination, among others [112]. A high immunofluorescence signal for the active, 
phosphorylated nmMyoII light chain (p-nmMyoII, non-isoform-specific) was enriched at the 
apical aspect of epithelial cells, in a pattern consistent with localization along the F-actinBELT 
meshwork (Fig. 5.12A,B). P-nmMyoII was detected on most Muc1+ F-actinFOCAL structures, but 
showed significant variation in signal intensity (Fig. 5.12C,D), suggesting a dynamic localization 
during the delamination process. High levels of p-nmMyoII were also observed in the large 
blood vessels of the pancreas (data not shown), and relatively lower levels were observed 
throughout the parenchyma.  NmMyoIIa and IIb isoforms showed high signal in the large blood 
vessels of the pancreas, and was seen at lower levels throughout the mesenchyme (Fig. 
5.12K,L). We were unable to detect IIa and IIb isoforms in the epithelium or in EGFP-expressing 
populations using the available reagents. Analysis of nmMyoIIC using a GFP-fusion line [212], 
however, showed surprisingly selective and intense expression throughout the epithelium at 
E14.5. This pattern became largely restricted to the non-acinar epithelium by E17.5 (Fig. 5.12E-
H), though there was a relatively low level of expression in differentiating endocrine cells (data 
not shown). These data are consistent with roles for nmMyoII activity in mediating epithelial 
morphogenesis and cell differentiation in the plexus.  
NmMyoII activity limits plexus-to-duct remodeling and promotes endocrine differentiation 
To evaluate potential functions for nmMyoII in regulating plexus morphogenesis, we isolated 
and explanted plexus-enriched segments of E15.5 dorsal pancreata (Fig. 5.13A), and cultured 
them in the presence or absence of the nmMyoII inhibitor blebbistatin (BBS) [213].  In control 
samples, the plexus maintained gross morphological features indistinguishable from those 
observed in vivo over 36 hours of culture (data not shown). Conversely, under nmMyoII-
inhibited conditions we observed a broad, rapid, and reproducible, albeit abnormal, 
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Figure 5.12. NmMyoII isoforms and are expressed and activated in the embryonic pancreas. (A,B) Split channels of 
p-nmMyoII along the Muc1
+
 lumen surface at E14.5. (C,D) P-nmMyoII localization along F-actin
FOCAL
 structures 
(yellow arrowheads) in the Neurog3
RG
 line. Muc1 and nuclear H2B-mCherry are shown in red, to indicate the lumen 
surface of Neurog3-expressing cells. (E) Localization of nmMyoIIC-GFP fusion in epithelial cells at E14.5. (F-I) 
Evidence for enriched co-localization of nmMyoIIC-GFP signal with intense phalloidin signal near the apical surface. 
(J) NmMyoIIC-GFP signal becomes enriched in the non-acinar epithelium by E17.5 (white dashed line demarcates 
acinar clusters). (K-L) nmMyoIIa and b isofoms detected in the parenchyma (main blood vessels and mesenchyme) 
of the embryonic pancreas. EGFP signal is from the Neurog3
EGFP/+
 knock-in strain. Scale bars are 10 m in A,B,E, 5 
m in C,D,F-I, 20 m in J, and 100 m in K,L. 
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Figure 5.13. NmMyoII activity limits apical expansion and plexus-to-duct transformation. (A) Diagram of plexus 
explant culture on microporous filters at the air-liquid interface. (B-G) Muc1 and Neurog3 immuno-detection in 
plexus explant cultured for 18 hours under vehicle-treated or BBS-treated conditions with manual traces of the 
epithelium in D and G. Inset shows a sectional plane from G at higher magnification, with DAPI to indicate position 
of nuclei around the duct-like structure. (H,I) Dimensions of F-actin
BELT
 in plexus treated with vehicle or BBS. Blue 
line indicates the maximum on the y-axis for F-actin
BELT
 dimensions measured in the plexus in vivo.  (J-L) Muc1 and 
F-actin in explants treated with increasing doses of BBS. (M) Diagram showing morphological transformation of the 
plexus-state into a duct-like state under conditions where nmMyoII is inhibited. Scale bars are 50 m in B-G, 30 m 
in inset of G, 20 m in J-L. 
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transformation of the plexus into a duct-like state (Fig. 5.13B-G). Within the transformed duct-
like-states, the F-actinBELT meshwork became dilated compared to the untreated plexus (Fig. 
5.13H-L), consistent with known roles for nmMyoII in regulating apical domain shape [112].  
 
Figure 5.14. NmMyoII-inhibition causes an abnormal plexus-to-duct-like transformation. (A) Qualities of the normal 
plexus-state in un-treated explants. (B-C) Representative images of abnormal plexus observed in BBS-treated 
explants. Qualities of the abnormal plexus state include localized sphere-like dilations of the epithelium (yellow 
arrowheads), malformations of the terminal acinar lumens (cyan arrowheads), and diminished numbers of F-
actin
FOCAL
 structures (red arrowheads). Scale bars are 20m. (D) Proposed diagram depicting the plexus-to-duct 
transformations observed under normal (in vivo) and (E) nmMyoII-inhibited conditions. Note the difference in time 
scales. (F) Depiction of the process of acinar lumen dilation observed under nmMyoII-inhibited conditions. 
Much of any remaining plexus exhibited abnormal morphological characteristics, such as 
dilation of the acinar lumens, luminal distensions at epithelial intersections within the plexus 
web (Fig. 5.14A-F). These BBS-mediated effects on the plexus were dose dependent and 
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reversible, because an 18 hour washout of the drug resulted in restoration of normal F-actinBELT 
morphology, except in locations where plexus had become fully transformed into duct-like  
 
Figure 5.15. Effects of BBS treatment on the plexus are dose-dependent and reversible. (A) Measurements of the 
relative Muc1
+
 pixel area exhibiting full duct-like transformation (red line), or typical abnormalities in plexus state 
morphology (blue line). Muc1 and F-actin localization in explants grown for 18 hr in DMSO (B), 18 hrs in 25 M BBS 
(C), 36 hrs in DMSO (D), or 18 hrs in 25 M BBS with a subsequent washout and 18 hr culture in DMSO (D). (F) 
Dimensions of F-actin
BELT
 in plexus treated with DMSO for 18 hrs (black dots F,G,H) or 25 M BBS for 18 hrs (red 
dots) used as reference for G,H. (G) Dimensions of F-actin
BELT
 in plexus treated with DMSO for 36 hrs (red dots). (H) 
Dimensions of F-actin
BELT
 in plexus treated with 25 M BBS for 18 hrs, with a subsequent washout and 18 hr culture 
in DMSO (red dots). Blue line indicates the maximum on the y-axis for F-actin
BELT
 dimensions measured in the plexus 
in vivo. Scale bars are 20 m. 
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states (Fig. 5.15A-H). The effect of nmMyoII inhibition on plexus morphology was not due to 
loss of epithelial cell polarity or epithelial cell-cell contact, as aPKC, the primary cilium marker 
gamma-tubulin, and Ecad maintained localization at their respective apical and basal-lateral cell 
membranes during these experimental time-frames (Fig. 5.16A-F). Interestingly, along the 
Muc1+ lumen of transformed duct-like-states in BBS treated explants there was a marked  
 
Figure 5.16. Apical polarity and cell contact are maintained under nmMyoII-inhibited conditions. (A-D) 
Representative images of E14.5 plexus explants treated for 18 hr with DMSO or 50 M BBS and labeled with the 
apical markers Muc1, and aPKC. (E,F) Untreated and treated samples labeled with the ciliary basal-body marker 
gamma tubulin, which is normally localized near the aPKC
+
 apical surface of epithelial cells. (G,H) Ecad localization 
in epithelial cells from treated and untreated explants. Scale bars are 10 m. 
decrease in the number of Neurog3+ cells (Fig. 5.13C,F). In these same samples, epithelium 
remaining in the plexus-state remained associated with large numbers of Neurog3+ cells. While 
Sox9 expression was reduced in the treated condition, there was no change in the epithelial 
expression pattern of Pdx1, suggesting that the changes in Neurog3 production were not the 
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result of loss of pancreatic identity. Moreover, the transcription factor Prox1, which represents 
an epithelial cell marker with known functions in regulating epithelial identity, was unchanged 
(Fig. 5.17A-H) [76]. These experiments show that nmMyoII inhibition causes acute 
morphological alterations to the plexus and a block in Neurog3 protein production, suggesting 
functions for nmMyoII in limiting plexus-to-duct remodeling and promoting endocrine 
differentiation within the plexus (Fig. 5.13M). 
 
Figure 5.17. Selective alterations in epithelial transcription factor expression under nmMyoII-inhibited conditions. 
(A-F) Immunodetection of Sox9 and Pdx1 in plexus explants treated with DMSO or 50 M BBS for 18 hrs. (G,H) 
Expression of Prox1 in plexus explants treated with DMSO or 50 M BBS for 18 hrs. Scale bars are 10 m. 
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ROCK-nmMyoII pathway activity mediates apical narrowing, leading edge migration, and cell 
rear retraction in Neurog3-expressing populations 
To address how cell morphogenesis influences endocrine cell-fate allocation, we next studied 
the effects of two small molecule inhibitors (BBS and Y-27632) on the cell delamination and 
Neurog3-activation. BBS inhibits nmMyoII directly by interfering with intrinsic GTPase motor 
activity [214], and can thus inhibit all nmMyoII-dependent processes. Y-27632 inhibits ROCK 
[215], which is known to limit cell migration (depending on the cell type) by modulating actin 
filament stabilization and nmMyoII activity [146], and is also required for cell rear retraction 
[153]. Using the Ngn3RG-reporter line, explants treated with BBS showed reductions in 
Neurog3RG+ populations along the Muc1+ lumen, consistent with the reductions of Neurog3+ 
cells observed in wild-type explants by immunodetection (Fig. 5.18A-D;Fig. 5.19A-F). In 
epithelium where Neurog3RG+ cells remained (likely due to reporter-protein purdurance in cells 
that had already begun the Neurog3-upregulation process), quantification of the proportion of 
non-apically narrowed, apically-narrowed, and migrating RG+ cells indicated a shift toward a 
non-apically narrowed state, and a flattened cell shape, with little to no migratory activity at 
the basal cell surface (Fig. 5.18G,G’). There was also a reduction in Muc1+ F-actinFOCAL 
structures, and the lengths of those remaining were decreased relative to control (Fig. 
5.18H,H’). These results are consistent with a requirement for nmMyoII activity in mediating 
apical-narrowing, F-actinFOCAL formation, and basal migration steps during cell delamination and 
Neurog3 upregulation.  
ROCK-inhibition, like nmMyoII inhibition, had several effects on tissue and cell morphology in 
the plexus. Contrary to BBS, Y27632-treated explants showed no evidence of plexus-to-duct-like 
transformation, or any apparent decrease in Neurog3RG+ cells along the Muc1+ lumen (Fig. 
5.18E,F,G”). Rather, the plexus was maintained in association with numerous delaminating 
Neurog3RG+ cells. The morphology of the Neurog3RG+ cells themselves, however, was altered.  
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Figure 5.18. ROCK-nmMyoII pathway activity mediates steps in endocrine cell birth. (A-F) Muc1
+
 and Neurog3
RG+
 
cells in plexus explants treated with DMSO, BBS, or Y-27632 for 18 hrs. Muc1
+
 F-actin
FOCAL
 structures are shown by 
yellow arrowheads. Note the reductions in apically-narrowed and migrating populations in the BBS treated 
condition. (G) Proportions of non-apically-narrowed, apically-narrowed, and migrating Neurog3-expressing 
populations in explants treated with DMSO, BBS, or Y27632. (H) Diagram of non-apically-narrowed, apically-
narrowed, and migrating Neurog3-expressing cells shown in G, and outlining the effects of nmMyoII versus ROCK 
inhibition on the endocrine cell birth process. (I-I”) Measurements of the lengths of typical F-actin
FOCAL
 structures in 
explants treated with DMSO, BBS, or Y27632. Green dashed line indicates the distinction between an apically-
narrowed surface (below line; F-actin
FOCAL
 length ~ 0.0 m) versus a fully formed and lengthened F-actin
FOCAL
 
structure (above line). (J) Quantification of the defect in tail retraction observed in Y-27632- treated explants by 
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EdU pulse-chase. (K-N) Representative images of EdU-labeled RG
+
 cells exhibiting attached (blue arrowheads) or 
detached (pink arrowheads) cell rears. Scale bars are 20 m. 
Consistent with known functions for ROCK in limiting protrusive migratory activity at the 
leading edge of migrating cells, most ROCK-inhibited Neurog3RG+ cells were elongated in shape, 
and displayed augmented protrusions at their basal cell surface (Fig. 5.19A-I). Live imaging of 
pancreatic explants cultured on fibronectin, in the presence or absence of BBS or Y27632, 
confirmed that nmMyoII inhibition reduced leading edge protrusive activity, while ROCK-
inhibition augments leading edge protrusive activity (Fig. 5.20). ROCK-inhibition increased the 
number and lengths of F-actinFOCAL structures distributed across the plexus, suggestive of a 
known defect in cell rear-retraction caused by reduced ROCK activity [148]. We tested and 
confirmed defective cell rear-retraction using EdU pulse chase methodology. Briefly, replicating 
progenitor cells incorporate EdU at S-phase, and then differentiate into delaminated endocrine 
cells over an estimated 17-18 hour period on average [211, Chapter II]. After a one hour 
injection of EdU into pregnant dams, pancreas was harvested from E13.5 embryos and explants 
cultured in the presence or absence of ROCK-inhibitor for 18 hours. If ROCK-inhibition causes a 
defect in cell retraction, then we predict a relative accumulation of Neurog3RG+ cells remaining 
attached to Muc1+ lumen in the ROCK-inhibited condition, whereas EdU+ Neurog3RG+ cells in 
untreated explants should be able to retract their cell rear and complete epithelial 
delamination. Z-stack volumes (~ 20 m thick) of EdU pulse-labeled RG+ cells were acquired so 
that attached and detached states could be unambiguously scored. In DMSO treated explants, 
63.4 ± 3.1% of RG+ cells were attached to the lumen, 30.6 ± 3.9% were detached, and 7.0 ± 
1.0% could not be definitively categorized as attached or detached (Fig. 5.18J-L). In Y-27632 
treated explants, 86.6 ± 3.1% of RG+ cells were attached to the lumen, 4.8 ± 2.9% were 
detached, and 8.6 ± 2.7% could not be definitively categorized as attached or detached (Fig. 
5.18J-N). Collectively, these data indicate that ROCK has functions in limiting protrusive 
migration at the basal surface during the early stages of endocrine cell birth, and then functions 
to direct retraction of the cell rear from the apical lumen surface upon completion of 
delamination. Thus, ROCK-nmMyoII pathway dynamics mediate multiple steps in cell 
delamination during endocrine cell birth by regulating initial apical narrowing and F-actinFOCAL 
formation, basally directed cell migration, and cell rear retraction. 
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Figure 5.19. ROCK-nmMyoII pathway inhibitors influence luminal expansion, apical narrowing, and basal 
migration processes during Neurog3 activation and upregulation. (A) Muc1+ lumen and Neurog3RG+ cell 
morphology in untreated, BBS-treated (B-E), and Y27632-treated (F-I) explants. Scale bars are 15 m. 
 
nmMyoII activity mediates escape from Notch signaling 
Comparison of the numbers of Neurog3+ over Neurog3-Muc1+DAPI+ cells in the epithelium of 
pancreatic explants treated with BBS or vehicle showed a near 50% reduction in Neurog3+ cells 
in the BBS-treated condition, indicating that Neurog3 activation and upregulation is blunted 
under conditions where nmMyoII is inhibited (Fig. 5.21A-B’,E). Because Notch signaling is also  
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Figure 5.20 Live imaging of explants treated with ROCK-nmMyoII pathway inhibitors confirms alterations to apical 
narrowing, basal migration, and Neurog3 upregulation. E12.5 Neurog3
RG
 pancreata were grown for 24 hours on 
fibronectin coated Met-Tek dishes. DMSO, 10 M Y27632, and 10 M BBS were applied for an additional 24 hour 
period, while explants were subjected to live imaging. (A-E) One hour snapshots from live imaging during 
delamination of Neurog3
RG
 cell in DMSO treated condition. (F-J) One hour snapshots from live imaging during 
delamination of Neurog3
RG
 cell in Y27632 treated condition. (K-O) One hour snapshots from live imaging during 
delamination of Neurog3
RG
 cell in BBS treated condition. Green arrowheads demarcate the apical domain, and blue 
arrowheads demarcate the basal leading edge, of individual Neurog3-expressing cells.  
known to block Neurog3 activation, we hypothesized that nmMyoII might function, at least in 
part, to mediate escape from Notch. To test this, we cultured explanted plexus in the presence 
of the Notch inhibitor DBZ [170], or BBS and DBZ together (BBS was applied 6 hr before DBZ), 
and scored (total Neurog3+)/(total Neurog3-Muc1+DAPI+) cells in each condition. Consistent 
with previous reports, pharmacological inhibition of Notch pathway activity in pancreatic 
explants caused much of the pancreatic epithelium to become Neurog3+ (Fig. 5.21C,C’,E) 
[72,80]. In explants treated with both BBS and DBZ, Neurog3+ cells were increased relative to 
DMSO and BBS treated conditions (Fig. 5.21D-E. These results indicate that the block in 
Neurog3-activation observed in nmMyoII-inhibited conditions can be bypassed through 
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inhibition of Notch, and suggest that nmMyoII activity mediates escape from repressive Notch 
signals. 
A ROCK-nmMyoII, Notch and Neurog3 gene-dosage circuit regulates cycles of endocrine cell 
birth 
A previous study showed that the upregulation of Neurog3 to high levels is required for full 
commitment to the endocrine lineage [69]. Cells that are genetically hypomorphic for Neurog3 
are more prone to being maintained in the Sox9 epithelium in a Neurog3LO state than their wild 
type counterparts, which rapidly progress to a delaminating Neurog3HI state.  We thus utilized 
an allelic series comprised of Neurog3 nullizygous (Neurog3EGFP/EGFP), hypomorphic 
(Neurog3EGFP/flox), and control (Neurog3EGFP/+) conditions to dissect the relationship between 
ROCK-nmMyoII, Notch, and Neurog3 gene dosage functions during the process of endocrine 
birth. To do this, we analyzed reporter activation (from the Neurog3EGFP allele) in explants from 
each genetic condition, and that were treated with ROCK inhibitor, Notch inhibitor, or both in 
combination. In Neurog3EGFP/EGFP explants, where the vast majority of the plexus is EGFPLO, 
neither ROCK inhibition, Notch inhibition, nor both in combination was sufficient to cause 
upregulation of Neurog3 to high levels (Fig. 5.21F-I,Q,R). Because Notch signaling is already 
reduced in this genetic condition [72,211], these results are consistent with the notion that 
Neurog3LO state is acquired in part through escape from Notch, but that escape from Notch is 
not sufficient to generate Neurog3HI cells when Neurog3 protein is absent. In explants from 
Neurog3 hypomorphs, there was a significant increase in the number of EGFPLO cells in the 
Sox9+ epithelium, and a significant decrease in the numbers of Sox9-EGFPHI cells, similar to what 
has been previously shown [69]. In ROCK-inhibited hypomorphic explants, however, we 
observed a large increase in Sox9-EGFPHI cells, and a corresponding decrease in Sox9+EGFPLO 
cells (Fig. 5.21J,K,Q,R). This indicates that ROCK-inhibition can convert Neurog3LO cells into 
Neurog3HI cells when Neurog3 gene dosage is limiting. DBZ treated hypomorphic explants also 
showed increased EGFPHI cells relative to the DMSO-treated condition, indicating that if 
Neurog3 protein is present, escape from Notch results in upregulation of Neurog3 to high levels  
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Figure 5.21. ROCK-nmMyoII, Notch, and Neurog3 gene dosage regulate the progression of cells through Neurog3-
expressing states.(A-D’) Immunodetection of Muc1 and Neurog3 protein in E15.5 Neurog3
RG+ 
pancreatic explants 
treated with DMSO, 25 M BBS, 20nM DBZ, or BBS and DBZ. BBS was applied for an 18 hour period. DBZ was 
administered 6 hour into the culture period, for a total DBZ culture period of 12 hours. Quantification of the number 
of Muc1
+
, DAPI
+
 (not shown) cells that are Neurog3
+
 in each condition (n = 3 for DMSO and BBS, n = 2 for DBZ and 
DBZ + BBS). Approximately 30% of each explants was scored for each condition, the numbers of each cell state were 
summed, and averaged between each explant for each condition. (F-I) Immunodetection of Muc1, EGFP, and Sox9 
(not shown) in E13.5 Neurog3
EGFP/EGFP
 explants treated with 10 mM Y27632, 20 nM DBZ, or Y27632 and DBZ for 18 
hours. (J-L) E13.5 Neurog3
EGFP/flox
 explants treated and analyzed according to F-H. (M-P) Immunodetection of Muc1, 
EGFP, and Sox9 in E13.5 Neurog3
EGFP/+
 explants treated according to F-I. (Q) Quantification of endocrine-committed 
EGFP
HI
Sox9- cells over total Sox9
+
 cells in 40x z-stack images (~20 m thick) Neurog3
EGFP/flox
 explants treated with 
DMSO, Y27632, or DBZ. (R) Quantification of the number of Sox9
+
 cells activating EGFP in Neurog3
EGFP/+
 explants 
treated with DMSO, Y27632, DBZ, or DBZ and Y27632. For Q and R, three explants were imaged (~30% of total 
explants by serial thick sections), numbers of cells were scored and summed for each image, and individual images 
for each condition were averaged. Error bars are S.E.M. Scale bars are 20 m for A-D’, and 10 m for F-P. Blue lines 
demarcate acinar clusters. N.D. No Data. 
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(Fig. 5.21L,Q,R). Finally, in the Neurog3EGFP/+ condition, explants treated with ROCK inhibitor 
showed only a minor increase in the number of EGFPHI cells relative to the untreated condition 
(Fig. 5.21M,N,R), indicating that ROCK inhibition is not sufficient to increase endocrine 
differentiation under normal genetic conditions. This suggests that the effect of ROCK inhibition 
in pushing cells toward the Neurog3HI state (observed in ROCK-inhibited Neurog3 hypomorphs) 
might be limited by the number of Neurog3HI cells. We thus hypothesized that the pro-
endocrine effect of ROCK inhibition could be limited by Notch-inhibition from Neurgo3HI cells. 
Consistent with this notion, administration of ROCK and DBZ together resulted in activation of 
Neurog3 in the vast majority of the plexus (Fig. 5.21O-R). These collective results indicate that 
ROCK-nmMyoII, Notch and Neurog3 gene activities together orchestrate the progression of 
cells in the plexus through sequential Neurog3 expressing states during endocrine-cell birth. 
Adaptive self organization in the plexus confers a robust endocrine differentiation program  
The data presented thus far indicate that Neurog3 activity influences epithelial plexus 
morphogenesis, and that morphogenetic inputs within the plexus, such as ROCK-nmMyoII, 
influence Neurog3 activity. We therefore hypothesized that, together, endocrine differentiation 
and plexus morphogenesis processes feed-forward to confer robustness on the endocrine 
lineage allocation program.  To test this, we quantified and compared the relative numbers of 
EGFPHI cells being born from the plexus (by measuring total EGFPHI/Sox9+ cells), during a time 
course (E13.5, E16.5, and E18.5) for normal plexus remodeling (Neurog3EGFP/+), for Neurog3-
deficeint corrective plexus remodeling (Neurog3EGFP/EGFP), and for an experimental condition 
wherein the plexus is supplemented with a sub-commitment dose of Neurog3 (Neurog3EGFP/flox) 
[69]. In Neurog3EGFP/+ pancreata, endocrine differentiation was robust and prolonged during the 
entire course of secondary transition. In Neurog3EGFP/EGFP pancreata, the early and pervasive 
defects in Neurog3 upregulation became progressively, but only partially rescued by E16.5 and 
E18.5, confirming that Neurog3 dependent processes are necessary for a full restoration of 
Neurog3 upregulation in the plexus. In Neurog3EGFP/flox pancreata, the early and pervasive 
defects in Neurog3 upregulation became progressively, and then completely rescued to normal 
levels by E18.5. These results indicate that in addition to the feed-back functions for Neurgo3 in 
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limiting its own expression domain via Notch, there are also feed-forward functions for 
Neurog3 that promote endocrine differentiation from within the remodeling plexus-state.  
 
Figure 5.22. Adaptive self organization in the plexus confers a robust endocrine differentiation program. 
Immunodetection of Muc1, EGFP, and Sox9 (not shown) during a time-course for plexus remodeling in thick-
sectioned (30 m) Neurog3
EGFP/+
, Neurog3
EGFP/EGFP
, and Neurog3
EGFP/flox
 pancreata. (J) Quantification of delaminating 
endocrine committed EGFP
HI
Muc1
+
Sox9
-
 cells over total Sox9
+
EGFP
-
 cells at each stage. Images of plexus were taken 
from n = 3 pancreata at each stage (Neurog3
EGFP/+
 = 11, 10, and 9 images for E13.5, E16,5 and E18.5; 
Neurog3
EGFP/EGFP
 = 12, 10, and 9 images for E13.5, E16,5 and E18.5; Neurog3
EGFP/flox
 = 9, 11, and 14 images for E13.5, 
E16,5 and E18.5, respectively). Error bars are S.E.M. Scale bars are 15 m in A-I.  
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Discussion 
In studying the molecular and genetic control of epithelial-plexus remodeling and Neurog3 
activation during the pancreatic secondary transition, we arrive at a new model for how 
epithelial morphogenesis, progenitor maintenance, and lineage differentiation are integrated 
to direct the allocation of pancreatic duct/endocrine tissues. In the absence of Neurog3-
dependent differentiation, delamination, and Notch-pathway activities, essentially all 
progenitors in the plexus are maintained in an ‘equivalent' state of low Neurog3 expression. 
This Neurog3LO plexus-state is dependent on nmMyoII activity, because in normal tissue 
nmMyoII inhibition results in an epithelial transformation into non-plexus duct-like states, and 
causes an acute and early block in Neurog3 activation. The transition from the Neurog3LO to a 
Neurog3HI state is controlled by an nmMyoII-dependent narrowing of the apical cell-surface, 
which represents the initial step in a cell-delamination program that is specified within the 
plexus upstream of Neurog3. Later steps in delamination include basal migration and epithelial 
exit, which are nmMyoII-dependent, Neurog3-dependent, and limited by ROCK. ROCK activity 
gates the transition of the Neurog3LO to the Neurog3HI state, because its inhibition can promote 
both basal migration and Neurog3 upregulation under conditions where Neurog3 is limiting. 
Finally, differentiating endocrine cells exert multiple feedback effects on the epithelium to 
locally repress endocrine differentiation, but also to augment endocrine lineage allocation from 
the plexus as a whole. We propose endocrine differentiation and plexus morphogenesis 
programs cross-regulate one another to both achieve and maintain a physiologically optimized 
rate for the allocation of duct and endocrine tissues. In this manner, progenitors assembled and 
maintained in the plexus can make enough cells, the right type of cell, and place these cells in 
the right place and at the right time during organ formation. 
Tissue morphogenesis mediates acquisition of states of Neurog3 activation 
Our data suggest that states of Neurog3 activation are controlled within the plexus, at least in 
part, through regulated changes in cell morphology. In the absence of Neurog3, the normally 
heterogeneous spectrum of cells’ apical domain shapes observed within the plexus becomes 
misconfigured toward a relatively homogeneous and uniformly ‘circular’ state. This 
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reorganization of epithelial structure is associated with a broad acquisition of the Neurog3LO 
state, and a loss of both the Neurog3HI and Neurog3OFF states (E12.5-E15.5). During late-stage 
‘corrective remodeling’ of the dysmorphic Neurog3-deficeint epithelium (E16.5-E18.5), the 
spectrum of apical domain shapes is observed to progressively reconfigure toward a more 
normal configuration. As this occurs, cells moving into the Neurog3HI state are observed 
throughout the plexus, and appear to form in association with a process of apical narrowing 
and basal displacement.  
Apical narrowing or basal displacements have been previously proposed mechanisms for how 
epithelial progenitor populations escape from repressive Notch signals [218,245,246]. Our data 
showing that Notch inhibition does not induce Neurog3HI cells in the dysmorphic Neurog3-
deficient plexus explants at E13.5, however, combined with our data showing that Nuerog3HI 
cells form in the correctively remodeled Neurog3-deficient plexus from E16.5-E18.5 in vivo, rule 
out that Notch or Neurog3 are required for the conversion of the Neurog3LO state to Neurog3HI. 
We suspect, rather, that an nmMyoII-dependent process of apical narrowing and basal 
displacement, which is specified periodically within the normal plexus state, mediates (in 
addition to escape from Notch) the exposure of individual progenitor cells to a pro-endocrine 
cue(s) located at or near the basal ECM. NmMyoII inhibition blocks Neurog3 activation in 
normal explants, and consistent with a role for nmMyoII in mediating escape from Notch, 
administration of the Notch-inhibitor DBZ to nmMyoII-inhibited explants results in activation of 
Neurog3. The degree of Neurog3 activation, however, is reduced in comparison to explants 
treated with DBZ alone, suggesting that nmMyoII also mediates access to a pro-endocrine 
cue(s). The idea that states of Neurog3 activation might be mediated by apical versus basal 
positioning within the epithelium, is in line with a previous study showing that the cell polarity 
determinant Cdc42 plays important roles in regulating epithelial tubulogenesis as well as 
endocrine differentiation in the pancreas [25]. We envision that further investigations in the 
polarity regulators such as Rho and Rac, which have known functions in regulating actomyosin 
contractility [109-125], actin dynamics [128,132-134], and apical versus basal polarization in 
numerous cell types [146,147], could provide new entry points into dissecting the 
morphogenetic regulation of endocrine cell birth. The idea that ROCK, which is activated by Rho 
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and has been shown in some cell types to inhibit cell migration [140,146,150-154], limits the 
conversion of Neurog3LO to Neurog3HI cells in Neurog3 hypomorphs, is consistent with the 
notion that cell polarity pathways represents important mediators of endocrine fate allocation 
in the pancreas [25,259,260,261]. Collectively, these data support the concept that provided 
the right environmental conditions, small molecule manipulations on the activity of 
morphogenetic determinants could be a productive avenue toward guiding cell fate transitions 
during the artificial directed differentiation of embryonic stem cells toward the endocrine 
lineage. 
Transcriptional determinants of cell fate regulate tissue and cellular morphogenesis 
Tissue-specific inactivation of transcriptional regulators – such as HNF1b [74], HNF6 [73], Prox1 
[75,76] Neurog3 [72,211], and Pdx1 [13,258] – in the pancreatic epithelium all cause epithelial 
malformations concurrent with defects in endocrine cell lineage allocation. While the 
interpretations of these phenotypes have been based largely on direct transcriptional effects at 
promoter targets such as Neurog3, they are equally consistent with the idea that alterations to 
epithelial morphology can preclude efficient engagement of the endocrine-differentiation 
program. In animals deficient for Pdx1, which is a master regulator of pancreas formation and 
lineage specification, early dorsal evagination from the foregut, cell polarization, and 
microlumen-formation all occur [24,258], but there is a complete failure in pancreas-specified 
cells to subsequently assemble into a plexus. Thus, transcriptional regulators of cell fate are 
likely to have both direct and indirect roles in building and regulating precise states of tissue 
architecture, which in turn mediate the placement of the right types and numbers of organ 
specific lineages. In the future, a movement toward building increasingly integrated network 
models linking epithelial morphogenesis, gene transcription, and intracellular signaling as 
obligatory principle components of a larger “niche-framework” will improve our understanding 
of how specificity, robustness, and heterogeneity in multicellular behaviors are achieved during 
organ self-assembly.  
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Feedback control of progenitor maintenance, differentiation, and morphogenesis within a 
transient niche during organogenesis 
While the structure and function of stem-cell niches in homeostatic and regenerative systems 
[2,3,4,5,6] are becoming relatively well understood, the transient nature of organ-specific 
progenitors, and the complexity underlying the process of organ formation itself, has hindered 
our ability to build niche-based paradigms for how organ progenitors are regulated. Our data 
suggest that the epithelial plexus represents a niche for differentiating endocrine cells, and that 
differentiating endocrine cells represent a type niche ‘support cell’ for the epithelial plexus. In 
line with this, our studies and others have shown that Neurog3 functions not only as an 
endocrine lineage determinant and effector of Notch [34]. Rather, Neurog3 has broad functions 
in influencing multiple developmental programs in the plexus. These include supporting robust 
progenitor replication, regulating gene expression patterning, maintaining undifferentiated 
progenitors, shaping and maintaining a precise multicellular architecture of the plexus state, 
and stimulating endocrine differentiation [72,80,211]. While the mechanisms that directly or 
indirectly link these multiple processes together remain to be defined, it appears they are all 
guided by, or responding to, the Neurog3-dependent process of endocrine cell birth. Thus, 
Neurog3 represents an executive feedback-determinant that instructs multiple developmental 
processes within the plexus. 
Within the plexus, we proved evidence that a feedback-control circuit comprised of 
ROCK/nmMyoII, Notch, and Neurog3 gene dosage integrates differentiation, growth, and 
epithelial morphogenesis. This circuit functions to regulate the timely progression of cells from 
the plexus into a delaminating endocrine-committed state, and directs an appropriate growth, 
gene expression patterning, and morphogenesis in the plexus progenitor pool. We suspect that 
the process of cell delamination itself may represent a major contributor to the feedback 
effects than Neurog3 expressing cells exert on the epithelial environment. Conceivably, cell 
delamination could influence the developmental properties of the plexus through the 
transmission of mechanical cues [223-231,242-244], through the regulation of density 
dependent growth [232-234], the cell-cycle dependent regulation of transcription factor 
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stability [235-238], and/or through the sub-cellular trafficking of signaling molecules such as 
Notch ligands/receptors [216,217], among others. Another particular point relevant to 
feedback-control in the plexus is our observation that a Neurog3-dependent and pro-endocrine 
‘community effect’ [79] appears to promote a sustained and robust population-level flux 
toward the endocrine lineage. This suggests that the feedback mechanisms regulating 
endocrine progenitor growth, differentiation, and morphogenesis, are carefully metered to run 
at an optimal rate, and are capable of adaptively self organizing within the plexus to achieve 
and maintain a necessary level of productivity [240,241]. Understanding the minimum 
requirements necessary to stimulate this intrinsic property of self-organization within a 
multicellular context could be critical in moving forward artificial directed differentiation 
protocols for the study and treatment of diabetes. 
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CHAPTER VI 
SUMMARY OF MAIN FINDINGS AND CONCLUSIONS 
The plexus is an epithelial niche for pancreatic endocrine progenitors 
Our mapping and kinetic analyses on endocrine-progenitor dynamics showed that endocrine 
cells are continually born from a transient, but long-lived, epithelial intermediate comprised by 
the plexus state. Our measurements indicate that the bulk of the endocrine lineage is born 
from the plexus, that the plexus allocates roughly one-quarter to one-third of its cell mass 
toward the endocrine lineage every twelve hours, and that this endocrine differentiation ‘flux’ 
is balanced by a roughly twelve-hour cell cycle in the Sox9+ progenitors that remain behind in 
the growing, remodeling epithelium. Our in utero Notch-inhibition studies indicate that cells in 
the plexus are maintained in a Notch-responsive state and are, as a population, poised to 
activate Neurog3 upon escape from Notch-mediated repression. As the plexus undergoes its 
later-stage maturation and becomes remodeled into non-plexus states – that is, ducts and 
ductal branches – the window for endocrine lineage allocation becomes closed. Thus, the 
plexus represents a highly dynamic epithelial niche wherein endocrine progenitors are 
assembled and maintained, and where their growth and differentiation properties are 
regulated, during the process of pancreas organogenesis. 
Newly born endocrine cells are ‘support cells’ for the plexus niche  
Our studies on the manifold consequences of Neurog3 deficiency on progenitor growth, gene 
expression patterning, and epithelial morphogenesis in the plexus suggest that Neurog3 is not 
simply an endocrine fate determinant and effector of Notch signaling. Rather, our data suggest 
that Neurog3 functions broadly as a feedback determinant whose expression is tightly 
responsive to, but at the same time also instructive in, multiple aspects of the developmental 
programs that occur within the plexus. Neurog3-dependent processes support robust 
replication in the Sox9+ epithelium, diversify gene expression (which includes non-autonomous 
regulation of the Neurog3OFF, Neurog3LO, and Neurog3HI states), and shapes, maintains, and 
propagates the plexus tissue from which duct and endocrine tissues are derived. Consequently, 
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when Neurog3 is removed from the system, developmental programs of morphogenesis, 
differentiation and growth become mis-regulated, the diversity of cellular states within the 
epithelium is lost, and the plexus regresses into what appears to be a relatively inert ‘ground 
state’. Therefore, we propose that the differentiating endocrine cell represents a type of niche 
‘support cell’ for the plexus. We believe this is consistent with the concept that during 
development, transient ‘support cells’ regulate organ-specific progenitor states that are 
assembled, maintained, and regulated within interim niche environments.  
Endocrine cell-fate allocation is guided by the plexus morphogenesis program 
We have shown that at both tissue and cellular scales, specific states of epithelial cell 
morphology are associated with specific states of Neurog3 activity. We find that the transition 
along the spectrum of Neurog3 OFF-LO-HI is associated with a progressive apical narrowing and 
focalization of the cell’s apical domain, which represents the first phase in an epithelial 
delamination process that is specified within the plexus. Possibly our most interesting finding in 
this respect is that, even in the absence of Neurog3 protein, cells in the plexus that undergo this 
initial step in cell delamination activate Neurog3 gene expression to high levels. This suggests a 
new model where endocrine cell-birth is initiated by morphogenetic transitions that are 
encoded intrinsically within, and possibly patterned by, the plexus morphogenesis program. We 
propose that an optimum efficiency rate for endocrine-cell production from the epithelium 
requires that tight epithelial and cell-morphological constraints be imposed and maintained 
within the plexus. 
Cycles of endocrine-cell birth are governed by a ROCK-nmMyoII, Notch, and Neurog3 gene 
dosage circuit 
We have used an allelic series for Neurog3 gene dosage, comprised of Neurog3EGFP/EGFP (null), 
Neurog3EGFP/fl (hypomorph), and Neurog3EGFP/+ (heterozygous) conditions, to demonstrate the 
sequential requirements for ROCK-nmMyoII, Notch, and activity thresholds of Neurog3 in 
guiding the process of endocrine cell birth. We show that ROCK-nmMyoII, Notch, and Neurog3 
represent three principal components in a regulatory circuit governing the step-wise and re-
iterative progression of cells through Neurog3OFF, Neurog3LO, Neurog3HI, and delaminated 
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endocrine precursor states. Importantly, we show that at every transition point along this 
progression (OFF-LO, LO-HI, HI-delaminated), each of these principle components requires a 
change in the activity of one or both of the other components. Briefly, Neurog3OFF-LO and 
Neurog3LO-HI require nmMyoII-activity and escape from Notch, but do not require Neurog3. 
Escape from Notch is sufficient to cause Neurog3LO-HI only in the presence of Neurog3, and 
nmMyoII activity is largely dispensable in this context. ROCK inhibition can cause the Neurog3LO-
HI conversion in the presence of even low doses of Neurog3, but like Notch, cannot do so in the 
complete absence of Neurog3. ROCK activity is required again at the Neurog3HI-delaminated 
transition to regulate retraction and detachment of the cell’s rear from the apical surface, 
which similarly requires Neurog3. Finally, we provide evidence that successful completion of 
rear-surface retraction is important for disengaging Notch-mediated repression from the 
Neurog3HI state. Thus, ROCK-nmMyoII, Notch, and Neurog3 threshold-based functions are 
mechanistically coupled to, first, guide the cell-autonomous process of endocrine cell birth and, 
second, to mediate the deployment of Neurog3-dependent feedback influences that regulate 
both the form and function of the plexus niche. 
Adaptive self-organization of organ growth, morphogenesis, and differentiation in the plexus  
According to Jamie A. Davies’ Mechanisms of Morphogenesis [240]:  
“The addition of feedback to a self-assembling system gives it a property far more powerful 
than mere self-assembly. This property is referred to as ‘adaptive self-organization’. Systems 
that show adaptive self-organization can arrange their structures in ways not simply dictated by 
the properties of the structures’ subunits, but also according to the unpredictable environment 
in which they find themselves [240].” 
Our investigations suggest that differentiation, morphogenesis, and progenitor growth 
processes are coupled through feedback-control mechanisms to regulate the self-assembly of 
the duct and endocrine pancreas. Our analyses on Neurog3 gene activation and expression 
upregulation (OFF-LO-HI) as a function of normal (E13-E18.5; Neurog3EGFP/+), abnormal (E13.5-
E15.5; Neurog3 EGFP/flox & EGFP/EGFP), or “corrective” plexus remodeling (E16.5-E18.5; Neurog3 
EGFP/flox & EGFP/EGFP), indicate that there are cross-regulatory interactions administered between 
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the plexus morphogenesis program and the endocrine differentiation program, that are 
designed to both achieve and maintain a physiologically optimized ‘run rate’ for the 
developmental processes that result in the proper allocation of duct and endocrine tissues. 
While the molecular and cell-biological details of these feedback mechanisms remain to be 
investigated (discussed below), we propose that the tight integration between plexus form and 
plexus function reflect a genetically encoded, robust, and adaptive organ ‘self-assembly’ 
program that is deployed within the confines of a highly organized niche. In this manner, the 
developmental program of the pancreas ensures that enough cells, and of the right types, are 
distributed at the correct place and time as duct and endocrine tissues are generated. 
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CHAPTER VII 
FUTURE DIRECTIONS 
A working model for duct/endocrine pancreas formation  
In studying the regulation of the expansion of the endocrine-progenitor population, its 
differentiation, and morphogenesis during the secondary transition, we have arrived at a new 
working model for how pancreatic duct and endocrine tissues are formed from a plexus niche 
during pancreas organogenesis. In the absence of Neurog3-dependent feedback, essentially the 
whole plexus assumes an abnormal ‘ground state’ where essentially all progenitors exhibit sub-
commitment levels of transcriptional activity at the Neurog3 promoter (Neurog3LO). Alterations 
to the morphology of cells within this ‘ground state’ result in changes in Neurog3 
transcriptional activity. Cells which are instructed to initiate basally directed delamination will 
activate Neurog3 to high levels, whereas cells that undergo flattening and apical expansion will 
turn off Neurog3 and adopt a duct cell fate. In the Neurog3-deficient plexus, upregulation of 
Neurog3 only occurs during late-gestation when the plexus has moved well into a phase of 
autonomous ‘corrective remodeling’ to form a more ‘normal’ epithelial architecture. While 
Neurog3 protein is not required for cells to initiate the first part of the delamination program 
and to upregulate Neurog3 in this context, later steps in leading-edge protrusive/exploratory 
behavior, rear retraction, and epithelial exit require Neurog3. Neurog3 functions cell-
autonomously to drive the process of endocrine cell birth from the plexus, and non-cell-
autonomously to regulate tissue morphogenesis, progenitor growth, and gene expression 
patterning within the plexus. The collective functions for Neurog3 ensure that a ‘normal’ plexus 
state is assembled, maintained and propagated over time, and as the organ grows substantially 
in size, to ensure a processive allocation of endocrine cells for the duration of the secondary 
transition.   
On the fundamental unit(s) of endocrine cell birth 
In his book Self-Organization in Biological Systems [241], Scott Camazine writes: “In biological 
systems self-organization is a process in which global patterns in a system emerge solely from 
157 
 
numerous interactions among the lower-level components of the system. The rules specifying 
interactions among the system’s components are executed using only local information, 
without reference to the global pattern.”  
The concept of self-organization (in terms of what one defines as ‘global patterns,’ ‘lower-level 
components of a system,’ and ‘local information’) is directly relevant to how we will need to 
approach future investigations into the cell-biological regulatory mechanisms and networks of 
regulatory mechanisms that function within the plexus niche. A central tenet of our “Niche 
Framework” model was that the developmental programs guiding organ formation must be 
coupled by feedback mechanisms that are deployed within organized “units” of cells. In an ideal 
case, each organized “unit” of cells would comprise a “fundamental unit” of endocrine-cell 
birth. Our data suggest that, by a relatively loose definition, the plexus as a whole can be 
considered a ‘fundamental unit’ of endocrine-cell birth. This definition, however, does not 
account for the possibility that there may be ‘sub-units’ of cells tiled within the plexus that 
themselves can function independently as niche-environments for endocrine progenitors. 
Below, I propose several lines of investigation that could shed light on what are the basic, 
minimum requirements for a functional “fundamental unit” that can drive cycles of endocrine-
cell birth. First, I discuss how we might come to understand what collections of factors lead to 
specification of a single Neurog3HI state in the plexus when Neurog3 is absent (endocrine-cell 
birth initiation). Second, I focus on how we might move towards a better definition of the 
nature and scale of the intra-epithelial feedback that individual endocrine-cell birth events 
exert on the surrounding microenvironment. Last, I discuss how it might be incorrect to 
conceive of a ‘fundamental unit’ of endocrine-cell birth as a stable (or perhaps metastable), 
long lived, and independently functioning group of cells that is patterned in neat units 
throughout the epithelium. Rather, we propose that the ‘fundamental unit’ of endocrine-cell 
birth might be best represented as an interconnected multi-cellular field of somewhat 
interdependent subunits. In this case, morphogenesis, growth, and differentiation signals are 
relayed and sensed between subunits by a precisely geared and extensive ‘community effect’ 
[79] within the tissue, which is designed to achieve and maintain an efficient and optimized rate 
of endocrine birth and progenitor growth.  
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Initiation of Neurog3LO-HI in the Neurog3-deficient condition 
In the absence of Neurog3 and all Neurog3-dependent feedback effects on the epithelium, the 
plexus assumes a ‘ground state’ (discussed above) wherein essentially all cells have become 
more phenotypically ‘equivalent’ (for instance, all cells become Neurog3LO). Although this 
‘ground state’ is an abnormal condition, it represents an extremely powerful system for 
interrogating how pro-endocrine niche environments are built, and how they operate, within 
the plexus. We showed that numerous and scattered populations of cells can upregulate 
Neurog3 to high levels in the absence of Neurog3 protein function, but that this process 
appears to require the initially morphologically abnormal ‘ground state’ to undergo ‘corrective 
remodeling’, and a process of apical-narrowing and basally-directed epithelial displacement. 
Thus, in both a local and global sense, there appear to be precise morphological constraints 
imposed within the plexus that are important for moving cells from Neurog3LO through to 
Neurog3HI states.  A major point of interest here centers on understanding what causes a cell 
within the ‘ground state’ to decide to initiate apical-narrowing, basal displacement, and 
Neurog3HI. We have shown that Notch inhibition is not in and of itself sufficient to drive this 
process in the absence of Neurog3 (Chapter V). We suspect, rather, that there are specific types 
of Neurog3-independent cellular re-arrangements that precede and then guide the transition to 
the Neurog3HI state. One important future direction will be to understand the patterns of cell 
movements, especially with respect to one another, in cells upregulating Neurog3 and their 
neighbors. We propose that the Neurog3-deficient epithelium represents a useful platform for 
such studies, because changes in Neurog3 activity can be monitored as a function of both 
abnormal (E13.5-E15.5) and ‘normal’ (E16.5-E18.5) plexus morphogenesis. In these settings, 
one could use a membrane-localized fluorescence reporter (for instance Sox9 driving GPI-linked 
mCherry) to label the membranes of epithelial cells in the Neurog3EGFP/EGFP condition, and then 
visualize using live imaging and 3-dimensional reconstructions the patterns of cell movement 
that presage a Neurog3 upregulation event. Interestingly, the precise localization of nmMyoII 
along the sub-apical cell cortices of groups of cells, at least in some experimental systems, is 
proposed to reflect, if not precede (and thus predict), generic types of cellular re-arrangements 
occurring in an epithelium [111,242,243]. Our data showing that the nmMyoIIC isoform is 
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relatively selectively expressed in the epithelium suggests that live imaging of nmMyoIIC-GFP 
pancreatic epithelium, in combination with reporter alleles for Neurog3, could be a productive 
avenue to observe the patterns of group-cell morphogenesis that underlie the generation of a 
Neurog3HI cell. Lastly, a more detailed mapping of precisely where within the plexus Neurog3 
becomes activated could be informative. For instance, destabilized short half-life reporters for 
Neurog3 could enable a better resolution on whether Neurog3 activation occurs preferentially 
close to or far from the epithelial ‘nodes’ of the plexus (where multiple segments of epithelium 
intersect), within ‘inter-node’ segments of epithelium, and at specific distances away from 
other cells activating Neurog3. By these methods, we might gain important insights, especially 
when coupled with functional interventions, on how candidate ‘units’ of cells in the epithelium 
coordinate patterns of local cell re-arrangements to mediate endocrine commitment. 
One very important remaining question is what cue(s) actually cause(s) Neurog3 to become 
upregulated? We have shown that a morphogenetic process of delamination initiation, and 
basal-ward displacement of the cell body, mediates movement into the Neurog3HI condition 
(this occurs upstream of Neurog3 protein function). However, we still do not know the identity 
of the extrinsic signaling factor(s) that stimulate the Neurog3 promoter. We also do not know 
whether the process of delamination initiation is regulated upstream by epithelium-extrinsic 
factors, whether it is controlled solely by such processes, or whether the morphogenetic events 
that lead to Neurog3HI are mechanistically coupled to the factors that instruct the cell to turn 
on Neurog3. We discuss these topics in more detail below, in sections entitled “The plexus as an 
asymmetric niche” and “Identifying biochemical regulators of endocrine differentiation”. In sum, 
a major point of investigation on the ‘fundamental unit’ of endocrine cell birth will be to try and 
understand the minimum cellular components and signaling processes required to drive 
initiation of Neurog3HI within the plexus. 
Local feedback from the delaminating Neurog3HI state 
Another angle from which to study a proposed ‘fundamental unit’ of endocrine-cell birth will be 
to try and understand the nature and scale of the local feedback effects individual Neurog3+ 
cells exert on their surrounding epithelial neighbors, the detailed molecular mechanisms of 
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such feedback, and how temporal control is achieved with respect to those cells that must wait 
their turn to differentiate. We have shown that the absence of delaminating endocrine cells, 
and in some cases simple reductions in their numbers (as is the case for the Neurog3 
hypomorphs), causes alterations in gene expression, replication, and cell and tissue 
morphology. Future investigations could focus on understanding how individual delaminating 
endocrine cells influence gene expression, replication behaviors, and morphogenesis in 
neighboring cells, or even in cells at a distance. We designed the Neurog3OE model (Chapter II) 
specifically for getting at questions such as these. As discussed previously, especially when done 
in a Neurog3-deficient genetic condition, the Neurog3OE model (or similar models) should 
enable clonal-type analyses on how a single delaminating endocrine cell influences its 
surrounding environment during the process of endocrine cell birth. One could use this system 
(Neurog3OE in the Neurog3-deficient ‘ground-state’ plexus) to document, for instance, whether 
single delaminating endocrine cells cause Hes1 protein to become expressed in surrounding 
cells, and if so, how many. Does Hes1 become activated in non-neighboring cells? One could 
use similar approaches to ask: How do Neurog3+ cells alter the morphology of surrounding cells 
as they undergo, and then complete, delamination? Do Neurog3+ cells influence the cycling 
properties of surrounding cells? It should be possible to understand when and how, and how 
robustly, Neurog3+ cells influence programs of morphogenesis, differentiation and progenitor 
growth in the epithelium.  
We suspect that biomechanical influences (discussed below) will represent a major mediator of 
feedback influences emanating from Neurog3+ cells –an attractive subject for a number of 
reasons. For instance, the effective communication of Notch signals between cells is proposed 
to involve endocytosis-driven tension-dependent cleavage of Notch ligands as a critical step in 
Notch signal transduction to the cell nucleus [244]. Thus, as a cell begins to delaminate from 
the epithelium, it could ‘pull’ on neighboring cells in a manner that generates tension, which 
could be linked to Notch signal processing and lateral inhibition to repress Neurog3. In addition, 
our data show that Neurog3-dependent processes also stimulate Neurog3LO-HI transitions in the 
plexus. Does this non-autonomous stimulatory effect modulation or direct instruction by 
biomechanical mechanisms (discussed in more detail later)? It will be important to use models 
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such as Neurog3OE to study and gain control over this previously undocumented stimulatory 
effect, and to bring in interventions targeting the activity of biomechanical mediators such as 
nmMyoII, or tension-sensitive signaling pathways such as Hippo, to study the mechanistic basis 
of Neurog3-dependent feedback [223-228,230,231].  
Adaptive self-assembly and ‘community effect’ in the niche 
An appealing way to think about a ‘fundamental unit’ of endocrine-cell birth is to ask, what are 
the minimum molecular and cellular requirements necessary to generate a system that can: 1) 
feed-forward to drive endocrine cell birth; 2) feed-back to ensure progenitors are maintained;  
3) establish an optimum balance, over significant lengths of time, between differentiation and 
maintenance. As previously discussed, a very important finding from our studies is that 
Neurog3+ cells do not function simply to repress Neurog3 activation in surrounding progenitors 
via Notch, but that they also have functions in stimulating continued endocrine differentiation 
from the epithelium. Thus, while Neurog3-dependent Notch-mediated lateral inhibition is a 
simple model that explains how endocrine differentiation might be balanced with progenitor 
growth in local ‘units’ of neighboring cells, this model does not explain the stimulatory effects 
of Neurog3. A different way of looking at this issue is to propose that the ‘fundamental unit’ of 
endocrine-cell birth might actually comprise a much larger ‘fundamental network’ of 
interconnected cells (or cell groups), rather than a collection of spatially distributed clusters of 
independently operating cells similar to that seen, for instance, in the developing notum of 
Drosophila [217]. Our data argue that a major role for Neurog3 protein is to generate a 
‘community effect’ within the epithelium. This community effect appears to be comprised of 
very carefully metered feedback and feed-forward interactions, which determine a 
physiologically optimized rate at which endocrine cells are differentiated, and progenitor cells 
are replicated. It is unclear at this time how large or small of a population of cells is needed to 
generate and maintain this community effect, but it is interesting to imagine how a critical mass  
of committing endocrine cells (although one should remember that this could even work with a 
relatively small number) within the epithelium could set in motion, and progressively amplify, a 
much more robust endocrine differentiation program. It will be important in the future to 
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understand the nature, scale, and mechanistic underpinnings of this proposed community 
effect, as a basis to define ‘fundamental unit(s)’ of endocrine-cell birth.  
Cellular components in the plexus that regulate endocrine lineage differentiation 
While we have presented coherent arguments that the plexus represents a niche for endocrine 
progenitors, and that Neurog3-expressing cells represent support cells for the niche, there are 
still many unknowns regarding what signaling factors regulate states of Neurog3 activation. We 
note that in the Neurog3-deficient condition, there is a very broad expression of low level 
Neurog3, but a focalized distribution of a subset of these cells that activate Neurog3 to high 
levels. This suggests that the signals activating low levels of Neurog3 are distributed broadly 
throughout the plexus, but that the signals activating Neurog3 to high levels appear to be either 
administered or interpreted in a more scattered and dispersed pattern. It will be important to 
determine the degree to which these observations on a mutant, perturbed condition are 
transferable to the normal developmental context. And to address these issues: if there are 
distinct extrinsic signals that regulate the Neurog3LO and Neurog3HI states, or whether each 
state is controlled by a quantized exposure to the same signal(s). As I describe next, there are 
several interesting avenues of investigation to be pursued in this regard. 
The plexus as an asymmetric niche 
A common feature of the stem-cell niche in invertebrates and mammals is one of structurally 
asymmetry [1]. For example, factors that maintain the stem cell in an undifferentiated state 
could be localized near the apical surface of the stem cell, while factors that promote 
differentiation could be localized more basally. By this design, any process that regulates the 
exposure of the stem cell to apical or basal cues (by delamination or ACD, for instance) could 
potentially determine the stem-cell phenotype. One interpretation of our studies on the 
morphogenetic control of endocrine commitment is that the plexus is a niche environment 
where pro-maintenance and pro-differentiation cues are localized at or near the apical and 
basal surfaces of the epithelium, respectively. Our data suggest that the architecture of the 
plexus aligns progenitors at a balance point between epithelial maintenance versus 
differentiation outcomes (the Neurog3LO expression state is the default state in the plexus 
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when Neurog3 protein is removed). Upon Neurog3-upregulation and delamination initiation by 
apical narrowing (which occurs in a relatively scattered pattern), Neurog3HI cells become basally 
displaced, suggesting that apical versus basal positioning might mediate responses to 
oppositely localized cues. Studies in the zebrafish retina have shown, for instance, that 
neurogenesis is substantially controlled by the regulation of interkinetic nuclear migration 
along an apical-to-basal Notch signaling gradient [245]. Moreover, with respect to apically 
localized maintenance cues, studies in vertebrate neuroepithelium indicate that regulation of 
apical domain size and polarity modulates the strength of Notch activity [218,245,246]. Similar 
mechanisms could influence pancreas cell-fates, because high, medium, and low levels of Notch 
are known to influence duct, bipotent progenitor, or endocrine cell fates [41, 80], which we 
have shown are each associated with large, intermediate, or reduced apical domain sizes, 
respectively. Lastly, ROCK has been implicated as a regulator of transitions in cell migration and 
cell polarity [129,146], and so its downregulation within the plexus may represent a key 
symmetry-breaking step in the decision to be maintained as an undifferentiated progenitor, or 
to acquire an endocrine fate through basally directed migration. This is consistent with our data 
showing that ROCK inhibition can convert low Neurog3-expressers into high Neurog3-
expressers under conditions where Neurog3 gene dosage is limiting. Ongoing investigations 
into how polarity molecules such a Cdc42, Rac, and RhoA function, in concert with their 
downstream regulators and effectors, to establish and maintain a properly apically and basally 
‘tuned’ epithelium, will be vital in defining if asymmetric distribution of developmental cues is 
used within the plexus niche.  
Identifying biochemical regulators of endocrine-cell birth 
While our field has been very successful in identifying the function of the transcription factors 
that control lineage allocation, to date there is no extrinsic cue that has been identified as a 
direct positive regulator of endocrine commitment. Because we have found that Neurog3 
upregulation can occur in the absence of Neurog3 protein function, we propose that it should 
be possible to identify the biochemical signals that cause Neurog3 upregulation to occur. One 
line of investigation, arguably significantly under-developed in the “pancreas developmental 
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biology” community, centers on identifying the signaling pathways that become activated 
within the cell during Neurog3 upregulation. It will be beneficial to evaluate the 
phosphorylation states of molecules downstream of, for example, receptor tyrosine kinase, 
integrin, Wnt, and TGF-beta signaling pathways, as a basis to name and test candidate inputs 
that direct the initial step in endocrine birth. Such investigations could focus on proteomics-
based approaches, in sorted cells or in intact tissue, to analyze the active signaling pathways in 
Neurog3LO and Neurog3HI populations in Neurog3EGFP/+, Neurog3EGFP/flox, and Neurog3EGFP/EGFP 
pancreata. Ideally, such approaches will fill in a number of gaps in our understanding of the 
biochemical mechanisms regulating states of Neurog3 activation, and how they converge on 
the Neurog3 promoter to regulate a seemingly very rapid process of transcriptional 
upregulation. We suspect that a potentially fruitful direction will be to understand the 
molecular composition and function of signals embedded within the basal ECM, as a potential 
source for pro-endocrine cues regulating both the Neurog3LO and Neurog3HI states. 
The cell biology of delamination: a conserved process linking epithelial niche form and function? 
The process of cellular delamination from an epithelium is associated with the acquisition of 
cell fate during numerous developmental processes distributed across many phyla [248-255]. 
Our studies on endocrine-cell birth from the plexus argue for two important functions for cell 
delamination in the pancreas. First, sequential steps in cell delamination are vital for cell-
autonomously pushing progenitors into and through distinct states of Neurog3 activation. 
Second, the process of cell delamination is mechanistically coupled to the deployment of 
feedback signals emanating from Neurog3+ cells. These data together suggest the cell-
autonomous function for cell delamination in driving cell-fate acquisition, and its connection 
back to the regulation of the form and function of the epithelial niche from which these cells 
are derived, could represent a conserved mechanism through which organ formation is 
coordinated, and through which increasing complex organ systems have evolved. We propose 
that a major unexplored territory in pancreas development is to understand how the cellular 
mechanisms regulating distinct transitions in the cell delamination process are linked to the 
transmission of regulatory signals that guide different cell behaviors in the epithelium. 
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Cell delamination coupled to Notch Signaling 
It will be important to understand whether and how Notch ligands and receptors are shuttled 
to different cellular compartments of the cell during cell delamination. In Drosophila sensory-
organ precursors, Notch is trafficked during cytokinesis from the basal cell cortex to sub-apical 
endosomes [216]. In this subcellular location, Notch-receptor recycling becomes inhibited, and 
the cell escapes from Notch to differentiate. Studies in the Drosophila notum suggest that 
dynamic basal actin-based filopodial protrusions are important for sending transient Notch 
signals through membrane-bound Delta to refine bristle patterning [217]. These reports and 
others suggest that the regulated trafficking and sub-cellular localization of Notch/Notch 
ligands is important for mediating activation or inactivation of Notch pathway signaling 
[218,219]. In the pancreas, it remains unclear where Notch signal components localize within 
the plexus epithelium, or within cells that are undergoing commitment toward the endocrine 
lineage. As discussed previously, one interesting subcellular structure to investigate is the 
narrowed apical domain of differentiating endocrine cells. Our ROCK-inhibition studies argue 
that, in normal explants, blockade of the cell-rear retraction step in delamination appears to 
block entry of additional cells into the Neurog3HI condition. This suggests that timely rear 
retraction might be connected to how Notch-inhibitory signals are turned off, so that additional 
rounds of endocrine specification can occur. Initial entry points into such studies could focus on 
whether the Notch ligands produced by Neurog3-expressing cells become concentrated at the 
narrowed apical domain of these cells. Later investigations might be geared toward 
understanding if Notch signals deployed during delamination contribute to the periodicity or 
amplitude of Neurog3 or Hes1 oscillations [262]. Such knowledge will provide a foundation on 
which to dissect the mechanistic connections between Notch signaling and cell delamination, 
but will likely require the generation of new tools such as EGFP-fusions to Notch pathway 
components and good antibodies that target these proteins. 
Cell delamination couples tissue morphogenesis and differentiation  
One interesting idea is that the Neurog3-dependent cell-morphological changes that occur 
during cell delamination (basal migration, elongation of the F-actinFOCAL apical lumen contact, 
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and epithelial exit) result in the transmission of intraepithelial forces that can be sensed and 
interpreted by cells that are adjacent and even at a distance. A growing body of evidence has 
shown that contraction of the actomyosin cytoskeleton in relatively small numbers of cells, for 
instance, can transmit forces across cell-cell adhesion sites [223] to non-autonomously control 
large-scale tissue-morphogenetic processes [229]. Also, the control of cell-shape change, or the 
modulation of tensile properties in a cell’s environment, has also long been known to influence 
cell proliferation and fate [220,221,222]. While these biological principles are becoming firmly 
established from work in simple systems and in culture, their participation in regulating much 
more complex processes such as organogenesis in mammals remains unclear. With the 
identification of the plexus as an endocrine-progenitor niche, and the documentation of 
numerous influences that delaminating endocrine cells have on the surrounding tissue 
environment, we propose that a movement in the direction of biomechanics and 
mechanotransduction could yield fundamental insights into how organ systems build 
themselves during development. While there are numerous challenges currently in obtaining 
useful tools to study biomechanical mechanisms regulating endocrine progenitors, there are a 
few ready entry points. The activity of YAP (Yes-associated protein) and TAZ (transcriptional co-
activator with PDZ-binding motif) have been extensively linked to the transmission of 
mechanical signals to the nucleus [224,225,226]. YAP and TAZ are transcription factors that, in 
response to mechanical signals, shuttle between nuclear or cytoplasmic compartments to 
regulate gene expression [227,228]. YAP and TAZ associate primarily with the TEAD (TEA 
domain family member) transcription factors to regulate genes involved in proliferation, 
survival, differentiation, and organ size determination [223]. It was recently found that TEAD 
binding motifs represent a core component of cis-regulatory elements in certain pancreatic-
progenitor-defining genes, where they function in early pancreas development to regulate the 
growth program of the MPC [230]. Moreover, these authors and others were able to show that 
YAP-TEAD becomes inactivated upon differentiation, and that YAP protein is lost from the 
nucleus in Neurog3+ cells [231]. Therefore, there is evidence to suggest that factors with known 
functions in sensing and transmitting mechanical cues are present during differentiation 
transitions in the pancreas. While pancreas-specific deletions of the kinases Mst1 and Mst2, 
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which regulate YAP activity, early in development result in reductions in pancreas size, and 
lineage-allocation/differentiation defects throughout the organ, new highly pertinent and more 
specific information will likely be gained from studying YAP and TAZ activity specifically in the 
plexus. Genetic interventions might be enabled through the use of Sox9CreER or other trunk-
selective CreER-driver alleles. Analysis of YAP/TAZ expression and function in the Neurog3 null 
condition, as well as in a Neurog3-null condition where cells can be induced to ectopically 
express Neurog3 protein (such as described for Neurog3OE, in Chapter III), could shed light on 
how Neurog3-dependent processes such as cell delamination drive tension-dependent changes 
in gene expression and activity within the niche. 
Cell delamination coupled to progenitor growth 
It has been demonstrated in the fly notum that live-cell delamination counterbalances epithelial 
growth to limit tissue overcrowding [232]. The induction of forced cell delamination or cell-
extrusion in over-crowded tissues [233], are proposed mechanisms that tightly balance 
epithelial growth in order to ensure the well-ordered cell packing during development. This 
function for cell delamination in limiting tissue overcrowding is likely to impact proliferation 
rates in epithelia as well, and it has been successfully demonstrated that spatial constraints 
imposed on epithelial cells via experimental alterations in boundary conditions, stretching, and 
compression, have acute effects on cell proliferation [234]. Thus, consistent with the findings 
reported in Chapter IV, we propose that Neurog3-dependent cell delamination could have 
functions in directly or indirectly supporting robust mitotic states in the plexus. One implication 
is that the Neurog3LO state, as a prospective replicating intermediate progenitor state, could be 
regulated by indirect influences from cell-delaminating cells that confer a precise duration for 
the cell cycle in these cells. The length of time that cells spend in the G1 phase of the cell cycle 
has been linked to the likelihood that a cell will be maintained in an undifferentiated state or 
will undergo differentiation [235,236,237,238]. Cell cycle progression in neural progenitors has 
been linked as well to the regulation of Neurog2 stability, which has important functions in 
regulating neuronal differentiation, apparently through cell-cycle regulated and level-
dependent binding (or binding ON-OFF rates) to different ‘suites’ of pre- or pro-lineage-
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commitment genes [239,263]. This suggests that Neurog3 may be similarly regulated by cell 
cycle properties during pancreas development. It is interesting to think about how Neurog3 
deficiency (where there is no cell delamination) causes reduced replication rates in Sox9+ cells, 
and whether this change in replication status is connected to the spatial spreading of the 
Neurog3LO state within the epithelium. Thus, future investigations into the direct and indirect 
roles, and Notch-dependent and independent roles, for cell delamination in mediating 
replication rates in the progenitor epithelium as a prospective mechanism to non-cell 
autonomously control the levels of Neurog3 gene expression in neighboring cells should be 
pursued. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
169 
 
REFERENCES 
[1] Li L, Xie T. 2005. Stem cell niche: structure and function. Annu. Rev. Cell Dev. Biol. 21, 605–
31. 
[2] Xie T, Spradling AC. 2000. A niche maintaining germ line stem cells in the Drosophila ovary. 
Science 290:328–30. 
[3] Kawase E, Wong MD, Ding BC, Xie T. 2004. Gbb/Bmp signaling is essential for maintaining 
germline stem cells and for repressing bam transcription in the Drosophila testis. Development 
131:1365–75. 
 
[4] Kiger AA, Jones DL, Schulz C, Rogers MB, Fuller MT. 2001. Stem cell self-renewal specified 
by JAK-STAT activation in response to a support cell cue. Science 294:2542–45. 
[5] Shivdasani AA, Ingham PW. 2003. Regulation of stem cell maintenance and transit 
amplifyingcell proliferation by tgf-beta signaling in Drosophila spermatogenesis. Curr. Biol. 
13:2065–72. 
 
[6] Tulina N, Matunis E. 2001. Control of stem cell self-renewal in Drosophila spermatogenesis 
by JAK-STAT signaling. Science 294:2546–49. 
[7] Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, et al. 2003. Osteoblastic cells 
regulate the haematopoietic stem cell niche. Nature 425:841–46. 
 
[8] Zhang J, Niu C, Ye L, Huang H, He X, et al. 2003. Identification of the haematopoietic stem 
cell niche and control of the niche size. Nature 425:836–41. 
[9] Fuchs E, Segre JA. 2000. Stem cells: a new lease on life. Cell 100:143–55. 
 
[10] Fuchs E, Tumbar T, Guasch G. 2004. Socializing with the neighbors: stem cells and their 
niche. Cell 116:769–78. 
 
[11] Mills JC, Gordon JI. 2001. The intestinal stem cell niche: there grows the neighborhood. 
Proc. Natl. Acad. Sci. USA 98:12334–36. 
 
[12] Weissman IL. 2000. Stem Cells: Units of Development, Units of Regeneration, and Units of 
Evolution. Cell 1000:157-168. 
 
[13] Pan FC, Wright C. 2011. Pancreas organogenesis: From bud to plexus to gland. Dev. Dyn. 
240, 530–565. 
[14] Zhou Q, Law AC, Rajagopal J, Anderson WJ, Gray PA, Melton DA. 2007. A Multipotent 
Progenitor Domain Guides Pancreatic Organogenesis.  Developmental Cell 13:103-114. 
 
170 
 
[15] Kopp JL, Dubois C, Schaffer AE, Hao E, Shih HP, Seymour P, Ma J, Sander M. 2011. Sox9+ 
ductal cells are multipotent progenitors throughout development but do not produce new 
endocrine cells in the normal or injured adult pancreas. Development 138:653–665. 
[16] Desgraz R, Herrera PL. 2009. Pancreatic Neurogenin3-expressing cells are unipotent islet 
precursors. Development 136:3567–3574. 
[17] Stanger BZ, Akemi J, Melton D. 2007. Organ size is limited by the number of embryonic 
progenitor cells in the pancreas but not the liver. Nature 445:886-891. 
 
[18] Slack JM. 1995. Developmental biology of the pancreas. Development 121:1569-1580. 
 
[19] Lioubinski O, Muller M, Wegner M, Sander M. 2003. Expression of Sox transcription factors 
in the developing mouse pancreas. Dev Dyn 227:402–408. 
 
[20] Eberhard D, Lammert E. 2009. The pancreatic b-cell in the islet and organ community. Curr 
Opin Genet Dev 19:469-475. 
[21] Sherwood IR, Chen TA, Melton DA. 2009. Transcriptional Dynamics of Endodermal Organ 
Formation. Developmental Dynamics 238:29-42. 
[22] Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald RJ, Wright CV. 2002. The role of the 
transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nature 
Genetics 32:128-134. 
[23] Pan FC, Bankaitis ED, Boyer D, Xu X, Van de Casteele M, Magnuson MA, Heimberg H, 
Wright CV. 2013. Spatiotemporal patterns of multipotentiality in Ptf1a-expressing cells during 
pancreas organogenesis and injury-induced facultative restoration. Development 140:751-764. 
[24] Villasenor A, Chong DC, Henkemeyer M, Cleaver O. 2010. Epithelial dynamics of pancreatic 
branching morphogenesis. Development 137:4295-4305. 
[25] Kesavan G, Sand FW,Greiner TU, Johansson JK, Kobberup S, Xunwei W, Brakebusch C, Semb 
H. 2009. Cdc42-Mediated Tubulogenesis Controls Cell Specification. Cell 139:791–801. 
[26] Hick AC, van Eyll JM, Sabine C, Forez C, Passante L, Kohara H, Nagasawa T, Vanderhaeghen 
P, Courtoy P, Rousseau G, et. al. 2009. Mechanism of primitive duct formation in the pancreas 
and submandibular glands: a role for SDF-1. BMC Dev. Biol. 9:66. 
[27] Vidal VP, Chaboissier MC, Lutzkendorf S, Cotsarelis G, Mill P, Hui CC, Ortonne N, Ortonne 
JP, Schedl A. 2005. Sox9 is essential for outer root sheath differentiation and the formation of 
the hair stem cell compartment. Curr Biol 15:1340–1351. 
 
[28] Cheung M, Briscoe J. 2003. Neural crest development is regulated by the transcription 
factor Sox9. Development 130:5681–5693. 
 
171 
 
[29] Blache P, van de Wetering M, Duluc I, Domon C, Berta P, Freund JN, Clevers H, Jay P. 2004. 
SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses 
the CDX2 and MUC2 genes. J Cell Biol 166:37–47. 
 
[30] Kopp JL, Dubois C, Schaffer AE, Hao E, Shih HP, Seymour P, Ma J, Sander M. 2011. Sox9+ 
ductal cells are multipotent progenitors throughout development but do not produce new 
endocrine cells in the normal or injured adult pancreas. Development 138:653–665. 
[31] Seymour PA, Freude KK., Tran MN, Mayes EE, Jensen J, Kist R, Scherer G, Sander M. 2007. 
SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proc Natl Acad Sci USA 
104:1865–1870. 
 
[32] Shih HP, Kopp J, Sandhu M, Dubois C, Seymour P, Grapin-Botton A, Sander M. 2012. A 
Notch-dependent molecular circuitry initiates pancreatic endocrine and ductal cell 
differentiation. Development 139:2488-2499. 
[33] Simpson P. 1997. Notch signalling in development: on equivalence groups and asymmetric 
developmental potential. Current Opinion in Genetics and Development 7:537-542. 
[34] Serup P. 2012. Signaling pathways regulating murine pancreas development. Seminars in 
Cell and Developmental Biology 23:663-672.  
[35] Lammert E, Brown J, Melton DA. 2000. Notch gene expression during pancreatic 
organogenesis. Mech Dev 94:199–203. 
 
[36] Jensen J, Pedersen EE, Galante P, Hald J, Heller RS, Ishibashi M, Kageyama R, Guillemot F, 
Serup P, Madsen OD. 2000b. Control of endodermal endocrine development by Hes-1. Nature 
Genetics, 24:36–44. 
 
[37] Apelqvist A, Li H, Sommer L, Beatus P, Anderson DJ, Honjo T, Hrabe de Angelis M, Lendahl 
U, Edlund H. 1999. Notch signalling controls pancreatic cell differentiation. Nature 400:877–
881. 
 
[38] Fujikura J, Hosoda K, Iwakura H, Tomita T, Noguchi M, Masuzaki H, Tanigaki K, Yabe D, 
Honjo T, Nakao K. 2006. Notch/Rbp-j signaling prevents premature endocrine and ductal cell 
differentiation in the pancreas. Cell Metabolism 3:59–65. 
 
[39] Hald J, Hjorth JP, German MS, Madsen OD, Serup P, Jensen J. 2003. Activated Notch1 
prevents differentiation of pancreatic acinar cells and attenuate endocrine development. 
Developmental Biology 260:426–437. 
 
[40] Murtaugh LC, Stanger BZ, Kwan KM, Melton DA. 2003. Notch signaling controls multiple 
steps of pancreatic differentiation. Proc Natl Acad Sci USA 100:14920–14925. 
 
172 
 
[41] Ninov N, Borius M, Stainier DY. 2012. Different levels of Notch signaling regulate 
quiescence, renewal,  and differentiation in pancreatic endocrine progenitors. Development 
139, 1557-67. 
[42] Afelik S, Qu X, Hasrouni E, Bukys M, Deering T, Nieuwoudt S, Rogers W, MacDonald R, 
Jensen J. 2012. Notch-mediate patterning and cell fate allocation of pancreatic progenitor cells. 
Development 139, 1744-1753. 
[43] Schaffer AE, Freude K, Nelson S, Sander M. 2010. Nkx6 transcription factors and Ptf1a 
function as antagonistic lineage determinants in multipotent pancreatic progenitors.  
Developmental Cell 18, 1022-1029. 
[44] Masui T, Long Q, Beres TM, Magnuson MA, MacDonald RJ. 2007. Early pancreatic 
development requires the vertebrate Suppressor of Hairless (RBPJ) in the PTF1 bHLH complex. 
Genes Dev 21, 2629–2643. 
 
[45] Apelqvist A, Li H, Sommer L, Beatus P, Anderson DJ, Honjo T, Hrabe de Angelis M, Lendahl 
U, Edlund H. 1999. Notch signalling controls pancreatic cell differentiation. Nature 400, 877–
881. 
 
[46] Kopinke D, Brailsford M, Shea JE, Leavitt R, Scaife CL, Murtaugh LC. 2011. Lineage tracing 
reveals the dynamic contribution of Hes1+ cells to the developing and adult pancreas. 
Development 138, 431–441. 
 
[47] Solar M, Cardala C, Houbracken I, Martin M, Maestro MA, De Medts N, Xu X, Grau V, 
Heimberg H, Bouwens L, Ferrer J. 2009. Pancreatic exocrine duct cells give rise to insulin-
producing β cells during embryogenesis but not after birth. Dev. Cell 17, 849–860. 
[48] Huang HP, Liu M, El-Hodiri HM, Chu K, Jamrich M, Tsai MJ. 2000. Regulation of the 
pancreatic islet-specific gene BETA2 (neuroD) by neurogenin 3. Mol Cell Biol 20, 3292–3307. 
 
[49] Smith SB, Qu HQ, Taleb N, Kishimoto NY, Scheel DW, Lu Y, Patch AM, Grabs R, Wang J, Lynn 
FC, Miyatsuka T, Mitchell J, Seerke R, Desir J, Eijnden SV, Abramowicz M, Kacet N, Weill J, 
Renard ME, Gentile M, Hansen I, Dewar K, Hattersley AT, Wang R, Wilson ME, Johnson JD, 
Polychronakos C, German MS. 2010. Rfx6 directs islet formation and insulin production in mice 
and humans. Nature 463, 775–780. 
 
[50] Smith SB, Gasa R, Watada H, Wang J, Griffen SC, German MS. 2003. Neurogenin3 and 
hepatic nuclear factor 1 cooperate in activating pancreatic expression of Pax4. J Biol Chem 278, 
38254–38259. 
 
[51] Watada H, Scheel DW, Leung J, German MS. 2003. Distinct gene expression programs 
function in progenitor and mature islet cells. J Biol Chem 278, 17130–17140. 
 
173 
 
[52] Wang S, Zhang J, Zhao A, Hipkens S, Magnuson MA, Gu G. 2007. Loss of Myt1 function 
partially compromises endocrine islet cell differentiation and pancreatic physiological function 
in the mouse. Mech Dev 124, 898–910. 
 
[53] Soyer J, Flasse L, RaffelsbergerW, Beucher A, Orvain C, Peers B, Ravassard P, Vermot J, Voz 
ML, Mellitzer G, Gradwohl G. 2010. Rfx6 is an Ngn3-dependent winged helix transcription factor 
required for pancreatic islet cell development. Development 137, 203–212. 
 
[54] Mellitzer G, Bonne S, Luco RF, Van De Casteele M, Lenne-Samuel N, Collombat P, Mansouri 
A, Lee J, Lan M, Pipeleers D, Nielsen FC, Ferrer J, Gradwohl G, Heimberg H. 2006. IA1 is NGN3-
dependent and essential for differentiation of the endocrine pancreas. EMBO J 25, 1344–1352. 
 
[55] Gradwohl G, Dierich A, LeMeur M, Guillemot F. 2000. Neurogenin3 is required for the 
development of the four endocrine cell lineages of the pancreas. Proc Natl Acad Sci USA 97, 
1607–1611. 
 
[56] Gouzhi M, Kim Y, Katsumoto K, Johansson K, Grapin-Botton A. 2011. Neurogenin3 initiates 
stepwise delamination of differentiating endocrine cells during pancreas development.  
Developmental Dynamics 240, 589-604. 
[57] Johansson KA, Dursun U, Jordan N, Gu G, Beermann F, Gradwohl G, Grapin-Botton A. 2007.   
Temporal Control of Neurogenin3 Activity in Pancreas Progenitors Reveals Competence 
Windows for the Generation of Different Endocrine Cell Types. Dev. Cell 12, 457–465. 
[58] Lee CS, Sund NJ, Behr R, Herrera PL, Kaestner KH. 2005. Foxa2 is required for the 
differentiation of pancreatic alpha-cells. Dev Biol 278, 484–495. 
 
[59] Lee JC, Smith SB, Watada H, Lin J, Scheel D, Wang J, Mirmira RG., German MS. 2001. 
Regulation of the pancreatic pro-endocrine gene neurogenin3. Diabetes 50, 928–936. 
 
[60] Lynn FC, Smith SB, Wilson ME, Yang KY, Nekrep N, German MS. 2007. Sox9 coordinates a 
transcriptional network in pancreatic progenitor cells. Proc Natl Acad Sci USA 104, 10500–
10505. 
 
[61] Oliver-Krasinski JM, Stoffers DA. 2008. On the origin of the beta cell. Genes Dev 22, 1998–
2021. 
 
[62] Jensen J, Heller RS, Funder-Nielsen T, Pedersen EE, Lindsell C, Weinmaster G, Madsen OD, 
Serup P. 2000. Independent development of pancreatic alpha- and beta-cells from 
neurogenin3-expressing precursors: A role for the notch pathway in repression of premature 
differentiation. Diabetes 49:163–176 
  
[63] G. Gu, J. Dubauskaite, D. Melton. 2002. Direct evidence for the pancreatic lineage:  Ngn3+ 
cells are islet progenitors and are distinct from duct progenitors.  Development 129, 2447-57. 
174 
 
 
[64] Sander M, Sussel L, Conners J, Scheel D, Kalamaras J, Dela Cruz F, Schwitzgebel V, Hayes-
Jordan A, Germa M. 2000. Homeobox gene Nkx6.1 lies downstream of Nkx2.2 in the major 
pathway of beta-cell formation in the pancreas. Development 127:5533–5540. 
 
[65] Rukstalis JM, Habener JF. 2007. Snail2, a mediator of epithelial-mesenchymal transitions, 
expressed in progenitor cells of the developing endocrine pancreas. Gene Expr Patterns 7, 471–
479. 
 
[66] Morales AV, Acloque H, Ocana OH, de Frutos CA, Gold V, Nieto MA. 2007. Snail genes at 
the crossroads of symmetric and asymmetric processes in the developing mesoderm. EMBO 
Rep 8, 104–109. 
 
[67] Kim YH, Larsen HL, Rué P, Lemaire LA, Ferrer J, Grapin-Botton A. 2015. Cell cycle-
dependent differentiation balances growth and endocrine differentiation in the pancreas. PLOS 
Biology 13, 1-25. 
[68] Schonhoff SE, Giel-Moloney M, Leiter AB. 2004. Neurogenin 3-expressing progenitor cells 
in the gastrointestinal tract differentiate into both endocrine and non-endocrine cell types. Dev 
Biol 15, 443-454. 
 
[69] Wang S, Yan J, Anderson D, Xu Y, Maneesh K, Zheng C, Wright C, Gu G. 2010. Neurog3 gene 
dosage regulates allocation of endocrine and exocrine cell fates in the developing mouse 
pancreas.  Developmental Biology 339, 26-37. 
[70] Wang S, Hecksher-Sorensen J, Xu Y, Zhao A, Dor Y, Rosenberg L, Serup P, Gu G. Myt1 and 
Ngn3 form a feed-forward expression loop to promote endocrine islet cell differentiation. Dev 
Biol 317, 531-540. 
[71] Kesavan G, Sand FW,Greiner TU, Johansson JK, Kobberup S, Xunwei W, Brakebusch C, Semb 
H. 2009. Cdc42-Mediated Tubulogenesis Controls Cell Specification. Cell 139, 791–801. 
 
[72] Magenhiem J, Klein AM, Stanger BZ, Ashery-Padan R, Sosa-Pineda B, Gu G, Dor Y. 2011. 
Ngn3+ endocrine progenitor cells control the fate and morphogenesis of pancreatic ductal 
epithelium. Dev. Biol. 359, 26–36. 
 
[73] Pierreux CE, Poll AV, Kemp CR, Clotman F, Maestro MA, Cordi S, Ferrer J, Leyns L, Rousseau 
GG, Lemaigre FP. 2006. The Transcription Factor Hepatocyte Nuclear Factor-6 Controls the 
Development of Pancreatic Ducts in the Mouse. Gastroenterology 130, 532–541. 
[74] De Vas MG, Kopp J, Heliot C, Sander M, Cereghini S, Haumaitre C. 2015. Hnf1b controls 
pancreas morphogenesis and the generation of Ngn3+ endocrine progenitors.  Development 
142, 871-882.  
175 
 
[75] Wang J, Kilic G, Aydin M, Burke Z, Oliver G, Sosa-Pineda B. 2005. Prox1 activity controls 
pancreas morphogenesis and participates in the production of “secondary transition” 
pancreatic endocrine cells. Dev. Biol. 286, 182–194. 
[76] Westmoreland JJ, Kilic G, Sartain C, Sirma S, Blain J, Rehg J, Harvey N, Sosa-Pineda B. 2012. 
Pancreas-specific deletion of Prox1 affects development and disrupts homeostasis of the 
exocrine pancreas. Gastroenterology 142, 999-1009. 
[77] Jacquemin P, Durviaux SM, Jensen J, Godfraind C, Gradwohl G, Guillemot F, Madsen OD, 
Carmeliet P, Dewerchin M, Collen D, Rousseau GG, Lemaigre FP. 2000. Transcription factor 
hepatocyte nuclear factor 6 regulates pancreatic endocrine cell differentiation and controls 
expression of the proendocrine gene ngn3. Mol. Cell Biol. 20, 4445-4454. 
[78] Villasenor A, Chong DC, Cleaver O. 2008. Biphasic Ngn3 expression in the developing 
pancreas. Dev. Dyn. 237, 3270–3279. 
[79] Gurdon JB. 1988. A community effect in animal development. Nature 336, 772-774. 
[80] Shih HP, Kopp J, Sandhu M, Dubois C, Seymour P, Grapin-Botton A, Sander M. 2012. A 
Notch-dependent molecular circuitry initiates pancreatic endocrine and ductal cell 
differentiation. Development 139, 2488-2499. 
[81] Serup P. 2012. Signaling pathways regulating murine pancreas development. Seminars in 
Cell and Developmental Biology 23, 663-672.  
[82] Grapin-Botton A. 2005. Ductal Cells of the pancreas. International Journal of Biochemistry 
& Cell Biology 37, 504-510. 
[83] Miyatsuka T, Kosaka Y, Kim H, German MS. 2011. Neurogenin3 inhibits proliferation in 
endocrine progenitors by inducing Cdkn1a. Proc Natl Acad Sci 108: 185–190. 
[84] Petzold KM, Naumann H, Spagnoli FM. 2013. Rho signalling restriction by the RhoGAP 
Stard13 integrates growth and morphogenesis in the pancreas. Development 140, 126–135. 
[85] Cortijo C, Gouzi M, Tissir F, Grapin-Botton A. 2012 Planar Cell Polarity Controls Pancreatic 
Beta Cell Differentiation and Glucose Homeostasis.  Cell Reports 2, 1593-1606. 
[86] Han H, Tanagaki K, Yamamoto N, Kuroda K, Yoshimoto M, Nakahata T, Ikuta K, Honjo T. 
2002. Inducible gene knockout of transcription factor recombination signal binding protein-J 
reveals its essential role in T versus B lineage decision.  Int. Immunology 14, 637-645. 
 
[87] Davidson L. 2012. Epithelial machines that shape the embryo. Trends in Cell Biology 22, 82-
87. 
 
[88] Schock F, Perrimon N. 2002. Molecular Mechanisms of Epithelial Morphogenesis. Annual 
Reviews in Cell Biology 18, 463-493. 
[89] Hartstock A, Nelson JW. 2008. Adherens and Tight Junictions: Structure, Function and 
Connections to the Actin Cytoskeleton. Biochim Biophys Acta 1778, 660-669. 
176 
 
[90] Gumbiner BM. 2005. Regulation of  cadherin-mediated adhesion in morphogenesis. Nat 
Rev Mol Cell Biol 6, 622-634. 
[91] Yamada S, Pokutta S, Drees F, Weis WI, Nelson WJ. 2005. Deconstructing the cadherin-
catenin-actin complex. Cell 123, 889-901. 
[92] Drees F, Pokutta S, Yamada S, Nelson WJ, Weis WI. 2005. Alpha-catenin is a molecular 
switch that binds E-cadherin-beta-catenin and regulates actin filament assembly. Cell 123, 903-
915. 
[93] Perez-Moreno M, Fuchs E. 2006. Catenins: keeping cells from getting their signals crossed. 
Developmental Cell 11, 601-612. 
[94] Reynold AB, Herbert L, Cleveland JL, Berg ST, Gaut JR. 1992. p120, a novel substrate of 
protein tyrosine kinase receptors and of p60v, is related to cadherin-binding factors beta-
catenin, plakoglobin and armadillo. Oncogene 7, 2439-2445. 
[95] Yanagisawa M, Anastasiadis PZ. 2006. p120 catenin is essential for mesenchymal cadherin-
mediated regulation of cell motility and invasiveness. J Cell Biol 174, 1087-1096. 
[96] Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S. 1998. Claudin-1 and -2: novel integral 
membrane proteins localizing at tight junctions with no sequence similarity to occluding. J Cell 
Biol 141, 1539-1550. 
[97] Hou J, Shan Q, Wang T, Gomes AS, Yan Q, Paul DL, Bleich M, Goodenough DA. Transgenic 
RNAi Depletion of Claudin-16 and the Renal Handling of Magnesium. J Biol Chem 282, 17114–
17122. 
 
[98] Funke L, Dakoji S, Bredt DS.2005 Membrane-associated guanylate kinases regulate 
adhesion and plasticity at cell junctions. Annu Rev Biochem 74, 219–245.  
 
[99] Itoh M, Nagafuchi A, Moroi S, Tsukita S. 1997. Involvement of ZO-1 in cadherin-based cell 
adhesion through its direct binding to alpha catenin and actin filaments. J Cell Biol 138, 181–
192. 
 
[100]. Muller SL, Portwich M, Schmidt A, Utepbergenov DI, Huber O, Blasig IE, Krause G. 2005 
The tight junction protein occludin and the adherens junction protein alpha-catenin share a 
common interaction mechanism with ZO-1. J Biol Chem 280, 3747–3756.  
 
[101] Rajasekaran AK, Hojo M, Huima T, Rodriguez-Boulan E. 1996. Catenins and zonula 
occludens-1 form a complex during early stages in the assembly of tight junctions. J Cell Biol 
132, 451–463. 
 
[102] Itoh M, Morita K, Tsukita S. 1999. Characterization of ZO-2 as a MAGUK family member 
associated with tight as well as adherens junctions with a binding affinity to occludin and alpha 
catenin. J Biol Chem 274, 5981–5986.  
177 
 
 
[103] Wittchen ES, Haskins J, Stevenson BR. 2003. NZO-3 expression causes global changes to 
actin cytoskeleton in Madin-Darby canine kidney cells: linking a tight junction protein to Rho 
GTPases. Mol Biol Cell 14, 1757–1768.  
 
[104] Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM. 1998. The tight junction protein ZO-1 
establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J 
Biol Chem 273, 29745–29753. 
  
[105] Mattagajasingh SN, Huang SC, Hartenstein JS, Benz EJ Jr. 2000. Characterization of the 
interaction between protein 4.1R and ZO-2. A possible link between the tight junction and the 
actin cytoskeleton. J Biol Chem 275, 30573–30585.  
 
[106] Stricker J, Falzone T, Gardel ML. 2010. Mechanics of the F-actin cytoskeleton. Journal of 
Biomechanics 43, 9-14. 
 
[107] Le Clainche, C., Carlier, M.-F., 2008. Regulation of actin assembly associated with 
protrusion and adhesion in cell migration. Physiol. Rev. 88, 489–513. 
 
[108] Naumanen, P., Lappalainen, P., Hotulainen, P., 2008. Mechanisms of actin stress fibre 
assembly. J. Microsc. 231, 446–454. 
 
[109] St Johnston D, Sanson B. 2011. Epithelial polarity and morphogenesis. Current Opinion in 
Cell Biology 23, 540-546. 
 
[110] Sawyer JM, Harrell JR, Shemer G, Sullivan-Brown J, Roh-Johnson M, Goldstein B. 2010. 
Apical constriction: a cell shape change that can drive morphogenesis. Dev Biol 341, 5-19. 
 
[111] Gorfinkiel N, Blanchard GB. 2011. Dynamics of actomyosin contractile activity during 
epithelial morphogenesis. Current Opinion in Cell Biology 23, 531-539. 
 
[112] Martin AC, Goldstein G. Apical constriction: themes and variations on a cellular 
mechanism driving morphogenesis. Development 141, 1987-1998. 
 
[113] Baker PC, Schroeder TE. 1967. Cytoplasmic filaments and morphogenetic movement in 
the amphibian neural tube. Dev. Biol. 15, 432-450. 
 
[114] Burnside B. 1973. Microtubules and microfilaments in amphibian neurulation. Amer. Zool. 
13, 989-1006. 
 
[115] Chung MI, Nascone-Yoder NM, Grover SA, Drysdale T A, Wallingford JB. 2010. Direct 
activation of Shroom3 transcription by Pitx proteins drives epithelial morphogenesis in the 
developing gut. Development 137, 1339-1349. 
 
178 
 
 
[116] Ernst S, Liu K, Agarwala S, Moratscheck N, Avci ME, Dalle Nogare D, Chitnis AB, 
Ronneberger O, Lecaudey V. 2012. Shroom3 is required downstream of FGF signalling to 
mediate proneuromast assembly in zebrafish. Development 139, 4571-4581 
 
[117] Plageman T F, Jr Chauhan BK, Yang C, Jaudon F, Shang X, Zheng Y, Lou M, Debant A, 
Hildebrand JD, Lang R A. 2011. A Trio-RhoA-Shroom3 pathway is required for apical constriction 
and epithelial invagination. Development 138, 5177-5188. 
 
[118] Hildebrand JD. 2005. Shroom regulates epithelial cell shape via the apical positioning of 
an actomyosin network. J. Cell. Sci. 118, 5191-5203. 
 
[119] Hildebrand JD, Soriano P. 1999. Shroom, a PDZ domain-containing actin binding protein, is 
required for neural tube morphogenesis in mice. Cell 99,485-497. 
 
[120] Nishimura T, Takeichi M. 2008. Shroom3-mediated recruitment of Rho kinases to the 
apical cell junctions regulates epithelial and neuroepithelial planar remodeling. Development 
135, 1493-1502. 
 
[121] Anstrom JA. 1992. Microfilaments, cell shape changes, and the formation of primary 
mesenchyme in sea urchin embryos. J. Exp. Zool. 264, 312-322. 
 
[122] Nance J, Priess JR. 2002. Cell polarity and gastrulation in C. elegans. Development 129, 
387-397. 
 
[123] Harrell JR, Goldstein B. 2011. Internalization of multiple cells during C. elegans 
gastrulation depends on common cytoskeletal mechanisms but different cell polarity and cell 
fate regulators. Dev. Biol. 350, 1-12. 
 
[124] Williams M, Burdsal C, Periasamy A, Lewandoski M, Sutherland A. 2012. Mouse primitive 
streak forms in situ by initiation of epithelial to mesenchymal transition without migration of a 
cell population. Dev. Dyn. 241, 270-283. 
 
[125] Toyama Y, Peralta XG,Wells AR, Kiehart DP, Edwards GS. 2008. Apoptotic force and tissue 
dynamics during Drosophila embryogenesis. Science 321, 1683-1686. 
 
[126] Slattum G, McGee KM, Rosenblatt J. 2009. P115 RhoGEF and microtubules decide the 
direction apoptotic cells extrude from an epithelium.  J. Cell Biol. 186, 693-702. 
 
[127] Marinari, E, Mehonic A, Curran S, Gale J, Duke T, Baum B. 2012. Live-cell delamination 
counterbalances epithelial growth to limit tissue overcrowding. Nature 484, 542-545. 
 
[128] Jaffe AB, Hall A. 2005. Rho GTPases: biochemistry and biology. Annu. Rev. Cell Dev. Biol. 
21, 247-269. 
179 
 
[129] Amano M, Ito M, Kimura K, Fukata Y, Chihara K, Nakano T, Matsuura Y, Kiabuchi K. 1996. 
Phosphorylation and Activation of Myosin by Rho-associated Kinase (Rho-kinase). Journal of 
Biological Chemistry 34, 20246-20249. 
 
[130] Kimura K, Ito M, Amano M, Chihara K, Kukata Y, Nakafuku M, Yamamori B, Feng J, Nakano 
T, Okawa K, Iwamatsu A, Kiabuchi K. 1996. Regulation of myosin phosphatase by Rho and Rho-
associated kinase (Rho-kinase). Science 12, 245-248. 
 
[131] Bresnick AR. 1999. Molecular mechanisms of nonmuscle myosin-II regulation. Curr. Opin. 
Cell Biol. 11, 26-33. 
 
[132] Dawes-Hoang RE, Parmar KM, Christiansen AE, Phelps CB, Brand AH, Wieschaus EF. 2005. 
Folded gastrulation, cell shape change and the control of myosin localization. Development 132, 
4165-4178. 
 
[133] Homem CF, Peifer, M. 2008. Diaphanous regulates myosin and adherens junctions to 
control cell contractility and protrusive behavior during morphogenesis. Development 135, 
1005-1018. 
 
[134] Goode BL, Eck MJ. 2007. Mechanism and function of formins in the control of actin 
assembly. Annu. Rev. Biochem. 76, 593-627. 
 
[135] Heasman SJ, Ridley AJ. 2008. Mammalian Rho GTPases: new insights into their functions 
from in vivo studies. Nature 9, 690-701. 
 
[136] Watanabe N, Kato T, Fujita A, Ishizaki T, Narumiya S. 1999. Cooperation between mDia1 
and ROCK in Rho-induced actin reorganization. Nature Cell Biology 1, 136–143. 
 
[137] Kosako H, Yoshida T, Matsumura F, Ishizaki T, Narumiya S, Inagaki M. 2000. Rho 
kinase/ROCK is involved in cytokinesis through the phosphorylation of myosin light chain and 
not ezrin/ radixin/moesin proteins at the cleavage furrow. Oncogene 19, 6059–6064. 
 
[138] Watanabe S, Ando Y, Yasuda S, Hosoya H, Watanabe N, Ishizaki T, Narumiya S. 2008. 
mDia2 Induces the Actin Scaffold for the Contractile Ring and Stabilizes Its Position during 
Cytokinesis in NIH 3T3 Cells. Molecular Biology of the Cell 19, 2328–2338. 
 
[139] Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, Borisy G, Parsons JT, Horwitz 
AR. 2003. Cell migration: integrating signals from front to back. Science 302, 1704– 1709. 
 
[140] Narumiya S, Tanji M, Ishizaki T. 2009. Rho signaling, ROCK and mDia1, in transformation, 
metastasis and invasion. Cancer Metastasis Reviews 28, 65-76. 
 
180 
 
[141] Nobes CD, Hall A. 1999. Rho GTPases control polarity, protrusion, and adhesion during 
cell movement. Journal of Cell Biology 144, 1235–1244. 
 
[142] Allen WE, Zicha D, Ridley AJ, Jones GE. 1998. A role for Cdc42 in macrophage chemotaxis. 
Journal of Cell Biology 141, 1147–1157. 
 
[143] Itoh RE, Kurokawa K, Ohba Y, Yoshizaki H, Mochizuki N, Matsuda M. 2002. Activation of 
rac and cdc42 video imaged by fluorescent resonance energy transfer-based single molecule 
probes in the membrane of living cells. Molecular and Cellular Biology 22, 6582–6591. 
 
[144] Gomes ER, Jani S, Gundersen GG. 2005. Nuclear movement regulated by Cdc42, MRCK, 
myosin, and actin flow establishes MTOC polarization in migrating cells. Cell 121, 451–463. 
 
[145] Cory GO, Ridley AJ. 2002. Cell motility: braking WAVEs. Nature 418, 732–733. 
 
[146] Riento K, Ridley AJ. 2003. Rocks: multifunctional kinases in cell behavior. Nature 4, 446-
456. 
 
[147] Amano M, Nakayama M, Kaibuchi K. 2010. Rho-Kinase/ROCK: A key regulator of the 
cytoskeleton and cell polarity. Cytoskeleton 67, 545-554. 
 
[148] Worthylake RA, Burridge K. 2003. RhoA and ROCK promote migration by limiting 
membrane protrusions. J Biol. Chem. 278, 13578-13584. 
[149] Tsuji T, Ishizaki T, Okamoto M, Higashida C, Kimura K, Furuyashiki T, Arakawa Y, Birge RB, 
Nakamoto T, Hirai H, Narumiya S. 2002. ROCK and mDia antagonize in Rho-dependent Rac 
activation in Swiss 3T3 fibroblasts. J. Cell Biol. 157, 819-830. 
[150] Groysman M, Shoval I, Kalcheim C. 2008. A negative modulatory role for rho and rho-
associated kinase signaling in delamination of neural crest cells. Neural Development 22, 3-27. 
[151] Totsukawa G, Wu Y, Sasaki Y, Hartshorne DJ, Yamakita Y, Yamashiro S, Matsumura F. 
2004. Distinct roles of MLCK and ROCK in the regulation of membrane protrusions and focal 
adhesion dynamics during cell migration of fibroblasts. J Cell Biol 164, 427–439. 
 
[152] Magdalena J, Millard TH, Machesky LM. 2003. Microtubule involvement in NIH 3T3 Golgi 
and MTOC polarity establishment. J Cell Sci 116, 743–756. 
 
[153] Worthylake RA, Lemoine S, Watson JM, Burridge K. 2001. RhoA is required for monocyte 
tail retraction during transendothelial migration. J Cell Biol 154, 147-160. 
[154] Yoshinaga-Ohara N, Takahashi A, Uchiyama T, Sasada M. 2002. Spatiotemporal regulation 
of moesin phosphorylation and rear release by Rho and serine/threonine phosphatase during 
neutrophil migration. Experimental Cell Research 278, 112–122. 
 
181 
 
[155] Salic A, Mitchison TJ. 2008. A chemical method for fast and sensitive detection of DNA 
synthesis in vivo. Proc. Natl. Acad. Sci. USA 105, 2415-2420. 
[156] Fox P, Vought V, Hanazawa MH, Lee M, Maine E, Schedl T. 2011. Cyclin E and CDK-2 
regulate proliferative cell fate and cell cycle progression in the C. Elegans germline. 
Development 138, 2223-2234. 
[157] Cheraghali A, Knaus E, Wiebe L. 1994. Bioavailability and pharmacokinetic parameter for 
5-ethyl-2’-deoxyuridine. Antiviral Research, 3-4, 259-67. 
[158] Schwitzgebel VM, Scheel DW, Conners JR, Kalamaras J, Lee JE, Anderson DJ, Sussel L, 
Johnson JD, German MS. 2000. Expression of neurogenin3 reveals an islet cell precursor 
population in the pancreas. Development 127, 3533–3542. 
[159] Srinivas S, Watanabe T, Lin CS, William CM, Tanabe Y, Jessell TM, Costantini F. 2001. Cre 
reporter strains produced by targeted insertion of EYFP and ECFP into the ROSA26 locus. BMC 
Developmental Biology 1, Epub March 27. 
 
[160] Niwa Y, Masamizu T, Liu R, Nakayama C, Deng X, Kageyama R. 2007. The initiation and 
propagation of Hes7 oscillation are cooperatively regulated by Fgf and Notch signaling in the 
somite segmentation clock. Developmental Cell 13, 298-304. 
 
[161] Shimojo H, Ohtsuka T, Kageyama R. 2008. Oscillations in Notch signaling regulate 
maintenance of neural progenitors. Neuron 58, 52-64. 
[162] Kageyama R, Niwa Y, Shimojo H, Kobayashi T, Ohtsuka T. 2010. Ultradian Oscillations in 
Notch Signaling Regulate Dynamic Biological Events. Current Topics in Developmental Biology 
92, 311-331. 
[163] Kim YH, Larsen HL, Rué P, Lemaire LA, Ferrer J, Grapin-Botton A. 2015. Cell cycle-
dependent differentiation balances growth and endocrine differentiation in the pancreas. PLOS 
Biology 13, 1-25. 
[164] Beucher A, MartinM, Spenle C, Poulet M, Collin C, Gradwohl G. 2013. Competence of 
failed endocrine progenitors to give rise to acinar but not ductal cells is restricted to early 
pancreas development. Developmental Biology 361(2), 277-285. 
[165] Miyatsuka T, Li Z, German MS. 2009. Chronology of islet differentiation revealed by 
temporal cell labeling. Diabetes  58:1863–1868. 
[166] Ahnfelt-Ronne J, Jorgensen MC, Hald J, Madsen OD, Serup P, Hecksher-Sorensen J. 2007. 
An improved method for three-dimensional reconstruction of protein expression patterns in 
intact mouse and chicken embryos and organs. J Histochem Cytochem 55, 925–930. 
[167] Reichert M, Rustgi AK. 2011. Pancreatic ductal cells in development, regeneration, and 
neoplasia. J Clin Invest. 121, 4572-4578.   
182 
 
[168] Metzger DE, Gasperowicz M, Otto F, Cross JC, Gradwohl G, Zaret KS. 2012. The 
transcriptional co-repressor Grg3/Tle3 promotes pancreatic endocrine progenitor delamination 
-cell differentiation. Development 139, 1447-1456. 
[169] Qu X, Afelik S, Jensen JN, Bukys MA, Kobberup S, Schmerr M, Xiao F, Nyeng P, Veronica 
Albertoni M, et al. 2013. Notch-mediated post-translational control of Neurog3 protein stability 
regulates pancreatic patterning and cell fate commitment. Dev. Biol. 376, 1–12. 
[170] Milano J, McKay J, Dagenais C, Foster-Brown L, Pognan F, Gradient R, Jacobs R, Zacco A, 
-secretase inhibitors causes 
intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage 
differentiation.  Toxicological Science 82, 341-358. 
[171] van Es J, van Gijn M, Riccio O, van den Born M, Vooijs M, Begthel H, CozijnsenM, Robine S, 
Winton D, Radtke F, et al. 2005. -secretase inhibition turns proliferative cells in 
intestinal crypts and adenomas into goblet cells.  Nature 435. 959-963. 
[172] Kageyama R, Ohtsuka T, Shimojo H, Imayoshi I. 2008. Dynamic Notch signaling in neural 
progenitors and a revised view of lateral inhibition. Nature Neuroscience 11, 1247-1251. 
[173] Pierfelice T, Alberi L, Gaiano N. 2011. Notch in the vertebrate nervous system: an old dog 
with new tricks. Neuron 69, 840-855. 
[174] Hogan, Brigid. 1999. Morphogenesis. Cell 96, 225-233. 
[175] Metzger RJ, Klein OD, Martin GR, Krasnow MA. 2008. The branching programme of mouse 
lung development.  Nature 453, 745-750. 
[176] Franco CA, Jones ML, Bernabeu MO, Geudens I, Mathivet T, Rosa A, Lopes FM, Lima AP, 
Ragab A, Collins RT, et al. 2015. Dynamic endothelial cell rearrangements drive developmental 
vessel regression. PLOS Biology 13, 1-19. 
[177] Hart A, Papadopoulou S, Edlund H. 2003. Fgf10 Maintains Notch Activation, Stimulates 
Proliferation, and Blocks Differentiation of Pancreatic Epithelial Cells. Dev. Dyn. 185–193.  
[178] Kobberup S, Schmerr M, Dang ML, Nyeng P, Jensen JN, MacDonald RJ, Jensen J. 2010. 
Conditional control of the differentiation competence of pancreatic endocrine and ductal cells 
by Fgf10. Mech. Dev. 127, 220–234. 
[179] Landsman L, Nijagal A, Whitchurch TJ, VanderLaan RL, Zimmer WE, MacKenzie TC, Hebrok 
M. 2011. Pancreatic mesenchyme regulates epithelial organogenesis throughout development. 
PLoS Biol. 9, e1001143. 
[180] Huang S and Ingber DE. 1999. The structural and mechanical complexity of cell-growth 
control.  Nature Cell Biology 1, 131-138. 
183 
 
[181] Afelik S, Jensen J. 2032. Notch signaling in the pancreas: patterning and cell fate 
specification. WIREs Dev Biol 2, 531-544. 
[182] Petzold KM, Naumann H, Spagnoli FM. 2013. Rho signalling restriction by the RhoGAP 
Stard13 integrates growth and morphogenesis in the pancreas. Development 140, 126–135. 
[183] Huppert SS, Jacobsen TL, Muskavitch MA. 1997. Feedback regulation is central to Delta-
Notch signaling required for Drosophila wing vein morphogenesis. Development 124, 3283-
3291. 
[184] Kageyama R, Ohtsuka T, Shimojo H, Imayoshi I. 2008. Dynamic Notch signaling in neural 
progenitor cells and a revised view of lateral inhibition. Nature Neuroscience 11, 1247-1251. 
[185] Cornall RA, Eisen JS. 2005. Notch in the pathway: The roles of Notch signaling in neural 
crest development. Seminars in Cell & Developmental Biology 16, 633-672. 
[186] Simpson P. 1997. Notch signaling in development: on equivalence groups and asymmetric 
developmental potential. Current Opinion in Genetics and Development 7, 537-542. 
[187] Hofmann JJ, Iruela-Arispe ML. 2007. Notch Signaling in Blood Vessels: Who is talking to 
whom about what? Circulation Research 100, 1556-1568. 
[188] S. Artavanis-Tsakonas, M. Rand, and R. Lake. 1999.  Notch Signaling: cell fate control and 
signal integration in development.  Science 284, 770-776. 
 
[189] J. Jensen, Pedersen EE, Galante P, Hald J, Heller RS, Ishibashi M, Kageyama R, Guillemot F, 
Serup P, Madsen OD. 2000 Control of endodermal endocrine development Hes1.  Nature 
Genetics 24, 36-44. 
 
[190] H. Nakhai, J. Slveke, B. Klein, Mendoza-Torres L, Mazur PK, Alqul H, Radtke F, Strobl L, 
Zimber-Srobl U, Schmid RM. 2008. Conditional ablation of Notch signaling in pancreatic 
development.  Development 135, 2757-2765. 
 
[191] Tanigaki Kenji, Han H, Yamamoto N, Tashiro K, Ikegawa M, Kuroda K, Suzuki A, Nakano T, 
Honjo T. 2002. Notch-RBPJ signaling is involved in cell fate determination of marginal zone B 
cells. Nature Immunology 3, 443-450. 
[192] Kobayashi H, Spilde TL, Li Z, Marosky JK, Bhatia AM, Hembree MJ, Prasadan K, Preuett BL, 
Gittes GK. 2002. Lectin as a marker for staining and purification of embryonic pancreatic 
epithelium. Biochem Biophys Res Commun 293, 691-7. 
[193] Hamaguchi Y, Yamamoto Y, Iwanari H, Maruyama S, Furukawa T, Matsunami N, Honjo T. 
1992. Biochemical and Immunological Characterization of the DNA Binding Protein (RBPJx) to 
Mouse Jx Recombination Signal Sequence. Journal of Biochemistry 112, 314-320.  
[194] Liu J, Willet SG, Bankaitis ED, Xu Y, Wright CV, Gu G. 2013. Non-parallel recombination 
limits Cre-LoxP-based reporters as precise indicators of conditional genetic manipulation. 
Genesis 51, 436-442. 
184 
 
[195] Belteki G, Haigh J, Kabacs N, Haigh K, Sison K, Costantini F, Whitsett J, Quaggin SE, Nagy A. 
2005. Conditional and inducible transgene expression in mice through the combinatorial use of 
Cre-mediated recombination and tetracycline induction. Nucleic Acids Research 33, e51. 
[196] Bocker R, Estler CJ, Maywald M, Weber D. 1981. Comparison of distribution of 
doxycycline in mice after oral and intravenous application measured by a high-performance 
liquid chromatographic method. Arzneimittelforschung 31, 2116-2117. 
[197] Cras-Meneur C, Li L, Kopan R, Permutt MA. 2009. Presinilins, Notch dose contol the fate of 
pancreatic endocrine progenitors during a narrow developmental window. Genes and 
Development 23, 2088-2101. 
[198] Ejarque M, Cervantes S, Pujadas G, Tutusaus A, Sanchez L, Gasa R. 2013. Neurogenin3 
cooperates with Foxa2 to autoactivate its own expression. J Biol Chem 288: 11705–11717. 
[199] Lasko M, Pichel JG, Gorman JR, Sauer B, Okamoto Y, Lee E, Alt FW, Westphal H. 1996. 
Efficient in vivo manipulation of mouse genomic sequences at the zygote state. Proc Natl Acad 
Sci USA 93, 5860-5865. 
[200] Labosky PA, Barlow DP, Hogan BL. 1994. Mouse embryonic germ (EG) cell lines: 
transmission through the germline and differences in the methylation imprint of insulin-like 
growth factor 2 receptor (Igf2r) gene compared with embryonic (ES) cell lines. Development 
120, 3197-3204. 
 
[201] Chandler KJ, Chandler RL, Broeckelmann EM, Hou Y, Southard-Smith ME, Mortlock DP. 
2007. Relevance of BAC transgene copy number in mice: transgene copy number variation 
across multiple transgenic lines and correlations with transgene integrity and expression. 
Mammalian Genome 18, 693-708. 
 
[202] Branda CS, Dymecki SM. 2004. Talking about a Revolution: The Impact of Site-Specific 
Recombinases on Genetic Analysis in Mice. Developmental Cell 6. 7-28. 
 
[203] Liu P, Jenkins NA, Copeland NG. 2003. A Highly Efficient Recombineering-Based Method 
for Generating Conditional Knockout Mutations. Genome Research 13, 467-484. 
 
[204] Oka C, Nakano T, Wakeham A, de la Pompa JL, Mori C, SakaiT, Okazaki S, Kawaichi M, 
Shiota K, Mak TW, Honjo T. 1995. Disruption of the mouse RBPJ kappa gene results in early 
embryonic death. Development 121, 3291-3301. 
 
[205] Kawaguchi Y, Cooper B, Gannon M, Ray M, MacDonald R Wright CV. 2002. The role of the 
transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nature 
Genetics 32, 128-134. 
 
185 
 
[206] Masui T, Long Q, Beres TM, Magnuson MA, MacDonald RJ. 2007. Early pancreatic 
development requires the vertebrate suppressor of hairless (RBPJ) in the PTF1 bHLH complex. 
Genes and Development 21, 2629-2643. 
 
[207] Jonsson J, Carlsson L, Edlund T, Edlund H. 1994. Insulin-promoter-factor 1 is required for 
pancreas development in mice. Nature 371, 606-609. 
 
[208] Offield MF, Jetton TL, Labosky PA, Ray M, Stein RW, Magnuson MA, Hogan BL, Wright CV. 
1996. PDX-1 is required for pancreatic outgrowth and differentiation in the rostral duodenum. 
Development 122, 983-995. 
 
[209] Masui T, Swift GH, Deering T, Shen C, Coats WS, Long Q, Elasser HP, Magnuson MA, 
MacDonald RJ. 2010. Replacement of Rbpj with Rbpjl in the PTF1 complex controls the final 
maturation of pancreatic acinar cells. Gastroenterology 139, 270-280. 
 
[210] Heisenberg CP, Bellaiche Y. Forces in Tissue Morphogenesis and Patterning. 2013. Cell 
153, 948-962. 
[211] Bankaitis ED, Bechard ME, Wright CV. 2015. Feedback control of growth, differentiation, 
and morphogenesis of pancreatic endocrine progenitors in an epithelial plexus niche. Genes 
and Development 29, 2203-2216. 
 
[212] Ebrahim S, Fujita T, Millis BA, Kozin E, Ma X, Kawamoto S, Baird MA, Davidson M, 
Yonemura S, Hisa Y. 2013. NMII form a Contractile Transcellular Sarcomeric Network to 
Regulate Apical Cell Junctions and Tissue Geometry. Current Biology 23, 731-736. 
[213] Straight AF, Cheung A, Limouze J, Chen I, Westwood NJ, Sellers JR, Mitchison TJ. 2003. 
Dissecting temporal and spatial control of cytokinesis with a myosin II inhibitor. Science 14, 
1743-1747. 
[214] Kovacs Mihaly, Toth J, Hetensyi C, Malnasi-Csizmadia A, Sellers JR. 2004. Mechanism of 
Blebbistatin inhibition of Myosin II. Journal of Biological Chemistry 279, 35557-35563. 
[215] Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, 
Inui J, Maekawa M et al. Calcium sensitization of smooth muscle mediated by a Rho-associated 
kinase in hypertension. Nature 389, 990-994. 
[216] Couturier L, Mazouni K, Schweisguth F. 2013. Numb localizes at endosomes and controls 
the endosomal sorting of Notch after asymmetric division in Drosophila. Current Biology 23, 
588-593. 
 
[217] Cohen M, Georgiou M, Stevenson NL, Miodownik M, Baum B. 2010. Dynamic Filopodia 
Transmit Intermittent Delta-Notch Signaling to Drive Pattern Refinement during Lateral 
Inhibition. Developmental Cell 19, 78-89. 
 
186 
 
[218] Ossipova O, Sokol SY. 2010. Cell polarity, Notch signaling, and neurogenesis. Cell Cycle 9, 
1-2. 
 
[219] Bultje RS, Castaneda-Castellanos DR, Jan LY, Jan YN, Kriegstein AR, Shi SH. 2009. 
Mammalian Par3 Regulates Progenitor Cell Asymmetric Division via Notch Signaling in the 
Developing Neocortex. Neuron 63, 189-202. 
 
[220] Wozniak MA, Chen CS. 2009. Mechanotransduction in development: a growing role for 
contractility. Molecular Cell Biology 10, 34-43. 
 
[221] Mammoto A, Ingber DE. 2009. Cytoskeletal control of growth and cell fate switching. 
Current Opinion in Cell Biology 21, 864-870. 
 
[222] Discher DE, Mooney DJ, Zandstra PW. 2009. Growth factors, matrices, and forces combine 
and control stem cells. Science 324, 1673-1677. 
 
[223] Halder G, Dupont S, Piccolo S. 2012. Transduction of mechanical and cytoskeletal cues by 
YAP and TAZ. Nat Rev Mol Cell Biol. 9, 591-600. 
 
[224] Wada KI, Itoga K, Okano T Yonemura S, Sasaki H. 2011. Hippo pathway regulation by cell 
morphology and stress fibers. Development 138, 3907-3914. 
 
[225] Sansores-Garcia L, Bossuyt W, Wada K, Yonemura S, Tao C, Sasaki H, Halder G. 2011. 
Modulating F-actin organization induces organ growth by effecting the Hippo pathway. EMBO J. 
30, 2325-2335. 
 
[226] Fernandez BG, Gaspar P, Bras-Pereira C, Jezowska B, Rebelo SR, Janody F. 2011. Actin 
capping protein and the Hippo pathway regulates F-actin and tissue growth in Drosophila. 
Development 138, 2337-2346. 
 
[227] Pan D. 2010. The Hippo signaling pathway in development and cancer. Developmental Cell 
19, 491-505. 
 
[228] Zhao B, Li L, Lei Qm Guan KL. 2010. The Hippo-YAP pathway in organ size control and 
tumorigenesis: an updated version. Genes & Development 24, 862-874. 
 
[229] Monier B, Gettings M, Gay G, Mangeat T, Schott S, Guarner A, Suzanne M. 2015. Apico-
basal forces exerted by apoptotic cells drive epithelium folding. Nature 518, 245-248. 
 
[230] Cebola I, Rodriguez-Segui SA, Cho CH, Bessa J, Rovira M, Luengo M, Chhatriwala M, Berry 
A, Ponsa-Cobas J, Maestro MA, Jennings RE, Pasquali L, Moran I, Castro N, Hanley NA, Gomez-
Skarmeta JL, Vallier L, Ferrer J. 2015. TEAD and YAP regulate the enhancer network of human 
embryonic pancreatic progenitors. Nature Cell Biology 17, 615-626.   
 
187 
 
[231] George NM, Day CE, Boerner BP, Johnson RL, Sarvetnick NE. 2012. Hippo Signaling 
Regulates Pancreas Development through Inactivation of YAP. Mol. Cell Biol. 32, 5116-5128. 
 
[232] Marinari E, Mehonic A, Curran S, Gale J, Duke T, Baum B. 2012. Live-cell delamination 
counterbalances epithelial growth to limit tissue overcrowding. Nature 484, 542-545. 
 
[233] Eisenhoffer GT, Loftus PD, Yoshigi M, Otsuna H, Chien CB, Morcos PA, Rosenblatt J. 2012. 
Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia. Nature 
484, 546-549. 
 
[234] Streichan SJ, Hoerner CR, Schneidt T, Holzer D, Hufnagel L. 2014. Spatial constraints 
control cell proliferation in tissues. PNAS 111, 5586-5591. 
 
[235] Calegari F. 2005. Selective Lengthening of the Cell Cycle in the Neurogenic Subpopulation 
of Neural Progenitor Cells during Mouse Brain Development. J Neurosci 25: 6533–6538. 
 
[236] Hardwick LJ a, Ali FR, Azzarelli R, Philpott A. 2015. Cell cycle regulation of proliferation 
versus differentiation in the central nervous system. Cell Tissue Res 359: 187–200.  
[237] Hindley C, Ali F, McDowell G, Cheng K, Jones  a., Guillemot F, Philpott  a. 2012. Post-
translational modification of Ngn2 differentially affects transcription of distinct targets to 
regulate the balance between progenitor maintenance and differentiation. Development 139: 
1718–1723. 
[238] Pauklin S, Vallier L. 2013. The Cell-Cycle State of Stem Cells Determines Cell Fate 
Propensity. Cell 155: 135–147.  
[239] Ali F, Hindley C, McDowell G, Deibler R, Jones A, Kirschner M, Guillemot F, Philpott A. 
2011. Cell cycle-regulated multi-site phosphorylation of Neurogenin 2 coordinates cell cycling 
with differentiation during neurogenesis. Development 138: 4267–4277. 
[240] Davies JA. Mechanisms of Morphogenesis: Second Addition. London: Academic Press. 
2013. Print. 
[241] Camazine, Deneubourg, Franks, Sneyd, Theraulaz, Bonabeau. Self-Organization in 
Biological Systems. Princeton: Princeton University Press. 2003. Print. 
[242] Ebrahim S, Kachar B. 2013. Myosin transcellular networks regulate epithelial apical 
geometry. Cell Cycle 12, 2931-2932. 
[243] Munjal A, Philippe JM, Munro E, Lecuit T. 2015. A self-organized biomechanical network 
drives shape changes during tissue morphogenesis. Nature 524, 351-368. 
188 
 
[244] Meloty-Kapella L, Shergill B, Kuon J, Botvinick E, Weinmaster G. 2012. Notch Ligand 
Endocytosis Generates Mechanical Pulling Forge Dependent on Dynamin, Epsins, and Actin. 
Developmental Cell 22, 1299-1312. 
[245] Del Bene F, Wehman AM, Link BA, Baier H. 2008. Regulation of Neurogenesis by 
interkinetic nuclear migration through an apical-basal notch gradient. Cell 134, 1055-1065. 
[246] Clark BS, Cui S, Miesfeld JB, Klezovitch O, Vasioukhin V, Link BA. 2012. Loss of Llgl in 
retinal neuroepithelia reveals links between apical domain size, Notch activity and 
neurogenesis. Development 139, 1599-1610.  
[247] Thiery JP, Acloque A, Huang RY, Nieto MA. 2009. Eptihelial-Mesenchymal Transitions in 
Development and Disease. Cell 139, 871-890. 
[248] Ciruna B, Rossant J. 2001. FGF signaling regulates mesoderm cell fate specification and 
morphogenetic movement at the primitive streak. Cell 1, 37-49. 
 
[249] Dale JK, Malapert P, Chal J, Vilhais-Neto G, Maroto M, Johnson T, Jayasinghe S, Trainor P, 
Herrmann B, Pourquie O. 2006. Oscillations of the snail genes in the presomitic mesoderm 
coordinate segmental patterning and morphogenesis in vertebrate somitogenesis. 
Developmental Cell 10, 355-366. 
 
[250] Eastham AM, Spencer H, Soncin F, Ritson S, Merry CL, Stern PL, Ward CM. 2007. 
Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. 
Cancer Res. 67, 11254–11262. 
[251] del Barrio MG, Nieto MA. 2002. Overexpression of Snail family members highlights their 
ability to promote chick neural crest formation. Development 129, 1583-1593.  
[252] Heisenberg CP, Solnica Krezel L. 2008. Back and forth between cell fate specification and 
movement during vertebrate gastrulation. Curr. Opin. Genet. Dev. 18, 311-316. 
 
[253] Tanimizu N, Miyajima A. 2007. Molecular mechanisms of liver development and 
regeneration. Int. Rev. Cytol. 259, 1-48. 
 
[254] Yang J, Weinberg RA. 2008. Epithelial-mesenchymal transition: at the crossroads of 
development and tumor metastasis. Developmental Cell 14, 818-829. 
 
[255] Wu SY, Yang YP, McClay DR. 2008. Twist is an essential regulator of the skeletogenic gene 
regulatory network in the sea urchin embryo. Dev. Biol. 319, 406-415. 
 
[256] Coffinier C, Gresh L, Fiette L, Tronche F, Schutz G, Babinet C, Pontoglio M, Yaniv M, Barra 
J. 2002. Bile system morphogenesis defects and liver dysfunction upon targeted deletion of 
HNF1beta. Development 129, 1829-1838. 
 
189 
 
[257] Clissold RL, Hamilton AJ, Hattersley AT, Ellard S, Bingham C. 2015. HNF1B-associated renal 
and extra-renal disease-an expanding clinical spectrum. Nat. Rev. Nephrol. 11, 102-112. 
 
[258] Marty-Santos L, Cleaver O. 2016. Pdx1 regulates pancreas tubulogeneis and E-cadherin 
expression. Development 143, 101-112. 
[259] Sordella R, Jiang W, Chen GC, Curto M, Settleman J. 2003. Modulation of Rho GTPase 
signaling regulates a switch between adipogenesis and myogenesis. Cell. 113, 147‐158. 
 
[260] McBeath R, Pirone DM, Nelson CM, Chen CS. 2004. Cell shape, cytoskeletal tension, and 
RhoA regulate stem cell lineage commitment. Dev. Cell. 6, 483‐495. 
 
[261] Kim K, Ossipova O, Sokol SY. 2015. Neural crest specification by inhibition of the 
ROCK/Myosin II pathway. Stem Cells 33, 674-685. 
 
[262] Shimojo H, Ohtsuka T, Kageyama R. 2008. Oscillations in Notch Signaling Regulate 
Maintenance of Neural Progenitors. Neuron 58, 52-64. 
 
[263] Vosper JM, McDowell GS, Hindley CJ, Fiore-Heriche CS, Kucerova R, Horan I, Philpott A. 
2009. Ubiquitylation on canonical and non-canonical sites targets the transcription factor 
neurogenin for ubiquitin-mediated proteolysis. J Biol Chem 284, 15458-15468. 
 
